<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Cancer Discov</journal-id>
    <journal-id journal-id-type="iso-abbrev">Cancer Discov</journal-id>
    <journal-title-group>
      <journal-title>Cancer Discovery</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">2159-8274</issn>
    <issn pub-type="epub">2159-8290</issn>
    <publisher>
      <publisher-name>American Association for Cancer Research</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9975674</article-id>
    <article-id pub-id-type="pmid">36745048</article-id>
    <article-id pub-id-type="publisher-id">CD-22-0244</article-id>
    <article-id pub-id-type="doi">10.1158/2159-8290.CD-22-0244</article-id>
    <article-version id="ver1" article-version-type="VoR">Version of Record</article-version>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Research Articles</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Discovery of Targets for Immune–Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha</article-title>
      <alt-title alt-title-type="short">Discovery of Immune–Metabolic Drug Targets</alt-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" corresp="yes" equal-contrib="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2193-6276</contrib-id>
        <name>
          <surname>Sahu</surname>
          <given-names>Avinash</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
        <xref rid="aff2" ref-type="aff">2</xref>
        <xref rid="num1" ref-type="author-notes">#</xref>
        <xref rid="cor1" ref-type="corresp">*</xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7833-6108</contrib-id>
        <name>
          <surname>Wang</surname>
          <given-names>Xiaoman</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
        <xref rid="aff3" ref-type="aff">3</xref>
        <xref rid="num1" ref-type="author-notes">#</xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1635-3313</contrib-id>
        <name>
          <surname>Munson</surname>
          <given-names>Phillip</given-names>
        </name>
        <xref rid="aff4" ref-type="aff">4</xref>
        <xref rid="num1" ref-type="author-notes">#</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1313-2614</contrib-id>
        <name>
          <surname>Klomp</surname>
          <given-names>Jan P.G.</given-names>
        </name>
        <xref rid="aff5" ref-type="aff">5</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7476-8889</contrib-id>
        <name>
          <surname>Wang</surname>
          <given-names>Xiaoqing</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
        <xref rid="aff6" ref-type="aff">6</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4200-0864</contrib-id>
        <name>
          <surname>Gu</surname>
          <given-names>Shengqing Stan</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1892-4239</contrib-id>
        <name>
          <surname>Han</surname>
          <given-names>Ya</given-names>
        </name>
        <xref rid="aff7" ref-type="aff">7</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5068-0399</contrib-id>
        <name>
          <surname>Qian</surname>
          <given-names>Gege</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8526-5889</contrib-id>
        <name>
          <surname>Nicol</surname>
          <given-names>Phillip</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3905-3244</contrib-id>
        <name>
          <surname>Zeng</surname>
          <given-names>Zexian</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7573-3768</contrib-id>
        <name>
          <surname>Wang</surname>
          <given-names>Chenfei</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1395-5378</contrib-id>
        <name>
          <surname>Tokheim</surname>
          <given-names>Collin</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2233-299X</contrib-id>
        <name>
          <surname>Zhang</surname>
          <given-names>Wubing</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4028-3661</contrib-id>
        <name>
          <surname>Fu</surname>
          <given-names>Jingxin</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4785-0403</contrib-id>
        <name>
          <surname>Wang</surname>
          <given-names>Jin</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8832-0329</contrib-id>
        <name>
          <surname>Nair</surname>
          <given-names>Nishanth Ulhas</given-names>
        </name>
        <xref rid="aff8" ref-type="aff">8</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5737-9088</contrib-id>
        <name>
          <surname>Rens</surname>
          <given-names>Joost A.P.</given-names>
        </name>
        <xref rid="aff5" ref-type="aff">5</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6029-1028</contrib-id>
        <name>
          <surname>Bourajjaj</surname>
          <given-names>Meriem</given-names>
        </name>
        <xref rid="aff5" ref-type="aff">5</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5985-7656</contrib-id>
        <name>
          <surname>Jansen</surname>
          <given-names>Bas</given-names>
        </name>
        <xref rid="aff5" ref-type="aff">5</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6030-0641</contrib-id>
        <name>
          <surname>Leenders</surname>
          <given-names>Inge</given-names>
        </name>
        <xref rid="aff5" ref-type="aff">5</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1760-3329</contrib-id>
        <name>
          <surname>Lemmers</surname>
          <given-names>Jaap</given-names>
        </name>
        <xref rid="aff5" ref-type="aff">5</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9801-7334</contrib-id>
        <name>
          <surname>Musters</surname>
          <given-names>Mark</given-names>
        </name>
        <xref rid="aff5" ref-type="aff">5</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9819-5218</contrib-id>
        <name>
          <surname>van Zanten</surname>
          <given-names>Sanne</given-names>
        </name>
        <xref rid="aff5" ref-type="aff">5</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0094-8892</contrib-id>
        <name>
          <surname>van Zelst</surname>
          <given-names>Laura</given-names>
        </name>
        <xref rid="aff5" ref-type="aff">5</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0442-0371</contrib-id>
        <name>
          <surname>Worthington</surname>
          <given-names>Jenny</given-names>
        </name>
        <xref rid="aff9" ref-type="aff">9</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4450-7239</contrib-id>
        <name>
          <surname>Liu</surname>
          <given-names>Jun S.</given-names>
        </name>
        <xref rid="aff10" ref-type="aff">10</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2983-7704</contrib-id>
        <name>
          <surname>Juric</surname>
          <given-names>Dejan</given-names>
        </name>
        <xref rid="aff4" ref-type="aff">4</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8321-2839</contrib-id>
        <name>
          <surname>Meyer</surname>
          <given-names>Clifford A.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6765-9246</contrib-id>
        <name>
          <surname>Oubrie</surname>
          <given-names>Arthur</given-names>
        </name>
        <xref rid="aff5" ref-type="aff">5</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4736-7339</contrib-id>
        <name>
          <surname>Liu</surname>
          <given-names>X. Shirley</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5506-0575</contrib-id>
        <name>
          <surname>Fisher</surname>
          <given-names>David E.</given-names>
        </name>
        <xref rid="aff4" ref-type="aff">4</xref>
        <xref rid="aff11" ref-type="aff">11</xref>
        <xref rid="cor1" ref-type="corresp">*</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3402-0478</contrib-id>
        <name>
          <surname>Flaherty</surname>
          <given-names>Keith T.</given-names>
        </name>
        <xref rid="aff4" ref-type="aff">4</xref>
        <xref rid="cor1" ref-type="corresp">*</xref>
      </contrib>
    </contrib-group>
    <aff id="aff1"><label>1</label>Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.</aff>
    <aff id="aff2"><label>2</label>Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, Colorado.</aff>
    <aff id="aff3"><label>3</label>State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</aff>
    <aff id="aff4"><label>4</label>Department of Medicine and Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.</aff>
    <aff id="aff5"><label>5</label>Lead Pharma, Kloosterstraat, Oss, the Netherlands.</aff>
    <aff id="aff6"><label>6</label>Department of Cardiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.</aff>
    <aff id="aff7"><label>7</label>School of Life Sciences and Technology, Tongji University, Shanghai, China.</aff>
    <aff id="aff8"><label>8</label>Cancer Data Science Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.</aff>
    <aff id="aff9"><label>9</label>Axis Bioservices, Coleraine, United Kingdom.</aff>
    <aff id="aff10"><label>10</label>Department of Statistics, Harvard University, Cambridge, Massachusetts.</aff>
    <aff id="aff11"><label>11</label>Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.</aff>
    <author-notes>
      <fn fn-type="equal" id="num1">
        <label>#</label>
        <p><bold>Note:</bold> A. Sahu, X. Wang, and P. Munson contributed equally to this article.</p>
      </fn>
      <corresp id="cor1"><label>*</label><bold>Corresponding Authors:</bold> Keith T. Flaherty, Developmental Therapeutics, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114. Phone: 617-724-4000; E-mail: <email>kflaherty@mgh.harvard.edu</email>; David E. Fisher, Charlestown Navy Yard Building 149, 149 13th Street, Charlestown, MA 02129. Phone: 617-643-5428; E-mail: <email>dfisher3@mgh.harvard.edu</email>; and Avinash Sahu, Department of Data Sciences, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115. Phone: 240-391-8125; E-mail: <email>asahu@ds.dfci.harvard.edu</email></corresp>
      <fn fn-type="other">
        <p>Cancer Discov 2023;13:672–701</p>
      </fn>
    </author-notes>
    <pub-date pub-type="ppub" iso-8601-date="2023-03-01">
      <day>01</day>
      <month>3</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2023-02-06">
      <day>06</day>
      <month>2</month>
      <year>2023</year>
    </pub-date>
    <volume>13</volume>
    <issue>3</issue>
    <fpage>672</fpage>
    <lpage>701</lpage>
    <history>
      <date date-type="received" iso-8601-date="2022-03-02">
        <day>02</day>
        <month>3</month>
        <year>2022</year>
      </date>
      <date date-type="rev-recd" iso-8601-date="2022-09-13">
        <day>13</day>
        <month>9</month>
        <year>2022</year>
      </date>
      <date date-type="accepted" iso-8601-date="2022-11-23">
        <day>23</day>
        <month>11</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>©2023 The Authors; Published by the American Association for Cancer Research</copyright-statement>
      <copyright-year>2023</copyright-year>
      <copyright-holder>American Association for Cancer Research</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
        <license-p>This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="672.pdf"/>
    <related-article related-article-type="commentary" ext-link-type="doi" id="ra2" xlink:href="10.1158/2159-8290.CD-13-3-ITI" journal-id="2159-8274" journal-id-type="issn"/>
    <abstract abstract-type="teaser">
      <p>The computational tool BipotentR was used to reveal drug targets that can inhibit tumor growth by concurrent immune activation and inhibition of a separate oncogenic pathway, leading to identification of ESRRA as a top immune–metabolic target.</p>
    </abstract>
    <abstract>
      <title>Abstract</title>
      <p>Drugs that kill tumors through multiple mechanisms have the potential for broad clinical benefits. Here, we first developed an <italic toggle="yes">in silico</italic> multiomics approach (BipotentR) to find cancer cell–specific regulators that simultaneously modulate tumor immunity and another oncogenic pathway and then used it to identify 38 candidate immune–metabolic regulators. We show the tumor activities of these regulators stratify patients with melanoma by their response to anti–PD-1 using machine learning and deep neural approaches, which improve the predictive power of current biomarkers. The topmost identified regulator, ESRRA, is activated in immunotherapy-resistant tumors. Its inhibition killed tumors by suppressing energy metabolism and activating two immune mechanisms: (i) cytokine induction, causing proinflammatory macrophage polarization, and (ii) antigen-presentation stimulation, recruiting CD8<sup>+</sup> T cells into tumors. We also demonstrate a wide utility of BipotentR by applying it to angiogenesis and growth suppressor evasion pathways. BipotentR (<ext-link xlink:href="http://bipotentr.dfci.harvard.edu/" ext-link-type="uri" xlink:show="new">http://bipotentr.dfci.harvard.edu/</ext-link>) provides a resource for evaluating patient response and discovering drug targets that act simultaneously through multiple mechanisms.</p>
      <sec>
        <title>Significance:</title>
        <p>BipotentR presents resources for evaluating patient response and identifying targets for drugs that can kill tumors through multiple mechanisms concurrently. Inhibition of the topmost candidate target killed tumors by suppressing energy metabolism and effects on two immune mechanisms.</p>
        <p>
          <ext-link xlink:href="https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-13-3-ITI" ext-link-type="uri" xlink:show="new">This article is highlighted in the In This Issue feature, p. 517</ext-link>
        </p>
      </sec>
    </abstract>
    <funding-group>
      <award-group id="funding-1">
        <funding-source>
          <institution-wrap>
            <institution>Damon Runyon Cancer Research Foundation (DRCRF)</institution>
            <institution-id>https://doi.org/10.13039/100001021</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>DRQ-04-20</award-id>
        <principal-award-recipient>
          <name>
            <surname>Tokheim</surname>
            <given-names>C.</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group id="funding-2">
        <funding-source>
          <institution-wrap>
            <institution>National Cancer Institute (NCI)</institution>
            <institution-id>https://doi.org/10.13039/100000054</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>R01AR072304</award-id>
        <award-id>R01AR043369</award-id>
        <award-id>P01CA163222</award-id>
        <award-id>R01CA222871</award-id>
        <principal-award-recipient>
          <name>
            <surname>Fisher</surname>
            <given-names>D.E.</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group id="funding-3">
        <funding-source>
          <institution-wrap>
            <institution>Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF)</institution>
            <institution-id>https://doi.org/10.13039/100005984</institution-id>
          </institution-wrap>
        </funding-source>
        <principal-award-recipient>
          <name>
            <surname>Fisher</surname>
            <given-names>D.E.</given-names>
          </name>
          <name>
            <surname>Flaherty</surname>
            <given-names>K.T.</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group id="funding-4">
        <funding-source>
          <institution-wrap>
            <institution>China Scholarship Council (CSC)</institution>
            <institution-id>https://doi.org/10.13039/501100004543</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>201806210422</award-id>
        <principal-award-recipient>
          <name>
            <surname>Wang</surname>
            <given-names>X.</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group id="funding-5">
        <funding-source>
          <institution-wrap>
            <institution>National Cancer Institute (NCI)</institution>
            <institution-id>https://doi.org/10.13039/100000054</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>Intramural research program</award-id>
        <principal-award-recipient>
          <name>
            <surname>Nair</surname>
            <given-names>N.U.</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group id="funding-6">
        <funding-source>
          <institution-wrap>
            <institution>Eurostars (Eureka)</institution>
            <institution-id>https://doi.org/10.13039/100013297</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>PREVAIL 11590</award-id>
        <principal-award-recipient>
          <name>
            <surname>Klomp</surname>
            <given-names>J.P.</given-names>
          </name>
          <name>
            <surname>Rens</surname>
            <given-names>J.A.</given-names>
          </name>
          <name>
            <surname>Bourajjaj</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Jansen</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Leenders</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Lemmers</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Musters</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Zanten</surname>
            <given-names>S.v.</given-names>
          </name>
          <name>
            <surname>Zelst</surname>
            <given-names>L.v.</given-names>
          </name>
          <name>
            <surname>Oubrie</surname>
            <given-names>A.</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group id="funding-7">
        <funding-source>
          <institution-wrap>
            <institution>National Cancer Institute (NCI)</institution>
            <institution-id>https://doi.org/10.13039/100000054</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>K99CA248953</award-id>
        <principal-award-recipient>
          <name>
            <surname>Sahu</surname>
            <given-names>A.</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group id="funding-8">
        <funding-source>
          <institution-wrap>
            <institution>Human Vaccines Project (HVP)</institution>
            <institution-id>https://doi.org/10.13039/100018183</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>MP19-02-190</award-id>
        <principal-award-recipient>
          <name>
            <surname>Sahu</surname>
            <given-names>A.</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="30"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="sec1">
    <title>INTRODUCTION</title>
    <p>Cancer treatments designed to target two or more oncogenic pathways simultaneously often provide greater clinical benefits, with the advantage of being effective in distinct clinical populations (<xref rid="bib1" ref-type="bibr">1, 2</xref>). Such treatments can be designed by either combining multiple drugs or administering a single-agent drug that affects two pathways (bipotent drug). Medicating patients with combinations of multiple drugs is now a common strategy but raises patients’ risk to undesired drug interactions and adverse events such as liver injury (<xref rid="bib3" ref-type="bibr">3</xref>) and colitis (<xref rid="bib4" ref-type="bibr">4</xref>).</p>
    <p>Bipotent drugs may provide benefits similar to drug combinations without the complications that accompany combining multiple drugs. Few drugs are known to be bipotent. Most notable are CDK4/6 inhibitors (cell-cycle inhibitor and immunomodulatory; ref. <xref rid="bib5" ref-type="bibr">5</xref>), immunomodulatory imide drugs (IMiD; antiangiogenic and immunomodulatory; ref. <xref rid="bib6" ref-type="bibr">6</xref>), and itaconate (energy metabolism and immunity; ref. <xref rid="bib7" ref-type="bibr">7</xref>). Likewise, few bipotent gene regulators have been identified, with examples including HDAC6 (<xref rid="bib8" ref-type="bibr">8</xref>), CDC7 (<xref rid="bib1" ref-type="bibr">1</xref>), and PTPN3 (<xref rid="bib9" ref-type="bibr">9</xref>). Bipotent gene targets may be relatively common but undiscovered, with their clinical impact yet to be fully realized due to the lack of systematic approaches to identify them.</p>
    <p>The problem of identifying bipotent regulators of multiple pathways relates to a broader problem of inferring regulators of a single pathway, for which a few algorithms have been recently developed. BartWeb (<xref rid="bib10" ref-type="bibr">10</xref>) infers likely transcription factor or chromatin regulators (TFCR) of an input gene set by leveraging 13,000 chromatin immunoprecipitation sequencing (ChIP-seq) datasets. RePhine (<xref rid="bib11" ref-type="bibr">11</xref>) uses regression to ascertain TFCRs underlying response or resistance to an input drug. We previously developed eQTeL (<xref rid="bib12" ref-type="bibr">12</xref>), a Bayesian multiomics approach, to find regulators of variation of gene transcription within a population. We also recently developed LISA (<xref rid="bib13" ref-type="bibr">13</xref>), which predicts regulators directly responsible for an input gene set, but the input gene sets should be from differential expression or coregulation analyses. Another limitation of existing approaches is that they cannot handle sample-specific confounding effects of ChIP-seq data. Building on these approaches, we present BipotentR, a computational multiomics method for identifying genes that can simultaneously inhibit tumor growth by activating the immune system and suppressing another oncogenic pathway, such as angiogenesis, growth suppressor evasion, metastasis, immortality, or cancer's energy metabolism (<xref rid="bib14" ref-type="bibr">14</xref>).</p>
    <p>Tumors alter their energy metabolism to meet higher bioenergetic needs and sustain proliferation (<xref rid="bib14" ref-type="bibr">14</xref>). As a result, they become so dependent on energy metabolism (<xref rid="bib15" ref-type="bibr">15, 16</xref>) that targeting oncogenic energy metabolism can inhibit their proliferation (<xref rid="bib17" ref-type="bibr">17, 18</xref>). Oncogenic energy metabolism also helps cancer cells evade anticancer immunity (<xref rid="bib19" ref-type="bibr">19, 20</xref>). For example, increased glucose uptake by cancer cells (the Warburg effect) limits glucose availability for effector T cells in tumors (<xref rid="bib21" ref-type="bibr">21</xref>), which dampens immunity (<xref rid="bib22" ref-type="bibr">22</xref>). Thus, targeting energy metabolism can kill tumors directly (<xref rid="bib23" ref-type="bibr">23, 24</xref>) or through immune-mediated mechanisms (<xref rid="bib25" ref-type="bibr">25</xref>). This has led to the emergence of the immunometabolism field (<xref rid="bib19" ref-type="bibr">19</xref>) and several techniques, including single-cell, cytometry-based, multiomics, and genome-scale modeling approaches, for studying immunometabolism (<xref rid="bib26" ref-type="bibr">26</xref>). These approaches are almost exclusively focused on the metabolism of immune cells. Complementing these approaches, here we focused on finding targets that regulate metabolism of cancer cells that nonautonomously affect immune cells in tumors.</p>
    <p>BipotentR identified 38 immune–metabolic targets, whose knockouts induced metabolic and immune phenotypes. <italic toggle="yes">In vitro</italic> and <italic toggle="yes">in vivo</italic> inhibitions of the topmost-ranked candidate, ESRRA, elicited dual anticancer effects, and the inhibition is safe <italic toggle="yes">in vivo.</italic> Artificial intelligence and machine learning (AI/ML) techniques were then used to show that the activity of bipotent targets in tumors predicts the outcome of melanoma patients to anti–PD-1 treatment. Finally, the broad utility of BipotentR for applications beyond immunometabolism was demonstrated by applying it to angiogenesis and evasion of growth suppressor pathways. BipotentR enables the discovery of new cancer therapies by applying prior regulatory and immunologic knowledge to large bulk and single-cell omics data.</p>
  </sec>
  <sec sec-type="results" id="sec2">
    <title>RESULTS</title>
    <sec id="sec2-1">
      <title>Overview of BipotentR, an Approach to Identify Bipotent Targets</title>
      <p>BipotentR consists of two modules: “regulator” and “immune” (<xref rid="fig1" ref-type="fig">Fig. 1A</xref>). The regulator module predicts regulators of the input pathway(s) chosen by the user, whereas the “immune” module identifies immunomodulatory TFCRs (Methods). To infer bipotent regulators of energy metabolism and immune response (“immune–metabolic” regulators) from the regulator module, we inputted four energy metabolism pathways with a reported role in immunity (<xref rid="bib27" ref-type="bibr">27–32</xref>): glycolysis, oxidative phosphorylation (OXPHOS), tricarboxylic acid cycle (TCA cycle), and fatty acid (FA) metabolism. The regulator module estimates the potential of ∼700 individual TFCRs to bind <italic toggle="yes">cis</italic>-elements near input pathway genes by mining 24,000 ChIP-seq samples (<xref rid="bib33" ref-type="bibr">33, 34</xref>). For a given TFCR, BipotentR derives its core binding sites by combining all ChIP-seq samples and then estimates its binding potential while controlling for sample-specific confounding effects using a linear mixed model (Methods). BipotentR identified previously known [e.g., ESRRA and BCL3 regulate OXPHOS (<xref rid="bib35" ref-type="bibr">35, 36</xref>); PPARG and CEBPB regulate FA and glycolysis (<xref rid="bib37" ref-type="bibr">37, 38</xref>)] and new TFCRs for each pathway (<xref rid="fig1" ref-type="fig">Fig. 1B</xref>; Supplementary Table S1). It then prioritized the subset of these regulators that can affect multiple energy metabolism pathways (“master regulators”) by ranking TFCRs according to their average overall binding affinities across pathways. Master regulators were enriched in nuclear receptors (<italic toggle="yes">P</italic> &lt; 1E−7; <xref rid="fig1" ref-type="fig">Fig. 1C</xref>).</p>
      <fig position="float" id="fig1">
        <label>Figure 1.</label>
        <caption>
          <p>Identification of immune–metabolic regulators. <bold>A,</bold> Overall schematic of regulation and immune modules of BipotentR. The regulator module identifies regulators of an input pathway using ChIP-seq data. The immune module identifies TFCRs that show immunostimulatory or immunosuppressive properties in bulk tumor transcriptomes and are preferentially active in cancer cells (using single-cell tumor transcriptomes). <bold>B,</bold> Output of BipotentR regulator module. Potential and significance of regulators to bind <italic toggle="yes">cis</italic>-regulatory elements of genes in four energy metabolism pathways. Each dot indicates a regulator, colored by individual pathways. OXPHOS, oxidative phosphorylation; TCA, tricarboxylic acid cycle. <bold>C,</bold> The potential of top predicted master regulators to bind energy metabolism genes. Nuclear receptors are displayed in red. <bold>D,</bold> TFCRs with positive (or negative) associations with proinflammatory signatures are predicted immunostimulators (purple; or immunosuppressors, orange). <bold>E,</bold> Top TFCRs predicted to be preferentially active in cancer cells (orange; or CD8<sup>+</sup> T cells, purple) and their differential activity (estimated from single-cell data). <bold>F,</bold> Output of BipotentR immune module: combined association with proinflammatory signatures (<bold>D</bold>, estimate from bulk RNA-seq) and differential activity in cancer cells (<bold>E,</bold> estimate from single-cell data) are displayed for each TFCR. <bold>G,</bold> Immune–metabolic regulators identified by BipotentR. Energy regulatory potential (estimated by regulator module) and immune-modulatory potential (estimated by immune module) of TFCRs. Highlighted TFCRs are significant and among the top 15% in both modules. Immunostimulators (purple) and immunosuppressors (orange) are colored. <bold>H,</bold> Validation of BipotentR-identified targets. Effect of knockout (KO) of target identified by BipotentR on T cell–mediated killing of cancer cells.</p>
        </caption>
        <alt-text>Figure 1. Identification of immune-metabolic regulators. Abbreviations: TFCR, transcription factor and chromatin regulator; RP, regulatory potential of TFCR; TCA, tricarboxylic acid cycle; OXPHOS, oxidative phosphorylation. A, Overall schematic of regulation and immune modules of BipotentR. The regulator module identifies regulators of an input pathway using ChIP-seq data. The immune module identifies TFCRs that show immunostimulatory or immunosuppressive properties in bulk tumor transcriptomes, and are preferentially active in cancer cells (using single-cell tumor transcriptomes). B, Output of BipotentR regulator module. Potential and significance of regulators to bind cis-regulatory elements of genes in four energy metabolism pathways. Each dot indicates a regulator, colored by individual pathways. C, The potential of top predicted master regulators to bind energy metabolism genes. Nuclear receptors are displayed in red. D, TFCRs with positive (or negative) associations with proinflammatory signatures are predicted immunostimulators (purple; or immunosuppressors, orange). E, Top TFCRs predicted to be preferentially active in cancer cells (orange; or CD8+ T cells, purple) and their differential activity (estimated from single-cell data). F, Output of BipotentR immune module: combined association with proinflammatory signatures (D, estimate from bulk RNA-seq) and differential activity in cancer cells (E, estimate from single-cell data) are displayed for each TFCR. G, Immune-metabolic regulators identified by BipotentR. Energy regulatory potentials (estimated by regulator module) and immune-modulatory potentials (estimated by immune module) of TFCRs. Highlighted TFCRs are significant and among the top 15% in both modules. Immunostimulators (purple) and immunosuppressors (orange) are colored. H, Validation of BipotentR-identified targets. Effect of knockout of target identified by BipotentR on T-cell–mediated killing of cancer cells.</alt-text>
        <graphic xlink:href="672fig1" position="float"/>
      </fig>
      <p>Having identified regulators of energy metabolism, we next used the immune module of BipotentR to identify immunomodulatory TFCRs. This module estimates the immunomodulatory potential of ∼700 individual TFCRs from bulk RNA sequencing (RNA-seq) patient tumor data by associating TFCR expression in tumors with levels of a proinflammatory signature. The proinflammatory signature combines 32 key immune response biomarkers, such as mutation burden, neoantigen load, immune infiltration, and IFNγ response (ref. <xref rid="bib39" ref-type="bibr">39</xref>; Methods). TFCR immunomodulatory potential was estimated across several cancer types using a linear mixed model that is robust to cancer type–specific immune effects (Supplementary Fig. S1A and S1B) using data from The Cancer Genome Atlas (TCGA; 33 cancer types from 11,000 patients; ref. <xref rid="bib39" ref-type="bibr">39</xref>). We evaluated the robustness of immune-module outputs in two datasets comprising nonoverlapping cancer types (akin to 2-fold cross-validation; Methods). The results suggest that inferred TFCRs likely show immunomodulatory properties in several cancer types (<italic toggle="yes">R</italic> = 0.91, <italic toggle="yes">P</italic> &lt; 2.2E−16; Supplementary Fig. S1C). TFCRs with the highest inferred immune potential were enriched in immune ontologies, including T-helper differentiation, inflammatory disorders, and viral infection, in addition to carcinogenesis and transcriptional misregulation in cancer (<xref rid="fig1" ref-type="fig">Fig. 1D</xref>; Supplementary Fig. S1D). The module predicted well-known regulators of adaptive and innate immunity based on the input signature that was used, in this case, the proinflammatory signature. By changing the input signature, the module can be used to predict regulators of specific immune cells. For example, the module identified macrophage regulators using a macrophage polarization signature as input (Supplementary Note S1).</p>
      <p>The immune module also selects candidate TFCRs whose inhibition likely blocks cancer cells without adversely affecting CD8<sup>+</sup> T cells, which are essential for antitumor immunity (<xref rid="bib40" ref-type="bibr">40</xref>). We achieve this by selecting TFCRs that are present and active in cancer cells but not in CD8<sup>+</sup> T cells using single-cell RNA-seq (scRNA-seq) and single-cell assay for transposase-accessible chromatin using sequencing (scATAC-seq) data. TFCRs are deemed cancer cell–specific if they are differentially active in cancer cells relative to CD8<sup>+</sup> T cells across all five scRNA-seq cohorts (refs. <xref rid="bib41" ref-type="bibr">41–45</xref>; Methods). The module uses scATAC-seq data (<xref rid="bib46" ref-type="bibr">46</xref>) to ensure these TFCRs are functional in cancer cells but not in CD8<sup>+</sup> T cells. To this end, we examined if target genes (inferred by ChIP-seq) of predicted TFCRs are epigenetically accessible in cancer cells (Methods). We found that target accessibility differences between cancer cells and CD8<sup>+</sup> T cells were markedly correlated with scRNA-seq expression differences (Pearson correlation = 0.63, <italic toggle="yes">P</italic> &lt; 2E−59; Supplementary Fig. S1E), suggesting that predicted TFCRs are active and transcriptionally functional in cancer cells relative to CD8<sup>+</sup> T cells. The top predicted TFCRs included <italic toggle="yes">SUMO1, SUMO2</italic>, and <italic toggle="yes">DLX2</italic>, genes known to be tumorigenic and highly active in several cancers (<xref rid="fig1" ref-type="fig">Fig. 1E</xref>; refs. <xref rid="bib47" ref-type="bibr">47–49</xref>).</p>
      <p>We next investigated how cancer cell activities of TFCRs (predicted from single-cell data) relate to their immunomodulatory potential (predicted from bulk tumor data). Strikingly, predicted immunosuppressive TFCRs were preferentially active in cancer cells, and immunostimulatory TFCRs were active in CD8<sup>+</sup> T cells, evident from a strong Pearson correlation of 0.7 (<italic toggle="yes">P</italic> &lt; 2E−82) between immunosuppressive potential and cancer-cell activity (<xref rid="fig1" ref-type="fig">Fig. 1F</xref>). Thus, inhibiting immunosuppressive TFCRs would likely impact cancer cells but less likely impact CD8<sup>+</sup> T cells adversely.</p>
    </sec>
    <sec id="sec2-2">
      <title>Inhibition of the 38 Candidate Bipotent Immune–Metabolic Regulators Elicits Metabolic and Immune Effects</title>
      <p>With the two modules developed and validated, we integrated their outputs to identify 38 TFCRs (30 immunosuppressive and 8 immunostimulatory) with immune–metabolic dual functions (<xref rid="fig1" ref-type="fig">Fig. 1G</xref>; Supplementary Table S2). Among these were known immune–metabolic TFCRs such as CDK7, which regulates mitochondrial membrane potential (<xref rid="bib50" ref-type="bibr">50</xref>) and enhances immune suppression (<xref rid="bib51" ref-type="bibr">51</xref>), and NFATC1, which regulates energy consumption and CD8<sup>+</sup> T-cell effector function (<xref rid="bib52" ref-type="bibr">52, 53</xref>).</p>
      <p>First, we compared how well genetic inhibition of the 38 identified immune–metabolic regulators suppressed transcription of genes in energy metabolism pathways using a published transcriptome dataset comprised of 570 knockdown/knockout experiments for 308 TFCRs (<xref rid="bib54" ref-type="bibr">54</xref>). We found that inhibition of BipotentR-predicted regulators markedly suppressed energy metabolism pathways (Supplementary Fig. S2A; <italic toggle="yes">P</italic> &lt; 3.5E−25). Further, inhibition of BipotentR-predicted regulators suppressed energy genes more strongly than other TFCRs (Supplementary Fig. S2B; <italic toggle="yes">P</italic> &lt; 7.8E−10), indicating preferential regulation of energy metabolism by the identified TFCRs. We benchmarked BipotentR against recently published regulator prediction algorithms (<xref rid="bib10" ref-type="bibr">10, 13</xref>). We observed that BipotentR-identified regulators (<italic toggle="yes">n</italic> = 38) held six TFCRs in common with LISA-identified regulators (<italic toggle="yes">n</italic> = 38, Fisher exact test <italic toggle="yes">P</italic> &lt; 4E−4, Methods). Despite the overlap, inhibitions of BipotentR-identified regulators suppressed energy genes more strongly than those by LISA-identified regulators (Wilcoxon test <italic toggle="yes">P</italic> &lt; 1.5E−12; Supplementary Fig. S2C). This and a similar benchmark obtained against BartWeb (Supplementary Fig. S2D; Supplementary Note 2) suggest that BipotentR predicts functional regulators of energy metabolism as accurately as existing approaches.</p>
      <p>We next confirmed that inhibition of the identified TFCRs also regulates immunity. We examined a recently published CRISPR screen (<xref rid="bib55" ref-type="bibr">55</xref>) in which cancer cells were subjected to selection by effector T cells to identify gene knockouts that modulate T cell–mediated killing. CRISPR guide RNAs (gRNA) that knock out BipotentR-predicted immunosuppressive TFCRs were depleted (<xref rid="fig1" ref-type="fig">Fig. 1H</xref>; Supplementary Fig. S2E; <italic toggle="yes">P</italic> &lt; 8E−10, <italic toggle="yes">n</italic> = 240 and <italic toggle="yes">n</italic> = 79,481), suggesting that their knockout enhances T cell–mediated killing. In contrast, gRNAs against BipotentR-predicted immunostimulatory TFCRs were enriched, indicating their knockout decreases T cell–mediated killing (<xref rid="fig1" ref-type="fig">Fig. 1H</xref>; Supplementary Fig. S2E; <italic toggle="yes">P</italic> &lt; 1E−3, <italic toggle="yes">n</italic> = 64 and <italic toggle="yes">n</italic> = 79,481). Thus, genetic inhibition of immune–metabolic regulators elicited both immune and metabolic effects.</p>
    </sec>
    <sec id="sec2-3">
      <title>Among 38 Candidate Bipotent Immune–Metabolic Regulator Targets, the Orphan Nuclear Receptor ESRRA Is the Most Highly Ranked</title>
      <p>Having evaluated the set of identified bipotent immune–metabolic regulators, we followed up on the topmost bipotent target. An orphan nuclear receptor, ESRRA, was predicted to have the highest immune–metabolic potential. Targeting ESRRA in immunodeficient models has been shown to inhibit tumors by direct cell-intrinsic mechanisms (<xref rid="bib35" ref-type="bibr">35, 56</xref>), and we hypothesized that targeting ESRRA would also inhibit tumors by immune-mediated mechanisms. To illustrate a proof-of-principle bipotent target, we determined the dual potential and clinical relevance of ESRRA in different cancer types.</p>
    </sec>
    <sec id="sec2-4">
      <title>Inhibition of ESRRA Stimulates Antitumor Immunity</title>
      <p>We evaluated inhibiting ESRRA by small interfering RNA (siRNA) and two structurally similar diaryl ether–based thiazolidinediones, which function as selective ligands against ESRRA (compounds 29 and 39 from Johnson &amp; Johnson, with well-characterized pharmacokinetics; ref. <xref rid="bib57" ref-type="bibr">57</xref>). We first tested both small-molecule inhibitors <italic toggle="yes">in vitro</italic> by mutating the known compound binding site in the ESRRA ligand-binding domain (LBD; C229 site) and showing that the mutation rescued the ESRRA inhibition (Supplementary Fig. S2F and S2G). Next, we investigated siRNA and compound 39 for on-target and off-target effects through RNA-seq (Methods). Both approaches selectively suppressed putative ESRRA gene targets that had been identified from ESRRA ChIP-seq data (Supplementary Fig. S2H). An unbiased prediction of 700 putative regulators of the genes differentially expressed upon the two approaches (<xref rid="bib13" ref-type="bibr">13</xref>) yielded ESRRA as the top regulator of downregulated genes (topmost for drug inhibition, Supplementary Fig. S2I; second highest for siRNA, Supplementary Fig. S2J). These analyses showed that both siRNA and drug inhibition selectively suppress ESRRA and have limited off-target effects. We chose to pursue drug inhibition of ESRRA (“ESRRAi,” which refers to inhibition by compound 29 or compound 39) because of its translational potential and somewhat superior potency in targeting ESRRA. Compound 29 is more stable metabolically in human microsomes than compound 39 (<xref rid="bib57" ref-type="bibr">57</xref>), so we used compound 29 for <italic toggle="yes">in vivo</italic> testing (Methods).</p>
      <p>We next tested if ESRRAi could induce antitumor immunity in two immunosuppressive murine tumor models: 4T1 (triple-negative breast cancer) and B16F10 (melanoma). We treated the 4T1 mice with ESRRAi or vehicle control and surgically resected their tumors. We performed scRNA-seq of CD45<sup>+</sup> cells sorted from tumors, clustered and annotated cells using classic markers, and identified major tumor-infiltrating immune cells in both conditions (<xref rid="fig2" ref-type="fig">Fig. 2A</xref>; Methods). ESRRA was not expressed in CD45<sup>+</sup> cells (Supplementary Fig. S2K). We initially studied immune cells of lymphoid lineage for changes in their fraction by ESRRAi treatment and found higher CD8<sup>+</sup> T-cell infiltration with the treatment (Supplementary Fig. S2L). A CD8<sup>+</sup> T-cell marker, <italic toggle="yes">Cd8a</italic>, was the topmost upregulated gene in the lymphoid lineage of ESRRAi-treated tumors compared with controls (<xref rid="fig2" ref-type="fig">Fig. 2B</xref>). Markers of activated CD8<sup>+</sup> T cells (<xref rid="fig2" ref-type="fig">Fig. 2B</xref>), including perforin and granzymes, were also upregulated (<italic toggle="yes">P</italic> &lt; 3E−5; permutation test), suggesting that infiltrating CD8<sup>+</sup> T cells in treated tumors were also activated. We also showed increased infiltration of activated CD8<sup>+</sup> T cells with ESRRAi in tumors (<italic toggle="yes">P</italic> &lt; 2E−3) using fluorescence-activated single-cell sorting (FACS; <xref rid="fig2" ref-type="fig">Fig. 2C</xref>). We also analyzed published tumor transcriptomes from 33,000 patients (<xref rid="bib58" ref-type="bibr">58</xref>) and showed that tumors with the highest levels of immune infiltration, including CD8<sup>+</sup> T-cell infiltration, had the lowest ESRRA activity, whereas CD8<sup>+</sup> T cell–deficient (or immune-deficient) tumors showed the highest ESRRA activity in multiple cancer cohorts and cancer types (Supplementary Notes S3 and S4). This suggests that T-cell infiltration upon ESRRAi may be clinically relevant in multiple cancer types.</p>
      <fig position="float" id="fig2">
        <label>Figure 2.</label>
        <caption>
          <p>ESRRA inhibition activates antitumor immunity in 4T1 mice. <italic toggle="yes">P</italic> values using Wilcoxon rank-sum test unless stated otherwise. <bold>A,</bold> Uniform manifold approximation and projection (UMAP) display of scRNA-seq of tumor-infiltrating CD45<sup>+</sup> cells from ESRRAi- and vehicle-treated mice. NK, natural killer; Treg, regulatory T cell. <bold>B,</bold> Markers of activated CD8<sup>+</sup> T cells in genes differentially expressed by ESRRAi in lymphoid cells from treated mice. Significance of up/downregulation of marker sets estimated using permutation tests. <bold>C,</bold> Fraction of CD8<sup>+</sup> T cells identified by flow cytometry. <bold>D,</bold> Tumor volume comparisons between ESRRAi and control. <bold>E,</bold> Tumor volume comparisons between ESRRAi with and without CD8 antibody. <bold>F,</bold> Markers of Tregs in genes differentially expressed by ESRRAi in lymphoid cells from treated mice. Significance of up/downregulation of marker sets estimated using permutation tests. <bold>G,</bold> Fraction of Tregs identified by flow cytometry. <bold>H,</bold> Densities of macrophage polarization toward M1 (i.e., for each macrophage cell, macrophage polarization = average expression of M1 markers − average expression M2 markers); see also Supplementary Fig. S2O and S2P. <bold>I–K,</bold> Measurements done after tumors were surgically removed in ESRRAi- or vehicle-treated mice comparing tumor regrowth rate (i.e., 1—relapse rate; <bold>I</bold>), lung metastasis deposits (<bold>J</bold>), circulating tumor cells in the blood (<bold>K</bold>). PBMC, peripheral blood mononuclear cell. *, <italic toggle="yes">P</italic> &lt; 0.05; **, 0.05 &lt; <italic toggle="yes">P</italic> &lt; 0.01; ***, <italic toggle="yes">P</italic> &lt; 0.001; ns, <italic toggle="yes">P</italic> &gt; 0.05.</p>
        </caption>
        <alt-text>Figure 2. ESRRA inhibition activates antitumor immunity in 4T1 mice. P values using Wilcoxon rank-sum test unless stated otherwise. Tregs, regulatory T cells; ESRRAi, ESRRA inhibitor. A, UMAP display of scRNA-seq of tumor-infiltrating CD45+ cells from ESRRAi and vehicle-treated mice. B, Markers of activated CD8+ T cells in genes differential expressed by ESRRAi in lymphoid cells from treated mice. Significance of up/downregulation of marker sets estimated using permutation tests. C, Fractions of CD8+ T cells identified by flow cytometry. D, Tumor volume comparisons between ESRRAi and control. E, Tumor volume comparisons between ESRRAi with and without CD8 antibody. F, Markers of Tregs in genes differential expressed by ESRRAi in lymphoid cells from treated mice. Significance of up/downregulation of marker sets estimated using permutation tests. G, Fractions of Tregs identified by flow cytometry. H, Densities of macrophage polarization toward M1 (i.e., for each macrophage cell, macrophage polarization = average expression of M1 markers − average expression M2 markers), also see Supplementary Fig. S2O and S2P. I–K, Measurements done after tumors were surgically removed in ESRRAi or vehicle-treated mice comparing: tumor regrowth rate (i.e., 1—relapse rate; I), lung metastasis deposits (J), circulating tumor cells in the blood (K).</alt-text>
        <graphic xlink:href="672fig2" position="float"/>
      </fig>
      <p>Next, we asked if ESRRAi-induced infiltrating CD8<sup>+</sup> T cells exert an antitumor effect and if ESRRAi also modulates regulatory T-cell (Treg) infiltration. ESRRAi treatment markedly reduced tumor growth (<xref rid="fig2" ref-type="fig">Fig. 2D</xref>), which we confirmed in another immune-cold tumor B16F10 mouse model (Supplementary Fig. S2M). Two lines of evidence linked this tumor elimination with CD8<sup>+</sup> T cells. First, among ESRRAi-treated mice, those with higher CD8<sup>+</sup> T infiltration showed superior tumor elimination (Spearman correlation = −0.62; <italic toggle="yes">P</italic> &lt; 0.043; Supplementary Fig. S2N). Second, CD8<sup>+</sup> T-cell depletion abrogated the antitumor effect of ESRRAi (<xref rid="fig2" ref-type="fig">Fig. 2E</xref>; 4T1 tumor growth is shown to be unaltered by CD8<sup>+</sup> T depletion alone; ref. <xref rid="bib59" ref-type="bibr">59</xref>). Another ESRRAi-induced change in the lymphoid lineage was downregulated (<italic toggle="yes">P</italic> &lt; 7E−3; permutation test) markers of Tregs (<xref rid="fig2" ref-type="fig">Fig. 2F</xref>). Correspondingly, lower Treg infiltration in the ESRRAi condition was observed in single-cell data (Supplementary Fig. S2L), which was further confirmed using FACS (<italic toggle="yes">P</italic> &lt; 9E−4; <xref rid="fig2" ref-type="fig">Fig. 2G</xref>), indicating that ESRRAi treatment suppressed Treg infiltration into tumors. These analyses revealed the specific roles of different T-cell populations in ESRRAi antitumor immunity.</p>
      <p>ESRRA-deficient mice in a noncancer context have shown macrophage-mediated inflammation (<xref rid="bib60" ref-type="bibr">60</xref>). Therefore, we postulated that ESRRAi might affect tumor macrophages. Indeed, monocytes/macrophages were polarized toward proinflammatory M1 in the ESRRAi-treated tumors (<xref rid="fig2" ref-type="fig">Fig. 2H</xref>; Supplementary Fig. S2O). In contrast, macrophages were polarized toward protumorigenic M2 in controls (Supplementary Fig. S2P). Moreover, monocytes/macrophages of treated tumors expressed M1 markers (<italic toggle="yes">Tnf, Ccl5, Nos2</italic>, and <italic toggle="yes">Il1a</italic>; ref. <xref rid="bib61" ref-type="bibr">61</xref>) and downregulated M2 markers (Supplementary Fig. S2Q). Consistent with this result, we found that macrophage polarity was markedly correlated with ESRRA activity in tumors across most cancer types in data from 33,000 patients (ref. <xref rid="bib58" ref-type="bibr">58</xref>; Supplementary Fig. S3A; Supplementary Note S3).</p>
      <p>Next, we tested the effect of ESRRAi treatment on tumor relapse from minimal residual disease. After surgical removal of 4T1 tumors, ESRRAi-treated mice experienced significantly fewer tumor relapses (<xref rid="fig2" ref-type="fig">Fig. 2I</xref>). Moreover, their relapsed tumors had significantly attenuated growth (Supplementary Fig. S2R). We examined incised lungs from treated mice and observed fewer lung metastatic deposits than the control group (<xref rid="fig2" ref-type="fig">Fig. 2J</xref>). We also cultured the circulating tumor cells from the blood of treated mice and observed a significant decrease in the number of colonies relative to the control group (<xref rid="fig2" ref-type="fig">Fig. 2K</xref>). These data suggest that ESRRAi can prevent the relapse of surgically resected tumors.</p>
      <p>Similar ESRRAi antitumor responses were observed in the 4T1 model using two delivery formulations, Solutol and PEG (Supplementary Fig. S5A–S5D; Methods). Thus, our data indicate that ESRRAi polarizes macrophages toward M1 and induces antitumor effects that depend on T cells.</p>
    </sec>
    <sec id="sec2-5">
      <title>Immune Signaling Pathways Link ESRRAi to Immune Response</title>
      <p>We next asked what cell-autonomous immune–metabolic pathways underlie ESRRAi antitumor immunity. We treated a human breast cancer cell line (SKBR3) with ESRRAi and measured transcriptomic changes at three time points. ESRRAi suppressed metabolic genes at all time points, particularly energy metabolic pathway genes (<xref rid="fig3" ref-type="fig">Fig. 3A</xref> and <xref rid="fig3" ref-type="fig">B</xref>; Supplementary Fig. S6A and S6B), which we confirmed using siRNA (Supplementary Fig. S6C and S6D).</p>
      <fig position="float" id="fig3">
        <label>Figure 3.</label>
        <caption>
          <p>Signaling induced by ESRRAi <italic toggle="yes">in vitro.</italic><bold>A,</bold> Differentially expressed genes (DEG) between ESRRAi and control in the SKBR3 cell line at three time points. Genes were clustered by K-means. <bold>B,</bold> Pathway enrichment scores corresponding to clusters of DEGs shown in <bold>A</bold>. GSVA, gene set variation analysis. <bold>C,</bold> ESRRA knockout potentiates T-cell killing as observed in CRISPR knockout screens in cancer cells cocultured with T cells. The black line represents the relative position of ESRRA knockout among all gene knockouts ranked from most depleted to least depleted. The significance of ESRRA knockout in screens is also displayed. KO, knockout; SKCM, skin cutaneous melanoma. *, <italic toggle="yes">P</italic> &lt; 0.05; **, 0.05 &lt; <italic toggle="yes">P</italic> &lt; 0.01; ***, <italic toggle="yes">P</italic> &lt; 0.001; ns, <italic toggle="yes">P</italic> &gt; 0.05.</p>
        </caption>
        <alt-text>Figure 3. Signaling induced by ESRRAi in vitro. Abbreviations: GSVA, gene set variation analysis. A, DEGs between ESRRAi and control in the SKBR3 cell line at three-time points. Genes were clustered by K-means. B, Pathway enrichment scores corresponding to clusters of DEGs shown in A. C, ESRRA knockout potentiates T-cell killing as observed in CRISPR knockout screens in cancer cells cocultured with T cells. The black line represents the relative position of ESRRA knockout among all gene knockouts ranked from most depleted to least depleted. The significance of ESRRA knockout in screens is also displayed.</alt-text>
        <graphic xlink:href="672fig3" position="float"/>
      </fig>
      <p>In contrast, the effect on immune pathways showed a striking temporal trend: The treatment upregulated innate immune signaling at 24 hours, whereas at 72 hours, it upregulated adaptive immune signaling (<xref rid="fig3" ref-type="fig">Fig. 3A</xref> and <xref rid="fig3" ref-type="fig">B</xref>). The treatment at 24 hours upregulated (Toll-like, Fc-epsilon-RI, Rig-I–like, and NOD-like receptors) receptor signaling that is known to promote antigen presentation and inflammatory cytokine secretion (<xref rid="bib62" ref-type="bibr">62</xref>). Accordingly, genes involved in antigen presentation (Supplementary Fig. S6E; Fig. 3B) and cytokine interactions, especially macrophage-polarizing cytokines (Supplementary Fig. S6F; Fig. 3B), were upregulated 72 hours after the treatment. This upregulation of macrophage-polarizing cytokines is consistent with macrophage polarization by ESRRAi observed in our <italic toggle="yes">in vivo</italic> single-cell experiments (<xref rid="fig2" ref-type="fig">Fig. 2H</xref>). The ESRRAi treatment also upregulated 20 immunomodulatory TFCRs identified by BipotentR (Supplementary Fig. S6G; Fisher exact test <italic toggle="yes">P</italic> &lt; 4.7E−12), suggesting that ESRRA is an upstream regulator of other immune regulators.</p>
      <p>We next examined if the knockout of ESRRA in cancer cells induces antigen presentation by analyzing data from CRISPR knockout screens (<xref rid="bib63" ref-type="bibr">63–66</xref>) designed to identify regulators of type-I antigen presentation genes (MHC-I). These screens sort cancer cells transduced with gRNA into low or high MHC-I groups based on their MHC-I protein expression. gRNAs that knock out ESRRA were enriched in high MHC-I and depleted in low MHC-I groups (Supplementary Fig. S7A; Supplementary Note S5), confirming that ESRRA knockout increases MHC-I antigen presentation.</p>
      <p>Because increased MHC-I antigen presentation in tumors enhances the ability of T cells to kill cancer cells (<xref rid="bib55" ref-type="bibr">55, 67</xref>), we hypothesized that ESRRAi would enhance tumor killing by T cells. We tested this hypothesis using published CRISPR screens that coculture cancer cells with T cells to identify which gene knockouts in cancer cells enhance their T cell–mediated killing (<xref rid="bib55" ref-type="bibr">55, 68–71</xref>). ESRRA knockout potentiated the killing of cancer cells by both patient-derived and engineered effector T cells in various experimental and cell line contexts (<xref rid="fig3" ref-type="fig">Fig. 3C</xref>). Because T cell–mediated killing has previously been shown to be enhanced by OXPHOS suppression (<xref rid="bib27" ref-type="bibr">27, 55</xref>), we asked if OXPHOS targets of ESRRA (derived from ESRRA ChIP-seq; Methods) can explain this effect. Indeed, knockout of <italic toggle="yes">COX10, ATP51B</italic>, and <italic toggle="yes">NDUFA6</italic> alone not only potentiated T cell–mediated killing (Supplementary Table S3), but also increased protein levels of antigen presentation genes (Supplementary Table S4). Thus, OXPHOS suppression by ESRRAi can explain the activation of antigen presentation and T cell–mediated immunity by ESRRAi.</p>
      <p>Finally, we generated a signature based on differential expression upon ESRRAi. Using this signature, we divided both 33,000 tumors and 1,000 cell lines from the Cancer Cell Line Encyclopedia data (<xref rid="bib72" ref-type="bibr">72</xref>) by high and low ESRRA activity. Cell lines or tumors with low ESRRA activity exhibited decreased energy metabolism and upregulated immune pathways, including antigen presentation genes and cytokines that polarize macrophages to M1 (Supplementary Figs. S3A–S3H, S4A–S4G, and S7A–S7G; see Supplementary Notes S3–S5).</p>
    </sec>
    <sec id="sec2-6">
      <title>ESRRAi Does Not Adversely Affect CD8<sup>+</sup> T Cells</title>
      <p>Targeting tumor energy metabolism by ESRRAi would be detrimental to patients if it also affects T-cell metabolism (<xref rid="bib27" ref-type="bibr">27, 73</xref>). To validate predicted cancer cell specificity for ESRRA, we investigated the likely effects of ESRRAi on T cells and cancer cells. We compiled and analyzed 78 single-cell transcriptome datasets from patients with 27 different major cancer types (refs. <xref rid="bib74" ref-type="bibr">74, 75</xref>; Methods). We found that ESRRA was expressed at the highest levels in cancer cells but also at lower levels in macrophages and T cells (Supplementary Fig. S8A). Because the functional activity of a nuclear receptor depends not only on its expression but also on its ligands, cofactors, and stimulation, we reasoned that ESRRA might have low functional activity in T cells despite being expressed in T cells. Indeed, ESRRA activity levels, quantified as the expression of ESRRA targets, were lowest in T cells (<xref rid="fig4" ref-type="fig">Fig. 4A</xref>; Methods). In contrast, the highest and second-highest levels of ESRRA activity were observed in cancer cells and macrophages (<xref rid="fig4" ref-type="fig">Fig. 4A</xref>). Macrophages with high ESRRA activity also expressed M2 markers, suggesting they are M2 macrophages (Supplementary Fig. S8B–S8D).</p>
      <fig position="float" id="fig4">
        <label>Figure 4.</label>
        <caption>
          <p>ESRRA is activated in immunotherapy-resistant tumors and its inhibition does not adversely affect CD8<sup>+</sup> T cells. <italic toggle="yes">P</italic> values estimated by the Wilcoxon rank-sum test. <bold>A,</bold> ESRRA activity in cancer and immune cells from 30 scRNA-seq cohorts. ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BCC, basal cell carcinoma; BRCA, breast cancer; COAD, colon adenocarcinoma; CHOL, cholangiocarcinoma; DC, dendritic cell; EryPro, erythroid progenitor cell; GBM, glioblastoma multiforme; GMP, granulocyte-macrophage progenitor; HNSC, head and neck squamous cell carcinoma; LIHC, liver hepatocellular carcinoma; MB, medulloblastoma; MM, multiple myeloma; NK, natural killer; NSCLC, non–small cell lung cancer; OPC, oligodendrocyte precursor cell; PAAD, pancreatic adenocarcinoma; pDC, plasmacytoid dendritic cell; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; UVM, uveal melanoma. <bold>B,</bold> The chromatin accessibility of ESRRA targets in different cell types from scATAC-seq data of a skin cancer cohort. <bold>C,</bold> Cancer cell ESRRA activity in patient (skin cancer) tumors with pre– and post–anti–PD-1 treatment for responders and nonresponders. <bold>D,</bold> Enrichment analysis of an ESRRA-regulated gene set in nonresponding CT26 mice after anti–PD-1 treatment.</p>
        </caption>
        <alt-text>Figure 4. ESRRA is activated in immunotherapy-resistant tumors and its inhibition does not adversely affect CD8+ T cells. Abbreviations: CTL, cytotoxic T cell; MDSC, myeloid-derived suppressor cells; P values estimated by the Wilcoxon rank-sum test. A, ESRRA activity in cancer and immune cells from 30 scRNA-seq cohorts. B, The chromatin accessibility of ESRRA targets in different cell types from scATAC-seq data of a skin cancer cohort. C, Cancer cell ESRRA activity in patient (skin cancer) tumors with pre- and post- anti–PD-1 treatment for responders and nonresponders. D, Enrichment analysis of ESRRA-regulated gene set in nonresponding CT26 mice after anti–PD-1 treatment.</alt-text>
        <graphic xlink:href="672fig4" position="float"/>
      </fig>
      <p>Next, we examined ESRRA cell-specific function by comparing the accessibility of its target genes (inferred from ESRRA ChIP-seq; Methods) in different cell types using scATAC-seq data from patients with nonmelanoma skin cancer (<xref rid="bib46" ref-type="bibr">46</xref>). ESRRA target gene accessibility was highest in cancer cells, second highest in macrophages, and lowest in CD8<sup>+</sup> T cells (<xref rid="fig4" ref-type="fig">Fig. 4B</xref>), consistent with ESRRA activity distribution in scRNA datasets. The data support a model in which ESRRA has a higher level of activity in cancer cells relative to CD8<sup>+</sup> T cells, as measured by gene expression, target transcription, and chromatin accessibility. Thus, ESRRAi likely has a lower impact on the energy metabolism of CD8<sup>+</sup> T cells.</p>
      <p>To specifically test whether ESRRAi treatment affects the energy metabolism of CD8<sup>+</sup> T cells, we analyzed scRNA data from CD45<sup>+</sup> cells from our <italic toggle="yes">in vivo</italic> 4T1 mouse model, in which the antitumor effect of ESRRAi was measured. ESRRA activity in CD8<sup>+</sup> T cells was unchanged in ESRRAi-treated mice relative to control (Supplementary Fig. S9A). Macrophages/monocytes were the only CD45<sup>+</sup> cells that showed decreased ESRRA activity after treatment. We also evaluated our scRNA data using Augur (<xref rid="bib76" ref-type="bibr">76</xref>), a method that identifies cell types affected by treatments, which also found no significant cell-intrinsic changes in CD8<sup>+</sup> T cells post-ESRRAi (Supplementary Fig. S9B). ESRRAi treatment in 4T1 mice did not significantly change body weights or health parameters (Supplementary Fig. S9C), which we further confirmed in the B16F10 mouse model (Supplementary Fig. S9D), suggesting that ESRRAi treatment was not nonspecifically toxic. These data strongly indicate that ESRRAi enhances CD8<sup>+</sup> T-cell recruitment into tumors without adversely affecting CD8<sup>+</sup> T cells themselves.</p>
    </sec>
    <sec id="sec2-7">
      <title>ESRRA Activation in Immunotherapy-Resistant Tumors</title>
      <p>Next, we studied the effect of immunotherapy on ESRRA activity. Analysis of a cohort of patients with immunotherapy-resistant melanoma (<xref rid="bib77" ref-type="bibr">77</xref>) revealed an intriguing trend: Cancer cells from postimmunotherapy tumors had markedly higher ESRRA activity than those from pretreatment tumors (Supplementary Fig. S9E). As the cohort contained only immunotherapy-resistant patients, we asked whether the trend is specific to resistant patients or also present in responders. To that end, we analyzed a nonmelanoma skin cancer scRNA-seq cohort (<xref rid="bib78" ref-type="bibr">78</xref>) containing both immunotherapy-responder and -resistant patients. Indeed, the trend of immunotherapy-induced ESRRA activity increase was specific to immunotherapy-resistant tumors (<xref rid="fig4" ref-type="fig">Fig. 4C</xref>). In fact, in responders, ESRRA activity decreased in cancer cells upon immunotherapy (<xref rid="fig4" ref-type="fig">Fig. 4C</xref>). These data are consistent with the hypothesis that immunotherapy-resistant tumors achieve high levels of immune suppression via ESRRA.</p>
      <p>We experimentally tested the trend of increased ESRRA activity and resulting immune suppression upon immunotherapy. Specifically, we chose a syngeneic mouse model of colorectal cancer (CT26) known for its heterogeneous immunotherapy (anti–PD-1) response (<xref rid="bib79" ref-type="bibr">79</xref>), treated the mice with anti–PD-1, and conducted bulk tumor RNA-seq. Target genes of ESRRA were upregulated in immunotherapy-resistant mice (<xref rid="fig4" ref-type="fig">Fig. 4D</xref>) but not in responders (Supplementary Fig. S9F), suggesting that ESRRA activity increases in immunotherapy-resistant tumors upon immunotherapy. Increased ESRRA activity was accompanied by immune suppression, including decreased CD8<sup>+</sup> T infiltration and increased M2 macrophages in tumors (Supplementary Fig. S9G). This <italic toggle="yes">in vivo</italic> experiment supports a model in which immune-checkpoint blockade (ICB) increases ESRRA activity, specifically in immunotherapy-resistant tumors. Increased ESRRA activity may also increase the vulnerability of tumors to ESRRA inhibition. The potential vulnerability is supported by our <italic toggle="yes">in vivo</italic> experiment showing ESRRAi effectiveness in 4T1 and B16F10 models—both of which respond poorly to ICB. Future clinical investigations are required to reveal whether immunotherapy-resistant tumors benefit from the immunostimulatory effect of ESRRA inhibition.</p>
    </sec>
    <sec id="sec2-8">
      <title>AI/ML-Based Aggregation of Bipotent Target Activity in Tumors Predicts Patient Response to Anti–PD-1</title>
      <p>The FDA recently approved using tumor mutation burden as a diagnostic biomarker to select patients with solid tumors for an anti–PD-1 treatment (<xref rid="bib80" ref-type="bibr">80</xref>). However, tumor mutational burden and other ICB biomarkers fail to identify which patients will best respond to ICB therapy (<xref rid="bib81" ref-type="bibr">81, 82</xref>), and complementary biomarkers are needed. Adopting the strategy from Wang and colleagues (<xref rid="bib83" ref-type="bibr">83</xref>), we evaluated bipotent target activity in tumors as a potential ICB biomarker. We focused on anti–PD-1 treatment in melanoma because of the availability of multiple melanoma cohorts with RNA-seq (<xref rid="bib84" ref-type="bibr">84–88</xref>), making it possible to evaluate biomarkers rigorously. Our algorithm first learned a risk score (<xref rid="fig5" ref-type="fig">Fig. 5A</xref>; see Methods) that combined tumor activity of bipotent targets through a multivariate Cox hazards model (<xref rid="bib89" ref-type="bibr">89</xref>): <inline-formula><tex-math id="M1">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\rm{log}}(r(t)) = {\textbf{\em{W}}}^{\textbf{\em{T}}}{\textbf{\em{X}}}$\end{document}</tex-math></inline-formula>. Here, <bold><italic toggle="yes">X</italic></bold> is the expression of bipotent targets in tumors, <italic toggle="yes">r</italic>(<italic toggle="yes">t</italic>) is risk score parameter, and <bold><italic toggle="yes">W</italic></bold> is weights learned using 465 immunotherapy-naïve melanoma patients from the TCGA (Methods). We refer to the risk scores as bipotent target activity scores (BTAS).</p>
      <fig position="float" id="fig5">
        <label>Figure 5.</label>
        <caption>
          <p>Machine learning evaluation of immune–metabolic targets in predicting patient response to anti–PD-1. <bold>A,</bold> Overview of the estimation of bipotent target activity score in tumors using a linear function (BTAS). <bold>B,</bold> Kaplan–Meier plots showing PFS and OS differences for patients receiving anti–PD-1 between the low-risk and high-risk groups defined by the median value of BTAS. <bold>C,</bold> Survival stratification performance of BTAS versus seven other previously published ICB biomarkers for patients with melanoma receiving ICB. Significance of survival was estimated using log-rank <italic toggle="yes">P</italic> value (−log<sub>10</sub>). <bold>D–K,</bold> Kaplan–Meier plots similar to <bold>B</bold>, with the low-risk and high-risk groups defined by the median value of the signatures. Signatures displayed are TIDE (<bold>D</bold>; ref. <xref rid="bib97" ref-type="bibr">97</xref>), T-cell inflamed (<bold>E</bold>; ref. <xref rid="bib96" ref-type="bibr">96</xref>), immune (<bold>F</bold>; ref. <xref rid="bib90" ref-type="bibr">90</xref>), cytotoxic (<bold>G</bold>; ref. <xref rid="bib91" ref-type="bibr">91</xref>), IFNG (<bold>H</bold>; ref. <xref rid="bib92" ref-type="bibr">92</xref>), melanocytic plasticity (<bold>I</bold>; ref. <xref rid="bib98" ref-type="bibr">98</xref>), immune checkpoint (<bold>J</bold>), and PD-L1 expression (<bold>K</bold>; ref. <xref rid="bib96" ref-type="bibr">96</xref>). <bold>L,</bold> Overview of the estimation of BTAS in tumors using a nonlinear function (deepBTAS). <bold>M,</bold> Kaplan–Meier plots similar to <bold>B</bold> with the low-risk and high-risk groups defined by the median deepBTAS. <bold>N,</bold> Performance improvement (OS and PFS) with the addition of deepBTAS to biomarkers (rows). An improvement quantified as (<italic toggle="yes">P</italic> value of) increase in the likelihood of multivariate model containing a biomarker and deepBTAS over a model containing the biomarker alone. LRT P, <italic toggle="yes">P</italic> value from likelihood ratio test. <bold>O,</bold> Kaplan–Meier plots similar to <bold>M</bold> done separately on tumors with high (left) and low (right) immune signature.</p>
        </caption>
        <alt-text>Figure 5. Machine learning evaluation of immune-metabolic targets in predicting patient response to anti–PD-1. Abbreviations: PFS, progression-free survival; OS, overall survival differences. A, Overview of the estimation of bipotent target activity score in tumors using a linear function (BTAS). B, Kaplan–Meier plots showing PFS and OS differences for patients receiving anti–PD-1 between the low-risk and high-risk groups defined by the median value of BTAS. C, Survival stratification performance of BTAS score versus seven other previously published ICB biomarkers for melanoma patients receiving ICB. Significance of survival was estimated using log-rank P value (−log10). D–K, Kaplan–Meier plots similar to B with the low-risk and high-risk groups defined by the median value of the signatures. Signatures displayed are: (D) TIDE (97), (E) T-cell inflamed (96), (F) immune (90), (G) cytotoxic (91), (H) IFNG (92), (I) melanocytic plasticity (98), (J) immune checkpoint, and (K) PD-L1 expression (96). L, Overview of the estimation of bipotent target activity score in tumors using a nonlinear function (deepBTAS). M, Kaplan–Meier plots similar to B with the low-risk and high-risk groups defined by the median deepBTAS. N, Performance improvement (OS and PFS) with the addition of deepBTAS to biomarkers (rows). An improvement quantified as (P value of) increase in the likelihood of multivariate model containing a biomarker and deepBTAS over a model containing the biomarker alone. O, Kaplan–Meier plots similar to M done separately on tumors with high (top) and low (bottom) immune signature.</alt-text>
        <graphic xlink:href="672fig5" position="float"/>
      </fig>
      <p>Without additional training on ICB cohorts, we used the model learned on TCGA to quantify the BTAS for each patient in ICB cohorts. We found that the BTAS stratified patients into likely ICB responders and nonresponders. In particular, when we stratified patients into the low-risk and high-risk groups based on median BTAS, the groups showed significant differences in progression-free survival (PFS; log-rank <italic toggle="yes">P</italic> &lt; 1.7E−3; Cox <italic toggle="yes">P</italic> &lt; 3.6E−4) and overall survival (OS; log-rank <italic toggle="yes">P</italic> &lt; 5.1E−3; Cox <italic toggle="yes">P</italic> &lt; 5.7E−3; <xref rid="fig5" ref-type="fig">Fig. 5B</xref>). To show that such stratification is unlikely by random chance, we used an empirical sampling procedure. We randomly sampled a gene set (from 20,000 protein-coding genes) of the same size as bipotent targets (<italic toggle="yes">N</italic> = 38), combined their activity using a similar procedure used to learn BTAS, and calculated its predictive power for stratifying anti–PD-1 outcome in terms of PFS and OS. We repeated this procedure for 10,000 randomly sampled gene sets and observed that only 27 sets showed higher predictive power than BTAS (i.e., empirical <italic toggle="yes">P</italic> &lt; 2.7E−3; <xref rid="fig5" ref-type="fig">Fig. 5C</xref>). We also asked whether the higher predictive power in ICB cohorts of BTAS could be explained by its predictive power within TCGA survival relative to random gene sets. However, out of 5,888 gene sets with higher TCGA predictive power than BTAS, only 21 gene sets outperformed BTAS in ICB cohorts (i.e., empirical <italic toggle="yes">P</italic> &lt; 3.6E−3). These observations suggest that BTAS has predictive power to stratify ICB responders and nonresponders.</p>
      <p>How does the predictive power of BTAS compare with other biomarkers? We collected seven other previously published ICB biomarkers (<xref rid="bib90" ref-type="bibr">90–98</xref>) and evaluated them in our ICB cohort collection. The highest predictive power was displayed by immune (<xref rid="bib90" ref-type="bibr">90, 94</xref>), T cell–inflamed (<xref rid="bib95" ref-type="bibr">95, 96</xref>), and cytotoxic (<xref rid="bib91" ref-type="bibr">91, 95</xref>) signatures (<xref rid="fig5" ref-type="fig">Fig. 5C</xref>–<xref rid="fig5" ref-type="fig">K</xref>). Importantly, BTAS achieved a predictive power comparable with these best performing ICB biomarkers. We then separately evaluated biomarkers on patients who received anti–PD-1 alone and patients who received the combination of anti–PD1 and anti-CTLA4. For anti–PD-1 alone, the immune signature (<xref rid="bib90" ref-type="bibr">90</xref>) achieved the best survival stratification (Supplementary Fig. S10A–S10J), whereas, for the combination, the T cell–inflamed signature (<xref rid="bib96" ref-type="bibr">96</xref>) performed the best (Supplementary Fig. S11A–S11J). BTAS showed comparable performances in both therapy regimens (Supplementary Figs. S10B and S11B), albeit at lower significance levels, highlighting the importance of larger cohorts for assessing the robustness of biomarkers. Note that to make biomarker estimates comparable across cohorts, we normalized the expression uniformly across cohorts, which would differ when normalization is done within a single cohort, as was the case in original publications. We also used immune-checkpoint genes, generated their tumor activity scores similar to BTAS (Methods), and showed that resulting activity scores have predictive power comparable to BTAS (<xref rid="fig5" ref-type="fig">Fig. 5J</xref>), further supporting the role of bipotent targets in determining ICB response.</p>
      <p>BTAS captures likely ICB response through a linear relationship between bipotent TFCRs, but TFCRs could interact nonlinearly (<xref rid="bib99" ref-type="bibr">99</xref>). Therefore, nonlinear functions of bipotent targets might capture ICB responses more accurately than linear functions. To test this, we fit a nonlinear model (<xref rid="fig5" ref-type="fig">Fig. 5L</xref>): <inline-formula><tex-math id="M2">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\rm{log}}(r(t)) = {\textbf{\em{W}}}_{\bf feedforward}({\textbf{\em{X}}})$\end{document}</tex-math></inline-formula> of bipotent target expression <bold><italic toggle="yes">X</italic></bold>. Here to capture nonlinear relationships between targets, we modeled <inline-formula><tex-math id="M3">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\textbf{\em{W}}}_{\bf feedforward}$\end{document}</tex-math></inline-formula> using a feedforward neural network (see Methods; <xref rid="fig5" ref-type="fig">Fig. 5L</xref>) with two hidden layers (with rectified linear activations). To learn the parameters of the feedforward network, we used 85% of 465 TCGA patients with melanoma for training and the rest, 15%, for testing. We optimized the parameters that minimized the partial log-likelihood (<xref rid="bib100" ref-type="bibr">100</xref>) using stochastic gradient descent and stopped the training when the testing error started to increase to avoid overfitting (Supplementary Fig. S10K). We refer to the risk scores inferred from the feedforward network as deepBTAS.</p>
      <p>Without additional training on ICB cohorts, we used the trained feedforward network to quantify the deepBTAS score in patients from ICB cohorts. deepBTAS score stratified patients into likely ICB responders markedly more accurately than BTAS in both PFS (log-rank <italic toggle="yes">P</italic> = 8.3E−4) and OS (log-rank <italic toggle="yes">P</italic> = 2.3E−05; <xref rid="fig5" ref-type="fig">Fig. 5M</xref>). We further studied whether deepBTAS and BTAS can distinguish partial/complete responders from those with stable/progressive disease based on their tumor radiology. The deepBTAS classified ICB patients with an accuracy measure area under the curve (AUC) of 0.603, whereas BTAS AUC was 0.585 (Supplementary Fig. S12A). These classification accuracies were similar to those of the top performing ICB biomarker, immune signature, with an AUC of 0.602. deepBTAS outperformed BTAS when we evaluated biomarkers separately for patient anti–PD1 monotherapy and anti-CTLA4 + anti–PD-1 (Supplementary Figs. S10C and S11C). We, therefore, conclude that a nonlinear function of bipotent target activity captures ICB response more accurately than a linear function.</p>
      <p>We also investigated whether BTAS/deepBTAS can improve the predictive power of current ICB biomarkers. First, even when we accounted for differences in levels of other ICB biomarkers in tumors, BTAS/deepBTAS showed a significant association with ICB survival outcomes (Supplementary Fig. S12B–S12E; Methods), suggesting our AI/ML models learned information that is nonredundant with other biomarkers. Next, we combined BTAS/deepBTAS with current biomarkers and assessed whether the addition improved the biomarker performance (Methods). The addition of either BTAS or deepBTAS improved the performance of all ICB biomarkers in predicting PFS and OS (<xref rid="fig5" ref-type="fig">Fig. 5N</xref>; Supplementary Fig. S12F). Importantly, deepBTAS markedly improved the best ICB biomarker, immune signature (<xref rid="fig5" ref-type="fig">Fig. 5N</xref>). Interestingly, this improvement was observed in tumors with high immune signature (likely responders) but not in tumors with low immune signature (likely nonresponders; <xref rid="fig5" ref-type="fig">Fig. 5O</xref>; Supplementary Fig. S13A). This suggests that deepBTAS improves the biomarker by correctly identifying tumors that were misidentified as responders by the immune signature. deepBTAS also correctly identified tumors that were misidentified as responders by other top performing ICB markers: T cell–inflamed signature and cytotoxic signature (Supplementary Fig. S13B–S13E). These analyses indicate that our AI/ML models improve the performance of current ICB biomarkers.</p>
    </sec>
    <sec id="sec2-9">
      <title>Both Bulk and Single-Cell Submodules Contribute to BipotentR Predictive Power</title>
      <p>We assessed contributions from bulk RNA and scRNA submodules. We removed the single-cell submodule from BipotentR and evaluated the identified TFCRs (Supplementary Fig. S14A; Methods). The identified TFCRs showed predictive power in <italic toggle="yes">in vitro</italic> CRISPR screens but failed to stratify patients by ICB response (Supplementary Fig. S14B–S14D), indicating that the scRNA submodule is critical for predicting ICB response in patients. The fact that predictive power was observed in the <italic toggle="yes">in vitro</italic> screen but not in patient response may be because gene knockouts in the <italic toggle="yes">in vitro</italic> screen (<xref rid="bib55" ref-type="bibr">55</xref>) were performed on cancer cells and not immune cells.</p>
      <p>Next, we removed the bulk RNA-seq submodule from BipotentR. This version of BipotentR was still able to produce significant predictive power but to a lesser extent compared with the full BipotentR (Supplementary Fig. S15A–S15D; Methods). Together, these evaluations suggest that both submodules contribute to BipotentR and both are required for maximal predictive power.</p>
    </sec>
    <sec id="sec2-10">
      <title>Application of BipotentR to Angiogenesis and Growth Suppressor Evasion</title>
      <p>To demonstrate the utility of BipotentR using a different input pathway, we identified 14 bipotent TFCRs that simultaneously regulate angiogenesis and immune response (Supplementary Table S5) and 14 TFCRs that regulate evasion of growth suppressors and immune response (Supplementary Table S6), using these pathways as inputs to BipotentR (Methods). This included TBX21 and histone demethylase JMJD1C; whereas TBX21 is known to regulate angiogenesis and Tregs (<xref rid="bib101" ref-type="bibr">101, 102</xref>), JMJD1C is known to regulate angiogenesis (<xref rid="bib103" ref-type="bibr">103–105</xref>) and can polarize macrophages (<xref rid="bib106" ref-type="bibr">106</xref>). We also evaluated bipotent targets for angiogenesis and growth suppressor evasion analogously as was done for immunometabolism targets. Using existing CRISPR datasets (<xref rid="bib55" ref-type="bibr">55</xref>), we tested if genetic inhibitions of these 28 identified TFCRs can elicit dual antitumor efficacy. CRISPR knockouts of these TFCRs markedly improved the killing of cancer cells by T cells (<xref rid="fig6" ref-type="fig">Fig. 6A</xref>; <italic toggle="yes">P</italic> &lt; 1.3E−6). Knockdown or knockout of the identified TFCRs suppressed genes involved in angiogenesis or evasion of growth suppressors (Supplementary Fig. S16A, <italic toggle="yes">P</italic> &lt; 8.1E−24), and the suppressed genes were preferentially regulated by the bipotent TFCRs (Supplementary Fig. S16B, <italic toggle="yes">P</italic> &lt; 9E−10).</p>
      <fig position="float" id="fig6">
        <label>Figure 6.</label>
        <caption>
          <p>Evaluation of bipotent regulators of angiogenesis or growth suppressor evasion. <bold>A,</bold> Effect of knockout of 28 bipotent targets on T cell–mediated killing of cancer cells. <bold>B–M,</bold> Performance of BTAS and deepBTAS versus other previously published ICB biomarkers. <bold>C,</bold> Survival stratification performance of BTAS score versus other ICB biomarkers. Significance of survival was estimated using log-rank <italic toggle="yes">P</italic> value (−log<sub>10</sub>). <bold>B, D,</bold> and <bold>E,</bold> Kaplan–Meier plots show PFS and OS between the four equal quartiles of risk groups divided based on the following signatures: BTAS (<bold>B</bold>), immune (<bold>D</bold>; ref. <xref rid="bib90" ref-type="bibr">90</xref>), and cytotoxic (<bold>E</bold>; ref. <xref rid="bib91" ref-type="bibr">91</xref>). <bold>F–J,</bold> Kaplan–Meier plots show PFS and OS between the four equal quartiles of risk groups divided based on the following signatures: IFNG (<bold>F</bold>; ref. <xref rid="bib92" ref-type="bibr">92</xref>), T-cell inflamed (<bold>G</bold>; ref. <xref rid="bib96" ref-type="bibr">96</xref>), melanocytic plasticity (<bold>H</bold>; ref. <xref rid="bib98" ref-type="bibr">98</xref>), PD-L1 (<bold>I</bold>; ref. <xref rid="bib96" ref-type="bibr">96</xref>), and TIDE (<bold>J</bold>; ref. <xref rid="bib97" ref-type="bibr">97</xref>). <bold>K</bold> and <bold>L,</bold> Kaplan–Meier plots show PFS and OS between the four equal quartiles of risk groups divided based on the following signatures: immune checkpoint (<bold>K</bold>) and deepBTAS (<bold>L</bold>). <bold>M,</bold> Performance evaluation of ICB biomarkers in terms of AUC.</p>
        </caption>
        <alt-text>Figure 6. Evaluation of bipotent regulators of angiogenesis or growth suppressor. A, Effect of knockout of 28 bipotent targets on T-cell mediated killing of cancer cells. B–M, Performance of BTAS and deepBTAS versus other previously published ICB biomarkers: C, Survival stratification performance of BTAS score versus other ICB biomarkers. Significance of survival was estimated using log-rank P value (−log10). Kaplan–Meier plots show progression-free survival and overall survival between the four equal quartiles of risk groups divided based on signatures: (B) BTAS, (D) immune (90), (E) cytotoxic (91), (F) IFNG (92), (G) T-cell inflamed (96), (H) melanocytic plasticity (98), (I) PD-L1 (96), (J) TIDE (97), (K) immune checkpoint, and (L) deepBTAS. M, Performance evaluation of ICB biomarkers in terms of area under the curve (AUC).</alt-text>
        <graphic xlink:href="672fig6" position="float"/>
      </fig>
      <p>Finally, we evaluated whether tumor activity of bipotent targets (angiogenesis and growth suppressor evasion) can predict patient response to anti–PD-1. Analogous to immunometabolism targets, we first fit Cox hazard models to learn a BTAS function that quantifies the activity of angiogenesis and growth suppressor evasion bipotent targets in a tumor (Methods). BTAS showed a significant association with the OS of patients with melanoma treated with anti–PD-1 (Cox regression <italic toggle="yes">P</italic> &lt; 1.1E−3), but it failed to stratify patients into two groups with significant OS differences (Supplementary Fig. S16C). Dividing patients into 4 equal quartiles of the BTAS score resulted in patient stratification with marked survival differences in both PFS (log-rank <italic toggle="yes">P</italic> &lt; 2.2E−4) and OS (log-rank <italic toggle="yes">P</italic> &lt; 3E−3; <xref rid="fig6" ref-type="fig">Fig. 6B</xref>). We showed that such patient stratification is unlikely by random chance: Only 16 out of 10,000 randomly sampled gene sets showed higher predictive power than BTAS (<xref rid="fig6" ref-type="fig">Fig. 6C</xref>, i.e., empirical <italic toggle="yes">P</italic> &lt; 1.6E−3). The predictive power of BTAS in stratifying ICB patients was comparable to other top ICB biomarkers (<xref rid="fig6" ref-type="fig">Fig. 6D</xref>–<xref rid="fig6" ref-type="fig">L</xref>). We also trained a nonlinear version of BTAS using a feedforward network of the same architecture used for immune metabolism and learned deepBTAS scores for angiogenesis and growth-suppressor bipotent targets but observed only a marginal improvement over BTAS in patient stratification (<xref rid="fig6" ref-type="fig">Fig. 6M</xref>).</p>
      <p>Together, the data suggest that bipotent gene targets such as ESRRA are relatively common, and their discovery could enable therapies that kill cancer through multiple mechanisms simultaneously.</p>
    </sec>
  </sec>
  <sec sec-type="discussion" id="sec3">
    <title>DISCUSSION</title>
    <p>This study introduces a new computational tool, BipotentR, that identifies targets that can inhibit tumors by activating immunity and suppressing a second user-defined oncogenic pathway. BipotentR leverages public databases to link the user-defined pathway with immunity and find targets with previously unrecognized functions. Using BipotentR, we predicted its 38 bipotent regulators whose inhibition induced metabolic and immune phenotypes. Tumor activity of bipotent targets can stratify melanoma patients’ responses to anti–PD-1, which we showed by applying an AI/ML approach. We validated the topmost implicated target, ESRRA, and uncovered its two antitumor immune mechanisms (Supplementary Fig. S17A). ESRRA inhibition is safe <italic toggle="yes">in vivo</italic>, and its effects on energy metabolism are focused on cancer cells.</p>
    <p>ESRRA regulates OXPHOS and proliferation in tumors of breast (<xref rid="bib107" ref-type="bibr">107</xref>), prostate (<xref rid="bib108" ref-type="bibr">108</xref>), and endometroid (<xref rid="bib109" ref-type="bibr">109</xref>) cancers. ESRRA is amplified in endometrial cancers and associated with immune infiltration (<xref rid="bib109" ref-type="bibr">109</xref>). We observed that ESRRA was active in immunosuppressive and immunoresistant tumors (<xref rid="fig4" ref-type="fig">Fig. 4A</xref>–<xref rid="fig4" ref-type="fig">C</xref>; Supplementary Figs. S3A and S3B, and S4A and S4B), suggesting potential clinical relevance in several tumor types. Inhibiting ESRRA stunted tumors by stimulating antigen presentation and cytokines that recruited effector T cells to tumors and polarized macrophages. These findings are supported by studies showing OXPHOS suppression alters both T cells (<xref rid="bib27" ref-type="bibr">27, 55</xref>) and macrophages (<xref rid="bib110" ref-type="bibr">110–112</xref>) because ESRRA regulates OXPHOS.</p>
    <p>Nonetheless, we note several limitations of our study. First, because our approach aims to discover new gene targets and drugs to improve cancer therapy, particularly immunotherapy, it requires users to have basic cancer and immunology expertise. However, our group previously did not have metabolism expertise but was led by the algorithm prediction to investigate ESRRA, thus BipotentR can be of utility to a wide range of clinicians and researchers.</p>
    <p>Second, because metabolic dependencies are often affected by their context in the tumor microenvironment, our study relied on immunocompetent mouse models (4T1, B16F10, and CT26). To supplement these experiments, we performed <italic toggle="yes">in vitro</italic> experiments to uncover the signaling underlying antitumor immune functions of ESRRA. Previously, Yuk and colleagues showed in a noncancer context that ESRRA-deficient mice induce the cytokines TNFα, IL6, and IL1β (<xref rid="bib60" ref-type="bibr">60</xref>). In the cancer context, we show targeting ESRRA induced these cytokines, which in turn polarized macrophages toward proinflammatory states. CRISPR or drug targeting of ESRRA stimulated antigen presentation genes (Supplementary Figs. S6A and S7A) and recruited effector CD8<sup>+</sup> T cells to tumors (<xref rid="fig2" ref-type="fig">Fig. 2B</xref> and <xref rid="fig2" ref-type="fig">C</xref>), which in turn enhanced tumor elimination by T cells (<xref rid="fig2" ref-type="fig">Fig. 2D</xref> and <xref rid="fig2" ref-type="fig">E</xref>). ESRRA has also been shown to function in autophagy (<xref rid="bib113" ref-type="bibr">113</xref>), which is a regulator of antigen presentation genes (<xref rid="bib114" ref-type="bibr">114</xref>). Consistent with this, we found that ESRRA suppression activated autophagy-related genes (Supplementary Fig. S6H), particularly at 72 hours after the suppression, which is consistent with the activation of antigen presentation at 72 hours. Autophagy also regulates macrophage polarization (<xref rid="bib115" ref-type="bibr">115</xref>), consistent with our findings (<xref rid="fig2" ref-type="fig">Fig. 2H</xref>; Supplementary Fig. S3A). Finally, we observed that ESRRA regulates other immune regulators, including a bipotent target, FLI1 (Supplementary Fig. S18A), suggesting that regulators of bipotent targets are more likely to be bipotent themselves.</p>
    <p>Third, standardized metrics are lacking to benchmark compound multiomics approaches such as ours. Prediction of gene targets is an emerging area in which computational approaches have been published recently (<xref rid="bib10" ref-type="bibr">10–13</xref>). Another fast-emerging area is system immunometabolism. To study system immunometabolism, experimental and computational approaches have been proposed including single-cell (<xref rid="bib116" ref-type="bibr">116</xref>), cytometry-based (<xref rid="bib117" ref-type="bibr">117, 118</xref>), multiomics (<xref rid="bib119" ref-type="bibr">119</xref>), and genome-scale modeling approaches (<xref rid="bib26" ref-type="bibr">26</xref>). Although these approaches study metabolism within immune cells, BipotentR focuses on regulators of cancer cell adaptations that alter the immune microenvironment. Thus, these immunometabolism approaches differ fundamentally from BipotentR. For evaluating BipotentR predictions, we needed a multipronged strategy. (i) We benchmarked BipotentR against competing or simpler alternatives. First, BipotentR identified regulators of energy metabolism at least as accurately as regulator prediction approaches LISA and BARTWeb (Supplementary Fig. S2C and S2D). Because Rephine focuses on predicting drug response, we could not compare its output with BipotentR output. Second, BipotentR accurately predicted immune regulators when compared with an alternative approach focused on regulators of macrophage polarization (Supplementary Note S1; Supplementary Fig. S18B). Third, BipotentR showed a comparable statistical power in detecting regulators against alternatives of using modules and submodules serially in BipotentR (Supplementary Note S6; Supplementary Fig. S18C). Fourth, BipotentR's (regulation module) robustness to the class imbalance problem was comparable to Firth's regression (Supplementary Note S7). (ii) We deconvolved contributions of bulk RNA and scRNA submodules and showed both submodules are essential for BipotentR performance. (iii) We observed knockout of the set of immune–metabolic regulators potentiated CD8<sup>+</sup> T cells in the CRISPR screen. In this screen, gene knockouts are done only on cancer cells and not on immune cells. To overcome this limitation, we presented a complementary evaluation of BipotentR predictions focusing on melanoma. Specifically, we showed using AI/ML approaches that the activity of bipotent targets predicted the outcome of patients with melanoma to anti–PD-1 treatment. Importantly, combining these AI/ML approaches with current ICB biomarkers markedly improved biomarkers’ ability to predict patient outcomes. (iv) We experimentally followed up on BipotentR's top predicted candidate (ESRRA) and showed its antitumor functions. Experimental validations are needed to establish the dual anticancer potential of the other candidates identified by BipotentR.</p>
    <p>Although this work focused on targets for immune metabolism, BipotentR can be applied to prioritize drug targets for any given pathway. We used BipotentR to identify immunotherapeutic targets that regulate angiogenesis and growth-suppressor pathways. Overall, these data demonstrate the utility of BipotentR in the discovery of a single drug that suppresses one pathway in selected cell types while simultaneously stimulating an immune response.</p>
  </sec>
  <sec sec-type="methods" id="sec4">
    <title>METHODS</title>
    <p>Analyses and datasets included in the article, also available as a part of the “BipotentR” R package, are summarized in Supplementary Fig. S17B and Supplementary Table S7. It provides comprehensive resources to researchers and clinicians working on novel agents to explore the potential clinical relevance of agents using more than 200 cancer cohorts (33,000 patients), 80 cohorts of scRNA experiments (2.5 million cells), and several immunologic CRISPR screens curated.</p>
    <sec id="sec4-1">
      <title>Tumor Cell Lines</title>
      <p>The 4T1 cells were obtained from the Steele Lab (Massachusetts General Hospital) and routinely tested for <italic toggle="yes">Mycoplasma</italic> using the Lonza MycoAlert Mycoplasma Detection Kit. The B16F10 cells were purchased from ATCC, which carries out authentication prior to shipment. <italic toggle="yes">Mycoplasma</italic> testing was also carried out routinely using the Lonza MycoAlert Mycoplasma Detection Kit.</p>
    </sec>
    <sec id="sec4-2">
      <title>Mouse Models</title>
      <p>Female Balb-c mice were purchased from Harlan, and female C57BL/6 mice were obtained from Vivo Bio-Tech (under license from Taconic). All protocols used in this study have been approved by the Axis Bioservices Animal Welfare and Ethical Review Committee. All procedures were carried out under the guidelines of the Animal (Scientific Procedures) Act 1986.</p>
      <p>Wild-type Balb/c recipient mice were purchased from the Charles River Laboratory. All mice were housed in a standard cage in the Dana-Farber Cancer Institute Animal Resources Facility (ARF). All animal procedures were carried out under the ARF Institutional Animal Care and Use Committee (IACUC) protocol and were in accordance with the IACUC standards for the welfare of animals (CT26).</p>
    </sec>
    <sec id="sec4-3">
      <title><italic toggle="yes">In Vitro</italic> Treatment Procedures</title>
      <sec id="sec4-3-1">
        <title>siRNA Treatment of Cells.</title>
        <p>SK-BR-3 cells were seeded in a T75 flask (Greiner Bio-One, #658175) and transfected 4 days later with 25 nmol/L siRNA-ESRRA (Dharmacon; #L-03403) using dharmafect 1 (Dharmacon, #T-2001). As a negative control, a 25 nmol/L siRNA-nontargeting pool (Dharmacon, #D-0018) was used. The transfected cells were reseeded 48 hours after transfection into 6-well plates (Greiner Bio-One, #657160) at 5,000 cells per well. After 0, 3, and 5 days, RNA was isolated using QIAzol Lysis Reagent (Qiagen, #79306) according to the manufacturer's protocol.</p>
      </sec>
      <sec id="sec4-3-2">
        <title>Compound Treatment of Cells.</title>
        <p>We study two known structurally similar inhibitors (compounds 29 and 39) of ESRRA. The compounds’ efficacy against ESRRA was first analyzed using the AlphaScreen assay. Compounds were tested for their ability to bind to the ESRRA-LBD protein using AlphaScreen Technology (Perkin­Elmer). ESRRA-LBD protein was expressed in <italic toggle="yes">Escherichia coli</italic> as a 6xHis Small Ubiquitin-like Modifier (SUMO) fusion. This fusion bacterial protein (i.e., 6xHis-SUMO-ESRRA-LBD) was purified using affinity chromatography. All experiments were performed at room temperature in 384-well, white nonbinding plates (Greiner) using 50 mmol/L Tris-HCl pH 7.5, 100 mmol/L NaCl, 0.1% Pluronic F-127, 0.05% BSA, and 5 mmol/L TCEP as the buffer. The final DMSO concentration was 1% in the assay. Compounds were assayed in triplicate and incubated with 0.81 nmol/L ESRRA-LBD protein and 10 μg/mL streptavidin donor beads and 10 μg/mL Ni-chelate acceptor beads for 1 hour at room temperature, followed by a 2-hour incubation with 15 nmol/L biotin-PGC1α-3 peptide (QRRPCSELLKYLTTNDDPP) corresponding to amino acids 202 to 220. The AlphaScreen signal was measured using an Envision Xcite plate reader (PerkinElmer). Although both inhibitors were bound to the LBD, compound 39 (AlphaScreen log-IC<sub>50</sub> = −8.124 M) was more potent than compound 29 (AlphaScreen log-IC<sub>50</sub> = −6.349 M). Hence, compound 39 was used for conducting RNA-seq.</p>
      </sec>
      <sec id="sec4-3-3">
        <title>RNA-seq.</title>
        <p>SKBR3 cells were seeded in 6-well plates (Greiner Bio-One, #657160). Two different cell concentrations were used; 4E5 cells/well were seeded for the 24-hour samples, and 2.7E5 cells/well were seeded for the 48- and 72-hour samples. The next day, medium was refreshed, and 1 or 5 μmol/L compound 39 in culture medium was added to the cells. After 24, 48, and 72 hours of incubation with compound 39, RNA was isolated using QIAzol Lysis Reagent (Qiagen, #79306) according to the manufacturer's protocol (<italic toggle="yes">n</italic> = 3 per condition).</p>
        <p>Total RNA concentration was measured using a NanoDrop (Thermo Scientific), and 1.5 μg was sent for sequencing. Clustering and DNA sequencing using the Illumina NovaSeq 6000, paired-end 150 bp, were performed according to the manufacturer's protocols. NovaSeq control software NCS v1.6 was used. Image analysis, base calling, and a quality check were performed with the Illumina data analysis pipeline RTA3.4.4 and Bcl2fastq v2.20. Ensembl GRCh37.75 was chosen as the reference transcriptome sequence for the alignment of the reads. Data were analyzed as described below.</p>
      </sec>
    </sec>
    <sec id="sec4-4">
      <title><italic toggle="yes">In Vivo</italic> Treatment Procedures</title>
      <sec id="sec4-4-1_sec4T1">
        <title>4T1 Mouse Model.</title>
        <p>A total of 24 female Balb-c mice ages 6 to 8 weeks and weighing approximately 17 to 22 g were used for the study. The 4T1 cells (5 × 10<sup>4</sup> in Matrigel) were implanted orthotopically into the left inguinal mammary fat pad of mice using a 25-gauge needle. The compound was formulated in 15% vitamin E-TPGS:30% PEG400:55% PBS. Mice were treated with compound 39 (30 mg/kg; <italic toggle="yes">n</italic> = 12) and vehicle (<italic toggle="yes">n</italic> = 12) once a day from day −3 (implantation day = 0). Once tumors reached a mean volume of 150 mm³, the tumors were surgically removed under general anesthesia (Ketamine:xylazine; 100 mg/kg:10 mg/kg). Treatment continued for 21 days after surgery. At the end of the study, the lungs were removed and surface macroscopic nodules were counted using a dissecting microscope.</p>
        <p>A cardiac puncture was performed, and the blood was plated into 10-cm cell culture dishes with media containing 6-thioguanine to select for circulating tumor cells. Seven to 10 days after initial plating, any colonies that grew were counted. The colonies that formed were counted, and the cells were collected for RNA extraction.</p>
      </sec>
      <sec id="sec4-4-2">
        <title>Postsurgery and FACS Analysis of 4T1 Mice.</title>
        <p>Following surgery, all tumors from each compound 39 treatment group and 3 each of size and age-matched controls were digested into a single-cell suspension using collagenases. The cells were then fixed before further staining and analyzed on the FACSCanto II flow cytometer. Different populations of cells were quantified and expressed as a percentage:<list list-type="bullet"><list-item><p>Alloreactive T cells: CD8<sup>+</sup>/CD137<sup>+</sup> cells (% of CD8 cells)</p></list-item><list-item><p>Tregs: FoxP3<sup>+</sup>/CD25<sup>+</sup> (% of CD4<sup>+</sup> cells)</p></list-item></list></p>
      </sec>
      <sec id="sec4-4-3">
        <title>ESSRAi in CD8<sup>+</sup> T-Depleted 4T1 Mice.</title>
        <p>Mice were split into two groups (<italic toggle="yes">n</italic> = 10) to receive ESSRAi alone or in combination with CD8 depletion using an anti-CD8 antibody [InVivoMAb anti-mouse CD8β (Lyt 3.2), Bio X Cell]. The ESSRAi-alone group also received control antibody (InVivoMAb rat IgG1 isotype control, anti–horseradish peroxidase). Anti-CD8 (100 μg), or isotype control, was injected intraperitoneally at days −6, −3, 0, 3, 6, and 9. At day −3, ESSRAi was delivered by oropharyngeal gavage daily (M–F) in 100 μL at 30 mg/kg until the study endpoint. Day 0 marked the day of tumor implantation, where 5 × 10<sup>5</sup> 4T1 cells were injected into the inguinal mammary fat pad of BALBc mice (in 50 μL volume). Tumors were measured every 2 to 3 days until sizes reached &gt;1,000 mm<sup>3</sup>, and mice were then euthanized. Spleens were isolated from mice of each group to verify CD8 depletion efficacy.</p>
      </sec>
      <sec id="sec4-4-4">
        <title>Single-Cell Sequencing of ESRRAi-Treated 4T1 Mice.</title>
        <p>Mice were split into two groups (<italic toggle="yes">n</italic> = 3 each group) to receive ESSRAi alone or vehicle only (DMSO 10%, Solutol 20%, water 70%). On day −3, ESSRAi was delivered by oropharyngeal gavage daily (M–F) in 100 μL at 30 mg/kg until study day 14. Day 0 marked the day of tumor implantation, where 5 × 10<sup>5</sup> 4T1 cells were injected into the inguinal mammary fat pad of BALBc mice (in 50 μL volume). Tumors were measured every 2 to 3 days. On day 14, tumors were harvested for scRNA-seq.</p>
        <p>Tumors from mice were harvested and broken down into smaller fragments. Then, each sample was digested with reagents from the Mouse Tumor Dissociation Kit (Miltenyi, cat. # 130-096-730) according to the manufacturer's instructions using gentleMACS Octo Dissociator from Miltenyi, and cell suspensions were passed through a 70-μm filter twice before staining. Single tumor cells were washed with ice-cold PBS containing 2% FBS and stained with CD45.2-APC/Cy7 antibody (BioLegend, cat. #109823) at 4°C for 45 minutes. All cells were then washed and resuspended in ice-cold PBS with 2% FBS. Live CD45.2-positive cells were sorted with BD Aria after staining. Each tumor from the same group was processed individually and mixed according to the same cell number. After cell collection, immune cells were resuspended at 1 × 10<sup>6</sup> cells/mL in PBS with 0.04% BSA (Thermo Fisher Scientific, cat. #AM2616). Single-cell suspensions of all samples were then barcoded with a 10X Chromium Controller (10X Genomics). RNA from the barcoded cells for each sample was subsequently reverse-transcribed, and sequencing libraries were constructed with reagents from a Chromium Single-Cell 30 v2 reagent kit (10X Genomics, cat. #PN-120267) according to the manufacturer's instructions. Sequencing was performed with Illumina HiSeq according to the manufacturer's instructions (Illumina).</p>
      </sec>
      <sec id="sec4-4-5">
        <title>B16F10 Mouse Model.</title>
        <p>Experiments were performed in 20 female C57BL/6 mice weighing approximately 18 to 20 g. B16F10 cells (0.1 million) were suspended in 50 μL of serum-free medium and mixed at a 1:1 ratio with Matrigel before implanting subcutaneously into the right flank of mice using a 1-mL BD syringe attached to a 24-gauge needle. When the average tumor volume reached around 57 mm³, animals were dosed after randomization into different treatment groups keeping tumor volume and number of animals so that the average tumor volume of each group remained the same across the groups. Compound 39 (30 mg/kg; <italic toggle="yes">n</italic> = 10) and vehicle (<italic toggle="yes">n</italic> = 10) were performed by mouth once a day. Body weights were recorded on day 0 (animal randomization) and thrice weekly thereafter until study termination. Changes in percent body weight (% BW Change) were calculated according to: % BW change = (BWFinal – BWInitial)/(BWInitial) × 100. Growth of B16F10 allografts was recorded on days 1, 4, 6, 8, 11, and 13. The length and width of tumors were measured by caliper on the day of animal randomization based on tumor volume (day 1) and thrice weekly thereafter until study termination. Tumor dimensions were measured on day 0 (animal randomization based on tumor volume) and thrice weekly thereafter until study termination. Tumor volumes were calculated using the formula <italic toggle="yes">b</italic><sup>2</sup> × <italic toggle="yes">l</italic> × 0.52, where <italic toggle="yes">l</italic> = length, <italic toggle="yes">b</italic> = breadth.</p>
      </sec>
      <sec id="sec4-4-6">
        <title>CT26 Mouse Model.</title>
        <p>We transplanted 2.5 × 10<sup>5</sup> CT26 cells subcutaneously into the left and right flanks of 6- to 8-week-old female Balb/c mice (Charles River Laboratory). When the tumors became palpable (day 7 after transplantation), we began treatment with control IgG (clone 2A3) or anti–PD-1 (clone 1A12) by intraperitoneal injection (200 μg per mouse in 200 μL HBSS buffer) every 3 days for a total of 5 times. We identified “responder” or “nonresponder” tumors in the anti–PD-1 cohort based on their size at the end of treatment. The top 25% were classified as nonresponders, and the bottom 25% were classified as responders. Three days after the last treatment, we harvested tumors for RNA-seq. RNA extraction was performed using the AllPrep DNA/RNA Mini Kit (Qiagen, #80204) following the manufacturer's protocol. Total RNA was submitted to Novogene Inc. for sequencing. A standard mRNA library preparation kit was used for library preparation. Paired-end 150 bp sequencing was done on an Illumina HiSeq 2500. Sequencing reads were mapped to the mm10 genome by RSEM. Statistics for differentially expressed genes (DEG) were calculated by DESeq2.</p>
      </sec>
    </sec>
    <sec id="sec4-5">
      <title>Calculation of Regulatory Potential Using Epigenetic Data</title>
      <p>We adopt the definition of regulation potential from MARGE (<xref rid="bib120" ref-type="bibr">120</xref>). MARGE defines regulatory potential (RP) of a ChIP-seq sample <inline-formula><tex-math id="M4">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$i$\end{document}</tex-math></inline-formula> of a TFCR at a gene <italic toggle="yes">j</italic> as the sum of ChIP-seq signals weighted by genomic distance from the gene transcription start site (<inline-formula><tex-math id="M5">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\rm{ts}}{{\rm{s}}_j}$\end{document}</tex-math></inline-formula>), that is, <inline-formula><tex-math id="M6">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${R_{ij}} = {\sum _{k \in [{\rm{ts}}{{\rm{s}}_j} - L/2,{\rm{ts}}{{\rm{s}}_j} + L/2]}}{w_k}{C_{ik}}$\end{document}</tex-math></inline-formula>. <inline-formula><tex-math id="M7">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${C_{ik}}$\end{document}</tex-math></inline-formula> is signal of ChIP-seq sample <italic toggle="yes">i</italic> at genomic position <italic toggle="yes">k</italic>, which is weighted by <inline-formula><tex-math id="M8">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${w_k}{\mkern 1mu} \; = \;{\mkern 1mu} \frac{2}{{1{\mkern 1mu} \; + \;{\mkern 1mu} {\rm{exp}}\left( {2\mu |k{\mkern 1mu} \; - \;{\mkern 1mu} {\rm{ts}}{{\rm{s}}_j}|/L} \right)}}$\end{document}</tex-math></inline-formula> and aggregated within the window of genomic region <italic toggle="yes">L</italic> = 200 kb around <inline-formula><tex-math id="M9">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\rm{ts}}{{\rm{s}}_j}$\end{document}</tex-math></inline-formula>. <italic toggle="yes">μ</italic> is the decay rate of weights, which is set to −ln10/3. Analogous to RP for ChIP-seq data, RP can also be estimated for (both bulk and single-cell) chromatin accessibility data.</p>
    </sec>
    <sec id="sec4-6">
      <title>Description of BipotentR</title>
      <p>The BipotentR integrative framework is composed of a regulation module and an immune module.</p>
      <sec id="sec4-6-1">
        <title>Regulation Module.</title>
        <p>The regulation module identifies the regulator of an input pathway. Here we describe bipotent identification for energy metabolism as input. To identify putative energy metabolic regulators, we selected four major energy metabolic pathways from the Kyoto Encyclopedia of Genes and Genomes (KEGG) database as input: FA metabolism, glycolysis, OXPHOS, and TCA. The regulation module of BipotentR leveraged the Cistrome Data Browser (Cistrome DB) dataset (<xref rid="bib33" ref-type="bibr">33</xref>), which comprises human and mouse ChIP-seq, DNase I hypersensitive sites sequencing, and ATAC-seq chromatin profiling assays. Low-quality samples were filtered out, adopting our previously reported strategy (<xref rid="bib33" ref-type="bibr">33</xref>), resulting in 21,046 ChIP-seq of 672 TFCRs. Then, putative regulators of each of the four energy metabolism pathways were analyzed separately as follows.</p>
        <p>For an input pathway <italic toggle="yes">p</italic> and given <italic toggle="yes">m</italic> ChIP-seq samples of a TCFR <italic toggle="yes">T</italic>, we infer the potential of <inline-formula><tex-math id="M10">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$T$\end{document}</tex-math></inline-formula> to bind to genes <italic toggle="yes">j</italic> in <italic toggle="yes">p</italic> using the logistic generalized linear mixed model (LMM). For generalized LMM formulation, we extend the notation of Zhang (<xref rid="bib121" ref-type="bibr">121</xref>):</p>
        <p>
          <disp-formula>
            <graphic xlink:href="672uequ1.jpg" position="float"/>
          </disp-formula>
        </p>
        <p>The matrix containing RPs of <italic toggle="yes">N</italic> protein-coding genes in <italic toggle="yes">m</italic> ChIP-seq samples was flattened to generate the vector <bold><italic toggle="yes">R</italic></bold> of size Nm. <inline-formula><tex-math id="M11">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\textbf{\em{Y}}}_{\textbf{\em{p}}}$\end{document}</tex-math></inline-formula> (size Nm) is an incidence vector that relates genes in <bold><italic toggle="yes">R</italic></bold> to pathway <italic toggle="yes">p</italic>, that is, it contains indicator variables that equal 1 for genes in the target pathway <inline-formula><tex-math id="M12">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$p$\end{document}</tex-math></inline-formula> and 0 otherwise. The number of pathway and nonpathway genes, respectively, is 32 and 25,573 for TCA, 135 and 25,470 for OXPHOS, 42 and 25,563 for FA metabolism, 62 and 25,543 for glycolysis (Supplementary Fig. S18D). <inline-formula><tex-math id="M13">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\beta $\end{document}</tex-math></inline-formula> is unknown fixed effect, <inline-formula><tex-math id="M14">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${{\gamma }}$\end{document}</tex-math></inline-formula> is a vector of size <italic toggle="yes">m</italic> for unknown random sample–specific confounding effects having distribution <inline-formula><tex-math id="M15">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${{\boldsymbol{\gamma}}} \sim {\textbf{\em{N}}}(0, {\textbf{\em{I}}}\boldsymbol{\sigma} _a^2)$\end{document}</tex-math></inline-formula>, and <bold><italic toggle="yes">Z</italic></bold> (size <italic toggle="yes">n</italic> × <italic toggle="yes">t</italic>) is an incidence matrix of 1s and 0s relating genes in <bold><italic toggle="yes">R</italic></bold> to samples. <inline-formula><tex-math id="M16">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${{\boldsymbol{\epsilon}}}$\end{document}</tex-math></inline-formula> is a residual effect vector having distribution <inline-formula><tex-math id="M17">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${{\boldsymbol{\epsilon}}} \sim {\textbf{\em{N}}}({0}, {\textbf{\em{I}}}{{\boldsymbol{\sigma}}} _b^2)$\end{document}</tex-math></inline-formula>. <bold><italic toggle="yes">I</italic></bold> is the identity matrix, <inline-formula><tex-math id="M18">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$h$\end{document}</tex-math></inline-formula> is an inverse logistic link function (i.e., <inline-formula><tex-math id="M19">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$h(x)\; = \;\frac{1}{{1 + {e^{ - x}}}}$\end{document}</tex-math></inline-formula>), and <inline-formula><tex-math id="M20">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\sigma _a^2$\end{document}</tex-math></inline-formula> and <inline-formula><tex-math id="M21">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\sigma _b^2$\end{document}</tex-math></inline-formula> are unknown variances.</p>
        <p>Parameters of the model were estimated by maximizing the log-likelihood L(β, <inline-formula><tex-math id="M22">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${{\boldsymbol{\gamma}}}, \sigma _a^2$\end{document}</tex-math></inline-formula>, <inline-formula><tex-math id="M23">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\sigma _a^2$\end{document}</tex-math></inline-formula>|<inline-formula><tex-math id="M24">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\textbf{\em{Y}}}_{\textbf{\em{p}}}$\end{document}</tex-math></inline-formula>). To calculate <italic toggle="yes">P</italic> value, we test the null hypothesis <inline-formula><tex-math id="M25">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\beta $\end{document}</tex-math></inline-formula> = 0 using <italic toggle="yes">t</italic> test assuming the t-distribution with degrees of freedom calculated through Satterthwaite's approximation method (<xref rid="bib122" ref-type="bibr">122</xref>). Parameters were estimated using lmer (<xref rid="bib123" ref-type="bibr">123</xref>) and lmerTest (<xref rid="bib122" ref-type="bibr">122</xref>). The <italic toggle="yes">P</italic> value from the coefficient of <inline-formula><tex-math id="M26">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\beta $\end{document}</tex-math></inline-formula> was used as the significance of binding potential for the TFCR <italic toggle="yes">T</italic>. <italic toggle="yes">P</italic> values were adjusted for multiple hypotheses for a total number of TFCRs tested using the Benjamini–Hochberg correction (<xref rid="bib124" ref-type="bibr">124</xref>). We denote this final adjusted <italic toggle="yes">P</italic> value (<inline-formula><tex-math id="M27">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${P_{regulation}}$\end{document}</tex-math></inline-formula>). We also show <inline-formula><tex-math id="M28">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${P_{regulation}}$\end{document}</tex-math></inline-formula> is robust to class imbalance by benchmarking against Firth's regression, which is an approach developed to mitigate class imbalance (See Supplementary Note 7).</p>
        <p>For the TFCR <inline-formula><tex-math id="M29">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$T$\end{document}</tex-math></inline-formula>, we estimated the effect size of its binding potential to a pathway as the predictive power of TFCR RP to discriminate genes in the pathway <italic toggle="yes">p</italic> from other genes. We estimate a single binding potential of TFCR <inline-formula><tex-math id="M30">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$T$\end{document}</tex-math></inline-formula> that combines all its ChIP-seq samples. In particular, for each <inline-formula><tex-math id="M31">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${i^{th}}$\end{document}</tex-math></inline-formula> TFCR ChIP-seq sample, we first calculate area under curve <inline-formula><tex-math id="M32">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$AU{C_i}$\end{document}</tex-math></inline-formula> and its confidence interval <inline-formula><tex-math id="M33">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$C{I_i}$\end{document}</tex-math></inline-formula> for predictor <inline-formula><tex-math id="M34">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\textbf{\em{Y}}}_{\textbf{\em{p}}} \sim {\textbf{\em{R}}}_{\textbf{\em{i}}}$\end{document}</tex-math></inline-formula> (using “pROC” (<xref rid="bib125" ref-type="bibr">125</xref>)). Then <inline-formula><tex-math id="M35">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$AU{C_i}\;$\end{document}</tex-math></inline-formula> estimates from all ChIP-seq samples of same TFCR <italic toggle="yes">T</italic> are combined as: <inline-formula><tex-math id="M36">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\widehat {AUC}\;$\end{document}</tex-math></inline-formula>=<inline-formula><tex-math id="M37">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\sum _i}AU{C_i}\;/n$\end{document}</tex-math></inline-formula> and <inline-formula><tex-math id="M38">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\widehat {CI}\; = \;\left( {\sqrt {{\Sigma _i}(CI_i^2)} } \right)/m$\end{document}</tex-math></inline-formula>, where <inline-formula><tex-math id="M39">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$m$\end{document}</tex-math></inline-formula> is the number of ChIP-seq of the TFCR. The final binding potential (<inline-formula><tex-math id="M40">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${B_{Tp}}$\end{document}</tex-math></inline-formula>) of T for pathway <bold><italic toggle="yes">p</italic></bold> was defined as <inline-formula><tex-math id="M41">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\widehat {AUC}$\end{document}</tex-math></inline-formula> and at 95% of <inline-formula><tex-math id="M42">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\widehat {CI}$\end{document}</tex-math></inline-formula>.</p>
        <p>To integrate potential of energy metabolism pathways, we calculate the binding potential (<inline-formula><tex-math id="M43">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${B_{Tp}}$\end{document}</tex-math></inline-formula>) and their significance for each of the four metabolic pathways <bold><italic toggle="yes">p</italic></bold> separately. Then we combined the <inline-formula><tex-math id="M44">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${B_{Tp}}$\end{document}</tex-math></inline-formula> of four pathways by taking their average to get the final binding potential of energy metabolism as: <inline-formula><tex-math id="M45">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${B_T}$\end{document}</tex-math></inline-formula> = <inline-formula><tex-math id="M46">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\sum _{p \in energy - metabolism}}{B_{Tp}}/4$\end{document}</tex-math></inline-formula> To obtain significance of energy metabolism binding potential (<inline-formula><tex-math id="M47">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${P_{regulation}}$\end{document}</tex-math></inline-formula>), we combined the <italic toggle="yes">P</italic> values of each of the four pathways (Supplementary Fig. S18E) by using Fisher methods (R package “MetaRNaseq”).</p>
      </sec>
      <sec id="sec4-6-2">
        <title>Immune Module.</title>
        <p>The immune pipeline is divided into bulk-level identification and single cell–level identification.</p>
        <sec id="sec4-6-2-1">
          <title>Identification of immunomodulatory TFCRs using bulk tumor transcriptome:</title>
          <p>Signatures of immune response were collected from Thorsson and colleagues (<xref rid="bib39" ref-type="bibr">39</xref>), which included biomarkers such as mutation burden, immune infiltration, IFNγ response. Normal samples were excluded, and missing values were imputed (using missMDA; ref. <xref rid="bib126" ref-type="bibr">126</xref>). BipotentR first controls for cancer type–specific effects by regressing out cancer type–specific effects from immune signatures (using R package “remef”) and then derives their independent principal components to control confounding effect of cross-correlation between signatures and cancer type–specific effects. Because the resulting first principal component (PC1) in an unbiased manner gave high weights to proinflammatory signatures (Supplementary Fig. S1B), it was used to estimate TFCR association with proinflammatory signatures as follows.</p>
          <p>For given expression <bold><italic toggle="yes">E</italic></bold> of any TFCR <italic toggle="yes">T</italic> in TCGA samples (<italic toggle="yes">n</italic> = 10,000), its association with PC1 (<bold><italic toggle="yes">P</italic></bold>) was performed using a LMM while controlling for confounding effects of cancer type–specific transcription. Expression was quantified using transcript per million from TCGA bulk RNA-seq (obtained from Xena browser; <ext-link xlink:href="http://xena.ucsc.edu/public/" ext-link-type="uri" xlink:show="new">http://xena.ucsc.edu/public/</ext-link>). We use LMM formulation similar to LMM used in the regulation module:</p>
          <p>
            <disp-formula>
              <graphic xlink:href="672uequ2.jpg" position="float"/>
            </disp-formula>
          </p>
          <p>where <bold><italic toggle="yes">E</italic></bold> is a vector of size <italic toggle="yes">n</italic> (number of samples) containing log-transformed expression of the TFCR <italic toggle="yes">T</italic>; <bold><italic toggle="yes">P</italic></bold> is the vector (size <italic toggle="yes">n</italic>) of a PC1 in TCGA samples; <inline-formula><tex-math id="M48">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\beta $\end{document}</tex-math></inline-formula> is unknown fixed effect representing the association of PC1 with E; and <inline-formula><tex-math id="M49">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\gamma$\end{document}</tex-math></inline-formula> is a vector of size t (number of cancer types, t = 32) for unknown random cancer type–specific transcription effects having distribution <inline-formula><tex-math id="M50">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${{\boldsymbol{\gamma}}} \sim {\textbf{\em{N}}}(0, {\textbf{\em{I}}}{{\boldsymbol{\sigma}}} _a^2)$\end{document}</tex-math></inline-formula>. <bold><italic toggle="yes">Z</italic></bold> (size <italic toggle="yes">n</italic> × <italic toggle="yes">t</italic>) is an incidence matrix of 1s and 0s relating samples to cancer types. <inline-formula><tex-math id="M51">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${{\boldsymbol{\epsilon}}} $\end{document}</tex-math></inline-formula> is a residual effect vector having distribution <inline-formula><tex-math id="M52">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${{\boldsymbol{\epsilon}}} \sim {\textbf{\em{N}}}(0, {\textbf{\em{I}}}{{\boldsymbol{\sigma}}} _b^2).$\end{document}</tex-math></inline-formula><bold><italic toggle="yes">I</italic></bold> is the identity matrix, and <inline-formula><tex-math id="M53">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${{\boldsymbol{\sigma}}} _a^2$\end{document}</tex-math></inline-formula> and <inline-formula><tex-math id="M54">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${{\boldsymbol{\sigma}}} _b^2$\end{document}</tex-math></inline-formula> are unknown variances.</p>
          <p>Similar to the regulation module, parameters and their confidence interval were estimated by maximizing the log-likelihood L(β, <inline-formula><tex-math id="M55">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$ {{\boldsymbol{\gamma}}}, {{\boldsymbol{\sigma}}} _a^2$\end{document}</tex-math></inline-formula>, <inline-formula><tex-math id="M56">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${{\boldsymbol{\sigma}}} _b^2$\end{document}</tex-math></inline-formula>|<bold><italic toggle="yes">E</italic></bold>). A 95% confidence interval of <inline-formula><tex-math id="M57">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\beta $\end{document}</tex-math></inline-formula> was assumed at 1.96 standard deviation. <italic toggle="yes">P</italic>-value testing of the null hypothesis <inline-formula><tex-math id="M58">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\beta $\end{document}</tex-math></inline-formula> = 0 was done using <italic toggle="yes">t</italic> test (<xref rid="bib122" ref-type="bibr">122</xref>), and <italic toggle="yes">P</italic> value (<inline-formula><tex-math id="M59">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${P_{{\rm{bulkRNA}}}}$\end{document}</tex-math></inline-formula>) was adjusted for multiple hypotheses (number of TFCR tested) using the Benjamini–Hochberg correction (<xref rid="bib124" ref-type="bibr">124</xref>). Immunomodulatory potential <inline-formula><tex-math id="M60">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\hat{\beta }_{{\rm{bulkRNA}}}}$\end{document}</tex-math></inline-formula> of the TFCR was defined <inline-formula><tex-math id="M61">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\beta $\end{document}</tex-math></inline-formula> at 95% confidence. TFCRs with the significant (adjusted <italic toggle="yes">P</italic> &lt; 0.05) positive (negative) potential were predicted as putative immune-stimulatory (immune-suppressive) TFCRs.</p>
        </sec>
        <sec id="sec4-6-2-2">
          <title>Identification of TFCRs preferentially active in cancer cells using single-cell data:</title>
          <p>To identify TFCRs that are differentially active in cancer cells relative to CD8 T cells, we collected scRNA from five cancer cohorts (GSE103322, GSE72056, EMTAB6149, GSE117570, and GSE127465). Data preprocessing and cell annotation of each cohort were done by MAESTRO (<xref rid="bib127" ref-type="bibr">127</xref>). A challenge with read counts of TFCRs in single-cell experiments is that they are prone to high dropout rates, especially due to their low basal expression in cells. Therefore, their read counts are an unreliable measure of their activity. To mitigate this effect, we impute activity TCFRs. In particular, for a TFCR <italic toggle="yes">T</italic> we define its activity <inline-formula><tex-math id="M62">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\textbf{\em{A}}}_{Tc}$\end{document}</tex-math></inline-formula> of a cell <italic toggle="yes">c</italic> as: <inline-formula><tex-math id="M63">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\textbf{\em{A}}}_{Tc} = \sum {_j} {E_{jc}}/N$\end{document}</tex-math></inline-formula>, where <inline-formula><tex-math id="M64">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\textbf{\em{E}}_{jc}}$\end{document}</tex-math></inline-formula> is the normalized cell expression (TPM) of <italic toggle="yes">j</italic>th gene targets of <italic toggle="yes">T</italic>. Here, we used the top 15% direct targets of <italic toggle="yes">T</italic> from Cistrome Cancer (<xref rid="bib128" ref-type="bibr">128</xref>). Next, we determine if the TFCR <italic toggle="yes">T</italic> is differentially active in cancer cells relative to CD8<sup>−</sup> T cells. We perform differential activity analysis across scRNA cohorts while accounting for patient-specific differences in the cohorts by adopting an LMM-based strategy from (<xref rid="bib129" ref-type="bibr">129</xref>) as:</p>
          <p>
            <disp-formula>
              <graphic xlink:href="672uequ3.jpg" position="float"/>
            </disp-formula>
          </p>
          <p>where <inline-formula><tex-math id="M65">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\textbf{\em{A}}}_{\textbf{\em{T}}}$\end{document}</tex-math></inline-formula> is a vector of size <italic toggle="yes">n</italic> (total number of cancer and CD8<sup>−</sup> T cells in five scRNA cohorts) containing cell activity of the TFCR <italic toggle="yes">T</italic>; <bold><italic toggle="yes">X</italic></bold> is an incidence vector that relates cells to their annotation of cancer or CD8<sup>−</sup> T cells (cancer cells were coded as 1, CD8 T cells as 0); <inline-formula><tex-math id="M66">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${{\boldsymbol{\beta}}}$\end{document}</tex-math></inline-formula> is unknown fixed effect representing a differential expression of T in cancer cells relative to CD8<sup>−</sup> T cells; and <inline-formula><tex-math id="M67">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${{\boldsymbol{\gamma}}}$\end{document}</tex-math></inline-formula> is a vector of size <italic toggle="yes">P</italic> ( total number of patients in five scRNA cohorts) for unknown random patient-specific confounding effects having distribution <inline-formula><tex-math id="M68">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${{\boldsymbol{\gamma}}} \sim {\textbf{\em{N}}}(0, {\textbf{\em{I}}}{{\boldsymbol{\sigma}}} _a^2)$\end{document}</tex-math></inline-formula>, <bold><italic toggle="yes">Z</italic></bold> (size <italic toggle="yes">n</italic> × <italic toggle="yes">P</italic>) is an incidence matrix of 1s and 0s relating cells in <bold><italic toggle="yes">T</italic></bold> to patients. <inline-formula><tex-math id="M69">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${{\boldsymbol{\epsilon}}} $\end{document}</tex-math></inline-formula> is a residual effect vector having distribution <inline-formula><tex-math id="M70">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\epsilon \sim {\textbf{\em{N}}}(0, {\textbf{\em{I}}}{{\boldsymbol{\sigma}}} _b^2).$\end{document}</tex-math></inline-formula><bold><italic toggle="yes">I</italic></bold> is the identity matrix, and <inline-formula><tex-math id="M71">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${{\boldsymbol{\sigma}}} _a^2$\end{document}</tex-math></inline-formula> and <inline-formula><tex-math id="M72">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${{\boldsymbol{\sigma}}} _a^2$\end{document}</tex-math></inline-formula> are unknown variances.</p>
          <p>Parameters and their confidence interval and <italic toggle="yes">P</italic> values were estimated using a similar procedure used for bulk RNA-seq pipeline. <italic toggle="yes">P</italic> values (<inline-formula><tex-math id="M73">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${P_{{\rm{scRNA}}}}$\end{document}</tex-math></inline-formula>) were adjusted for the number of TFCR tested using the Benjamini–Hochberg correction (<xref rid="bib124" ref-type="bibr">124</xref>).</p>
        </sec>
        <sec id="sec4-6-2-3">
          <title>Integration of bulk and single-cell estimates:</title>
          <p>We define integrated immune-modulatory potential as <inline-formula><tex-math id="M74">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\hat{\beta }_{{\rm{immune}}}}\; = \;({\hat{\beta }_{{\rm{bulkRNA}}}} + {\hat{\beta }_{{\rm{scRNA}}}})/2$\end{document}</tex-math></inline-formula>, and <italic toggle="yes">P</italic> value as <inline-formula><tex-math id="M75">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${P_{{\rm{immune}}}}\; = \;{\rm{Fisher}}\;{\rm{method}}$\end{document}</tex-math></inline-formula><inline-formula><tex-math id="M76">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$({P_{{\rm{scRNA}}}},\;{P_{{\rm{bulkRNA}}}})$\end{document}</tex-math></inline-formula> (Supplementary Fig. S18F; ref. <xref rid="bib130" ref-type="bibr">130</xref>). Note, <inline-formula><tex-math id="M77">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${P_{{\rm{immune}}}}$\end{document}</tex-math></inline-formula> does not need correction for the number of TFCRs analyzed because <inline-formula><tex-math id="M78">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${P_{{\rm{bulkRNA}}}}$\end{document}</tex-math></inline-formula> and <inline-formula><tex-math id="M79">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${P_{{\rm{scRNA}}}}$\end{document}</tex-math></inline-formula> had been corrected for multiple hypotheses.</p>
        </sec>
      </sec>
      <sec id="sec4-6-3">
        <title>Model Integration.</title>
        <p>TFCRs were selected as immune–metabolic TFCRs if their <inline-formula><tex-math id="M80">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${P_{{\rm{regulation}}}} &lt; 0.05$\end{document}</tex-math></inline-formula>, <inline-formula><tex-math id="M81">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${B_T}$\end{document}</tex-math></inline-formula> &gt; 85% quantile of all <inline-formula><tex-math id="M82">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${B_T}$\end{document}</tex-math></inline-formula> and <inline-formula><tex-math id="M83">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${P_{{\rm{immune}}}} &lt; 0.05$\end{document}</tex-math></inline-formula>, <inline-formula><tex-math id="M84">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\hat{\beta }_{{\rm{immune}}}}$\end{document}</tex-math></inline-formula> &gt; 85% quantile &lt; 15% quantile of all <inline-formula><tex-math id="M85">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\hat{\beta }_{{\rm{immune}}}}$\end{document}</tex-math></inline-formula>. A more conservative threshold set at 95% (and 5%) failed to identify any TFCR. The procedure identified 38 metabolic TFCRs.</p>
      </sec>
    </sec>
    <sec id="sec4-7">
      <title>Validation of BipotentR Predictions</title>
      <sec id="sec4-7-1">
        <title>Validation of 38 Immune–Metabolic TFCRs Identified by BipotentR.</title>
        <sec id="sec4-7-1-1">
          <title>Validation of metabolic roles:</title>
          <p>TFCRs’ metabolic roles were studied using transcriptomic changes induced by their knockdown/knockout. Transcriptomic changes for 38 TFCRs were obtained from Feng and colleagues (<xref rid="bib54" ref-type="bibr">54</xref>), comprising 570 experiments. Each experiment measures transcriptomes in cell lines with and without TFCR inhibition and then quantifies levels of induced transcriptome changes by the TFCR inhibition using differential expression between inhibition and control conditions. We investigated the suppression of genes in immune–metabolic pathways by testing two hypotheses. The first hypothesis tested whether BipotentR-identified TFCRs knockdowns/knockouts suppress the expression of energy metabolism genes (relative to other genes). Specifically, we tested whether expression fold changes induced by inhibiting identified TFCRs were significantly lower for energy metabolism genes than those in other genes using the Wilcoxon rank-sum test. The second hypothesis tested whether BipotentR-identified TFCRs preferentially regulate energy metabolism genes as compared with other TFCRs. Specifically, for energy metabolism genes, fold changes induced in their expression by inhibiting BipotentR-identified TFCRs were compared with those induced by other TFCRs.</p>
        </sec>
        <sec id="sec4-7-1-2">
          <title>Validation of immune roles:</title>
          <p>Regulation of immune response by BipotentR-identified TFCRs was studied by examining how their knockout in cancer cells affected killing by T cells. A CRISPR screen was obtained from ref. <xref rid="bib55" ref-type="bibr">55</xref>, in which cancer cells (B16F10) induced with gRNAs were cocultured with (Pmel) T cells in the presence of IFNγ. Increase (or decrease) in T cell–mediated killing by a gene knockout was estimated by fold changes of depletion (or enrichment) of its guides (comparing with and without T-cell coculture), calculated using MAGeCK (<xref rid="bib131" ref-type="bibr">131</xref>). For BipotentR-identified immunosuppressive TFCRs, we tested whether fold changes of their guides were significantly lower than those of other genes using the Wilcoxon rank-sum test. Similarly, for BipotentR-identified immunostimulatory TFCRs, we tested whether fold changes were significantly greater than those of other genes.</p>
        </sec>
      </sec>
      <sec id="sec4-7-2">
        <title>Validation of Metabolic TFCRs Using scATAC-seq Data.</title>
        <p>TFCRs that were differentially active in cancer cells were evaluated for target accessibility in cancer cells versus CD8 T cells. Target accessibility in a cell was determined using an scATAC-seq dataset of skin cancer (<xref rid="bib46" ref-type="bibr">46</xref>). The scATAC-seq was processed by our MAESTRO pipeline (<xref rid="bib127" ref-type="bibr">127</xref>). Around 200,000 single cells from patients with basal cell carcinoma passed the default filtering criteria of MAESTRO, and the RPs of each cell at each gene were calculated. Then, given <italic toggle="yes">T</italic>, and the set of targets of the T from Cistrome Cancer (<xref rid="bib128" ref-type="bibr">128</xref>), we define the target accessibility of <italic toggle="yes">T</italic> as: <inline-formula><tex-math id="M86">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${W_{Tc}} = \sum {_j} {R_{cj}}/N,$\end{document}</tex-math></inline-formula> where <inline-formula><tex-math id="M87">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${R_{cj}}$\end{document}</tex-math></inline-formula> is the RP of <italic toggle="yes">j</italic>th gene targets of <italic toggle="yes">T</italic> (top 15% targets of <italic toggle="yes">T</italic> from Cistrome Cancer), and <italic toggle="yes">N</italic> is the total number of targets. Differential target accessibility of the TFCR <inline-formula><tex-math id="M88">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$({\beta _{{\rm{scATAC}}}})$\end{document}</tex-math></inline-formula> in cancer cells relative to CD8 T cells was determined using: <inline-formula><tex-math id="M89">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\textbf{\em{W}}}_{\textbf{\em{T}} = {\textbf{\em{X}}}{{\boldsymbol{\beta}}}_{{\rm{scATAC}}}} + {\textbf{\em{Z}}}{{\boldsymbol{\gamma}}} + {{\boldsymbol{\epsilon}}} $\end{document}</tex-math></inline-formula>, where <inline-formula><tex-math id="M90">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\textbf{\em{W}}}_{\textbf{\em{T}}}$\end{document}</tex-math></inline-formula> is a target accessibility vector of <italic toggle="yes">T</italic> across cancer and CD8<sup>−</sup> T cells; <bold><italic toggle="yes">X</italic></bold> is an incidence vector that relates cells to their annotation of cancer or CD8<sup>−</sup> T cells; and <inline-formula><tex-math id="M91">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${{\boldsymbol{\gamma}}}$\end{document}</tex-math></inline-formula> and <bold><italic toggle="yes">Z</italic></bold> are defined similar to single-cell module of BipotentR. <inline-formula><tex-math id="M92">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\beta _{{\rm{scATAC}}}}$\end{document}</tex-math></inline-formula> is an unknown fixed effect representing differential accessibility. <inline-formula><tex-math id="M93">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\beta _{{\rm{scATAC}}}}\;$\end{document}</tex-math></inline-formula> (at 95% confidence interval) were compared with <inline-formula><tex-math id="M94">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\beta _{{\rm{scRNA}}}}$\end{document}</tex-math></inline-formula> for each TFCR.</p>
      </sec>
      <sec id="sec4-7-3">
        <title>Assessment of the Robustness of the Bulk RNA-seq Immune Pipeline Using Cross-Validation.</title>
        <p>TCGA cancer types were randomly divided into two equal (nonoverlapping) subsets, TCGA samples were split into two groups based on their cancer-type assignment to the subsets, and the immune pipeline was applied separately to each group. The immune RP estimates were compared using Pearson correlation in the two groups.</p>
      </sec>
    </sec>
    <sec id="sec4-8">
      <title>Differential Expression Analysis</title>
      <p>An ER<sup>−</sup> breast cancer cell line, SKBR3, was treated with ESRRA inhibitor compound 39 at two concentrations (1 and 5 μmol/L), and the vehicle-only treatment was used as a control. Three replicates were collected for each treatment and control, and RNA-seq was performed 24, 48, and 72 hours after treatment. DEGs at each time point were also identified by analyzing the corresponding time point sample using DESeq2 (<xref rid="bib132" ref-type="bibr">132</xref>). In the analysis, differential effects of drug concentration were also controlled by defining a model matrix = treatment + concentration. The significance of DEGs was estimated using a likelihood ratio test between the above model with the NULL model (i.e., model matrix = concentration). The DEGs were selected with Benjamini–Hochberg adjusted <italic toggle="yes">P</italic> &lt; 0.05 and absolute log<sub>2</sub> fold change (logFC) &gt;0.5. Because the largest transcriptome changes were observed at 72 hours, it was chosen to identify the ESRRA activity signature.</p>
      <p>DEGs across all time points were also identified in an analogous manner by defining a model matrix = treatment + concentration + time point and the NULL model matrix = concentration + time point.</p>
    </sec>
    <sec id="sec4-9">
      <title>Comparison of ESRRAi by Drug or siRNA in Terms of Off-Target Effects</title>
      <p>The comparison of inhibition approaches was done through the following two methods:</p>
      <sec id="sec4-9-1">
        <title>Cistrome DB.</title>
        <p>Downregulated gene sets from the two inhibition approaches were compared for ESRRA potential to regulate these gene sets using ESRRA ChIP-seq data from Cistrome DB. Genome-wide ESRRA RP (defined as the sum of ChIP-seq peaks weighted by genomic distance to the target gene transcription start site) was downloaded from Cistrome DB (<xref rid="bib34" ref-type="bibr">34</xref>). RP values of downregulated genes were compared between two inhibition approaches as well as with background genes (using one-sided Wilcoxon test).</p>
      </sec>
      <sec id="sec4-9-2">
        <title>LISA.</title>
        <p>Putative regulators of the DEGs upon two inhibition approaches were identified unbiasedly using LISA (<xref rid="bib13" ref-type="bibr">13</xref>). LISA is a tool to identify transcription factors that underlie a query gene set. Predicted regulators by LISA were then compared between the two inhibition approaches.</p>
      </sec>
    </sec>
    <sec id="sec4-10">
      <title>Estimation of ESRRA Activity</title>
      <p>To estimate ESRRA activity in cell lines, bulk tumors, or single-cell datasets, we adopted a strategy from ref. <xref rid="bib97" ref-type="bibr">97</xref>. ESRRA activity in a sample from a dataset was estimated from the sample transcriptome using the ESRRA activity signature. The expression of each gene was first normalized by dividing its average across all samples in the dataset. Then, ESRRA activity of a sample was estimated as the correlation of ESRRA signature genes between their normalized sample expression and their differential expression by ESRRA inhibition, that is,</p>
      <p>
        <disp-formula>
          <graphic xlink:href="672uequ4.jpg" position="float"/>
        </disp-formula>
      </p>
      <p>where differential expression = −log<sub>10</sub>(<italic toggle="yes">P</italic><sub>adj</sub>) × sign(fold change) was used.</p>
    </sec>
    <sec id="sec4-11">
      <title>Pathway Enrichment in Samples with Low ESRRA Activities</title>
      <p>Pathway enrichment was conducted by comparing the top 10% with the bottom 10% samples based on ESRRA activity.</p>
    </sec>
    <sec id="sec4-12">
      <title>Association of Expression of Antigen Presentation Genes and ESRRA Activity</title>
      <p>The association of ESRRA activity with antigen presentation gene expression in CCLE and TCGA datasets was evaluated using the Spearman correlation. The association was estimated in each cancer type separately. In TCGA, cancer types with sample sizes &gt; 150 were considered for the analysis.</p>
    </sec>
    <sec id="sec4-13">
      <title>Analysis of Immune-Related CRISPR Screens</title>
      <p>We collected 18 published immune-related CRISPR screens, including 6 MHC-I screens from refs. <xref rid="bib63" ref-type="bibr">63–66</xref> and 8 T-cell coculture screens from refs. <xref rid="bib55" ref-type="bibr">55 and 68–71</xref>. In MHC-I screens, to identify genes that regulate MHC-I expression, cancer cells transduced with genome-wide single-guide RNA (sgRNA) had been sorted and classified into MHC-I–high or –low groups based on MHC-I protein expression. The logFC of depletion of each guide (comparing the sorted MHC-I population vs. the unsorted population) were calculated using MAGeCK (<xref rid="bib131" ref-type="bibr">131</xref>). Then, we estimated knockout's significance and effect size of each gene in increasing MHC-I expression using CRISPhieRmix (<xref rid="bib133" ref-type="bibr">133</xref>). CRISPhieRmix compares the logFC of all gene guides with the background and uses a hierarchical mixture model of CRISPR screens that leverage two group models to compute <italic toggle="yes">P</italic> value and were corrected for multiple hypothesis testing (<xref rid="bib133" ref-type="bibr">133</xref>).</p>
      <p>In coculture screens, cancer cells transduced with genome-wide sgRNA were subjected to T cell–mediated killing. LogFC was estimated for both for each guide by comparing experiments with and without coculture using MAGeCK. LogFC and significance were inferred for each gene from its guides’ LogFC using a similar approach used for MHC-I screen analyses described above.</p>
    </sec>
    <sec id="sec4-14">
      <title>Analysis of Immune Infiltration in Tumors</title>
      <p>Abundances of immune cells in all TCGA samples were estimated using CIBERSORT (<xref rid="bib134" ref-type="bibr">134</xref>), which estimates the abundance of 22 immune cells in bulk RNA-seq using default settings. Myeloid-derived suppressor cell abundance and the M2 polarization score (M2/M1 ratio) were estimated in a TCGA sample from its expression using the approach used previously (<xref rid="bib97" ref-type="bibr">97</xref>).</p>
      <p>For each immune infiltration estimate, its association with ESRRA activity was determined in each cancer type separately by two alternative methods: (i) Wilcoxon test comparing estimates between high and low ESRRA activity groups divided based on the median ESRRA activity, and (ii) Spearman correlations between the estimated infiltration and ESRRA activity (displayed using the R package “corrplot”).</p>
    </sec>
    <sec id="sec4-15">
      <title>Immune Feature Associations with ESRRA Activity</title>
      <p>Cytokine–cytokine interaction pathway and antigen presentation pathway were collected from the KEGG database (<xref rid="bib135" ref-type="bibr">135</xref>). The expression level of each pathway is estimated by the single-sample gene set enrichment analysis (GSEA; ref. <xref rid="bib136" ref-type="bibr">136</xref>) in each dataset using the “GSVA” R package (<xref rid="bib137" ref-type="bibr">137</xref>). Spearman correlations were calculated between ESRRA activities and these immune features across all patients from TCGA and PRECOG (<xref rid="bib138" ref-type="bibr">138</xref>) databases.</p>
    </sec>
    <sec id="sec4-16">
      <title>Bladder Cancer Cohort Analysis</title>
      <p>The RNA-seq data and clinical annotation were collected from the bladder cancer patient cohort (<xref rid="bib139" ref-type="bibr">139</xref>). Patients were clustered using cytokine expressions (genes in KEGG_CYTOKINE_CYTOKINE_INTERACTIONS pathway) by uniform manifold approximation and projection (UMAP) dimension reduction using “uwot” with parameters n_neighbors = 40; learning_rate = 0.1; min_dist = 0.001; number of PC = 10. The clustering resulted in two clusters. DEGs between two clusters were identified by the R package “Seurat.” Finally, ESRRA activities were compared among UMAP clusters, immune phenotypes, and Lund2 classification of bladder cancer (<xref rid="bib140" ref-type="bibr">140</xref>). The significance of comparisons was determined using the Wilcoxon test for pairwise comparison and the Kruskal–Wallis test for group-wise comparison.</p>
    </sec>
    <sec id="sec4-17">
      <title>Analysis of the CT26 Mouse Model</title>
      <p>Genes significantly suppressed by ESRRA drug inhibition were defined as ESRRA-regulated genes. Enrichment analysis of ESRRA-regulated genes was conducted using GSEA (<xref rid="bib141" ref-type="bibr">141</xref>), which calculates <italic toggle="yes">P</italic> values using a permutation test (100 permutations) across all KEGG pathways and adjusts multiple testing using the Benjamini–Hochberg correction. The immune cell-type abundance of mice was estimated using CIBERSORT, based on the mouse immune cell signature from ImmuCC (<xref rid="bib142" ref-type="bibr">142</xref>). The Spearman correlations of ESRRA activity with immune cell infiltration were calculated across all mice.</p>
    </sec>
    <sec id="sec4-18">
      <title>Single-Cell Analysis of Public Datasets</title>
      <p>Single-cell cancer cohorts were compiled from the Tumor Immune Single-Cell Hub (TISCH) database (<xref rid="bib74" ref-type="bibr">74</xref>). TISCH consists of single-cell transcriptomic profiles of nearly 2 million cells from 76 cohorts across 27 cancer types. The data from all cohorts were processed using our standardized MAESTRO workflow (<xref rid="bib127" ref-type="bibr">127</xref>), which included quality control, batch effect removal, clustering, and cell-type annotation. Thirty cohorts that contained annotated cancer cells, macrophages, T and B cells, as well as transcriptomes from at least 1,500 single cells were further selected for the analysis. scATAC-seq data were downloaded from ref. <xref rid="bib78" ref-type="bibr">78</xref> and were processed using a standardized pipeline that uses the RP to quantify chromatin accessibility of a genomic region (<xref rid="bib127" ref-type="bibr">127</xref>).</p>
      <p>The calculation of ESRRA activity for each cell was similar to the activity calculation for a bulk RNA-seq sample. The score was defined as the Spearman correlation between the normalized expression and differential expression (by ESSRAi). DEGs between clusters were found by FindMarkers with default parameters. Pathway enrichment was conducted using ClusterProfiler (<xref rid="bib143" ref-type="bibr">143</xref>). KEGG terms with adjusted <italic toggle="yes">P</italic> &lt; 0.05 were selected as significant.</p>
    </sec>
    <sec id="sec4-19">
      <title>scRNA-seq Analysis of the 4T1 Mouse Model</title>
      <p>Alignment, filtering, and counting were done using Cell Ranger with the human reference GRCh38. The filtered gene expression matrix was further analyzed in R using the standard workflow of Seurat v.3.0. Briefly, after removing low-quality cells (&lt;200 or &gt;2,500 genes, or &gt;5% genes from the mitochondrial genome), normalization, principal component analysis of highly variable genes, and clustering were performed using default Seurat parameters (<xref rid="bib144" ref-type="bibr">144</xref>). Marker genes were identified for each cluster using differential expression analysis. Matching identified markers of each cluster with known canonical markers (<xref rid="bib145" ref-type="bibr">145</xref>), each cluster was assigned putative cell types: CD4<sup>+</sup> T cells (<italic toggle="yes">Cd3e, Cd4</italic>), monocytes/macrophages (<italic toggle="yes">Fcgr2b</italic>, <italic toggle="yes">C1qa</italic>, <italic toggle="yes">Mmp12</italic>, and <italic toggle="yes">Thbs1</italic>), B cells (<italic toggle="yes">Ms4a1</italic>, and <italic toggle="yes">Iglv3</italic>), CD8<sup>+</sup> T cells (<italic toggle="yes">Cd8a, Cd3e, Cd3g</italic>, and <italic toggle="yes">Gzmb</italic>), Tregs (<italic toggle="yes">Cd4</italic>, <italic toggle="yes">Ctla4</italic>, and <italic toggle="yes">Foxp3</italic>), natural killer (NK) cells (<italic toggle="yes">Ncr1</italic>, <italic toggle="yes">Nkg7</italic>, and <italic toggle="yes">Klri2</italic>), and neutrophils (<italic toggle="yes">Cd15</italic>, <italic toggle="yes">Cd16, Mmp9</italic>, and <italic toggle="yes">Csf3r</italic>). This annotation was also further tested using SingleR (<xref rid="bib146" ref-type="bibr">146</xref>) and SciBet (<xref rid="bib147" ref-type="bibr">147</xref>).</p>
    </sec>
    <sec id="sec4-20">
      <title>Analysis of Macrophage Polarization</title>
      <p>Adopting the strategy of scoring a gene set at a single-cell level (<xref rid="bib42" ref-type="bibr">42</xref>), the average expression of M1 and M2 marker gene sets (<xref rid="bib61" ref-type="bibr">61</xref>) was used to evaluate macrophage polarization (Supplementary Fig. S19). This was done using the “AddModuleScore” function in Seurat.</p>
    </sec>
    <sec id="sec4-21">
      <title>Estimating Significance of Differential Expression of a Gene Set</title>
      <p>To calculate the significance of differential expression of any given gene set <italic toggle="yes">M</italic> of size <italic toggle="yes">N</italic>, empirical distribution was determined. Specifically, differential expression <inline-formula><tex-math id="M95">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${D_M}$\end{document}</tex-math></inline-formula> of the set <italic toggle="yes">M</italic> was calculated as the average of the differential expression of genes of the set <italic toggle="yes">M</italic>, where the differential expression of each gene was quantified as: <inline-formula><tex-math id="M96">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\rm{sign}}({\rm{logFoldChange}})\;{\rm{*}}\;( - {\rm{log}}(P\;{\rm{value}}))$\end{document}</tex-math></inline-formula>, which accounts for both fold change and <italic toggle="yes">P</italic> value of the differential expression. Then, a random gene set <italic toggle="yes">R</italic> of size <italic toggle="yes">N</italic> was sampled, and <inline-formula><tex-math id="M97">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${D_R}$\end{document}</tex-math></inline-formula> (i.e., average differential expression of genes in the set <italic toggle="yes">R</italic>) was calculated. Repeating this procedure 1E7 times, we constructed the empirical distribution of <inline-formula><tex-math id="M98">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${D_M}$\end{document}</tex-math></inline-formula>. <italic toggle="yes">P</italic> value of the significance of upregulation of <italic toggle="yes">M</italic> was calculated as <inline-formula><tex-math id="M99">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\frac{{\sum\nolimits_R^{} {{D_M}} &gt; {D_R}}}{{1E7}}_{}}$\end{document}</tex-math></inline-formula>, and significance of downregulation of <italic toggle="yes">M</italic> was calculated as <inline-formula><tex-math id="M100">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\frac{{\sum\nolimits_{\rm{R}} {{D_M}} &lt; {D_R}}}{{1E7}}{._{}}$\end{document}</tex-math></inline-formula></p>
      <p>We compared cells of lymphoid lineage (i.e., CD4<sup>+</sup> T, CD8<sup>+</sup> T, B, and NK cells) between ESRRAi treatment and control (vehicle). The significance of the differential expression of a marker set is determined by the empirical distribution procedure described above.</p>
    </sec>
    <sec id="sec4-22">
      <title>Identification and Validation of Candidate Bipotent Regulators of Angiogenesis and Evasion of Growth Suppressors</title>
      <p>To identify bipotent regulators that simultaneously modulate angiogenesis and tumor immunity, a gene set of angiogenesis (<xref rid="bib148" ref-type="bibr">148</xref>) was given as input to BipotentR. This identified 14 bipotent regulators. Bipotent regulators of growth suppressor evasion were also identified analogously. Validation of these candidate regulators was done similarly as was done for immune–metabolic bipotent regulators (see “Validation of metabolic roles” and “Validation of immune roles”).</p>
    </sec>
    <sec id="sec4-23">
      <title>Prediction of Melanoma Response to Anti–PD-1 Using Tumor Activity of Bipotent Targets</title>
      <p>Following an input set of bipotent targets, we followed BTAS and deepBTAS procedures described below to estimate bipotent target activity in tumors. We applied the procedure separately for (i) immune-metabolism bipotent targets and (ii) a set of bipotent targets of angiogenesis and growth suppressor evasion.</p>
      <sec id="sec4-23-1">
        <title>ICB Data and Preprocessing.</title>
        <p>We focused on melanoma cohorts with tumor RNA-seq from patients receiving anti–PD-1 alone or in combination with anti-CTLA4. The RNA-seq and outcomes (OS, PFS, and RECIST) response were obtained from cohorts (<xref rid="bib84" ref-type="bibr">84–88</xref>). We considered anti–PD-1 alone and anti–PD-1 + anti-CTLA4 as separate cohorts. Patient cohorts with fewer than 10 samples with RNA-seq and outcome were excluded. This resulted in samples from 296 patients (182 anti–PD-1 and 114 anti–PD-1 + anti-CTLA4) with RNA-seq and outcome information. Gene expression was quantile-normalized to normal distribution across all samples in cohorts.</p>
      </sec>
      <sec id="sec4-23-2">
        <title>BTAS Details.</title>
        <p>To learn a risk score combining tumor activity of bipotent targets through a Cox proportional hazards model (using notation from ref. <xref rid="bib100" ref-type="bibr">100</xref>)</p>
        <p>
          <disp-formula>
            <graphic xlink:href="672uequ5.jpg" position="float"/>
          </disp-formula>
        </p>
        <p>Here, <inline-formula><tex-math id="M101">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\lambda _j}(t|{\textbf{\em{X}}})$\end{document}</tex-math></inline-formula> and <inline-formula><tex-math id="M102">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\lambda _{0j}}(t)$\end{document}</tex-math></inline-formula> are hazard and baseline-hazard functions of <inline-formula><tex-math id="M103">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$j{\rm{t}}{{\rm{h}}^{}}$\end{document}</tex-math></inline-formula> strata (e.g., cohort or different outcomes within a cohort). <bold><italic toggle="yes">X</italic></bold> is the activity (normalized expression) of bipotent targets (vector of size: number of bipotent targets) in the tumor of a patient, <bold><italic toggle="yes">W</italic></bold> is the weights to be estimated, and our BTAS is risk score <italic toggle="yes">r</italic>(<italic toggle="yes">t</italic>) = <inline-formula><tex-math id="M104">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\rm{exp}}{\textbf{\em{W}}}^{\textbf{\em{T}}}{\textbf{\em{X}}} = \log \left( {\frac{{{\lambda _j}(t)}}{{{\lambda _{0j}}(t)}}} \right)$\end{document}</tex-math></inline-formula> which is effect of bipotent target activity on baseline hazard of the patient, which we defined as our BTAS.</p>
      </sec>
      <sec id="sec4-23-3">
        <title>deepBTAS Architecture.</title>
        <p>We used a feedforward full network to model <inline-formula><tex-math id="M105">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\textbf{\em{W}}}_{{\bf feedforward}}$\end{document}</tex-math></inline-formula>. Specifically, three stacked fully connected layers Fc1, Fc2, and Fc3, parameterized by <italic toggle="yes">Y</italic><sub>1</sub> ∈ ℝ<sup>n × 8</sup>, <italic toggle="yes">b</italic><sub>1</sub> ∈ ℝ<sup>8</sup>, and <italic toggle="yes">Y</italic><sub>2</sub> ∈ ℝ<sup>8× 4</sup>, <italic toggle="yes">b</italic><sub>2</sub> ∈ ℝ<sup>4</sup> , and <italic toggle="yes">Y</italic><sub>3</sub> ∈ ℝ<sup>4× 1</sup>, <italic toggle="yes">b</italic><sub>3</sub> ∈ ℝ<sup>1</sup>, each followed by rectified linear unit (ReLU) activation and batch normalization (BN), allowed us to model hazard function that aligns with outcomes. <italic toggle="yes">n</italic> is the number of inputs.</p>
        <p>
          <disp-formula>
            <graphic xlink:href="672uequ6.jpg" position="float"/>
          </disp-formula>
        </p>
        <p>where <italic toggle="yes">T</italic>(x) = BN(ReLU(<italic toggle="yes">x</italic>)).</p>
      </sec>
      <sec id="sec4-23-4">
        <title>Training Procedure.</title>
        <p>We learned the weights <bold><italic toggle="yes">W</italic></bold> for both BTAS and deepBTAS using expression, OS, and PFS from TCGA melanoma samples (<italic toggle="yes">N</italic> = 465). Normal samples were removed from TCGA samples. To leverage both OS and PFS during the training, we used those two different outcomes as two different strata in our training and validation procedure. <bold><italic toggle="yes">W</italic></bold> were estimated by minimization of the Cox partial likelihoods. Partial likelihoods for linear and feedforward weights were adopted from Katzman and colleagues (<xref rid="bib100" ref-type="bibr">100</xref>) as: <inline-formula><tex-math id="M106">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\textbf{\em{L}}}_{{{\rm strata}}}}({\textbf{\em{W}}}) = {\prod _{{\rm{i}}:{{\rm{E}}_{\rm{i}}}\; = \;1}}\frac{{{\rm{exp}}\;({\textbf{\em{W}}}^{{\rm T}}}{\textbf{\em{X}}}_{{\rm i}}})}}{{\prod\nolimits_{{\rm{j}} \in {\rm{R}}({{{\rm T}}_{{\rm i}}})} {{\rm{exp}}} ({\textbf{\em{W}}}^{{\rm T}}}{\textbf{\em{X}}}_{{\rm j}}})}}$\end{document}</tex-math></inline-formula>. Here, <inline-formula><tex-math id="M107">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${{\rm{T}}_{\rm{i}}}$\end{document}</tex-math></inline-formula>i, <inline-formula><tex-math id="M108">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${{\rm{E}}_{\rm{i}}}$\end{document}</tex-math></inline-formula>, and <inline-formula><tex-math id="M109">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\textbf{\em{X}}}_{\textbf{i}}$\end{document}</tex-math></inline-formula>are the event time, event indicator, and bipotent target expression vector data for the <italic toggle="yes">i</italic>th patient. <inline-formula><tex-math id="M110">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$R({{\rm{T}}_{\rm{i}}})$\end{document}</tex-math></inline-formula> is a set of the patient risk at time <inline-formula><tex-math id="M111">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${{\rm{T}}_{\rm{i}}}$\end{document}</tex-math></inline-formula>. Likelihoods were estimated separately for PFS and OS as strata, and the final likelihood was defined <inline-formula><tex-math id="M112">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\textbf{\em{L}}}({\textbf{\em{W}}}) = {\textbf{\em{L}}}_{{{\bf os}}}}({\textbf{\em{W}}}){\rm{*}}{\textbf{\em{L}}}_{{{\bf PFS}}}}({\textbf{\em{W}}})$\end{document}</tex-math></inline-formula>.</p>
        <p>For learning, linear weights were estimated by minimizing <inline-formula><tex-math id="M113">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\textbf{\em{L}}}({\textbf{\em{W}}})$\end{document}</tex-math></inline-formula>using the R package “survival coxph.” For feedforward <inline-formula><tex-math id="M114">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\textbf{\em{W}}_{\bf feedforward}}$\end{document}</tex-math></inline-formula>, we divided TCGA melanoma samples (<italic toggle="yes">N</italic> = 465) into 85% training and the rest 15% validation. We minimized the likelihood to update the model parameters using the Adam optimizer a learning rate of 1 × E−3. To avoid overfitting, we used dropout with <italic toggle="yes">P</italic> = 0.4 after every hidden layer, and early stopping that was triggered when the likelihood is not decreased for 20 consecutive epochs, and selected the model with the highest validation likelihood (Supplementary Fig. S10K).</p>
      </sec>
      <sec id="sec4-23-5">
        <title>ICB Evaluation.</title>
        <p>The activity (normalized expression) of bipotent targets in ICB cohorts was used as input <bold><italic toggle="yes">X</italic></bold> to get BTAS and deepBTAS scores from the learned models described above. Note, the parameters of models were not updated using data from the ICB cohort. The BTAS and deepBTAS scores were individually used for patient stratification and response prediction. For patient stratification, patients were divided into either two (using median score) or four equal groups (in &lt;25, 25–50, 50–75, and &gt;75 percentiles). Kaplan–Meier plots were plotted using the stratifications, and the significance of survival difference was estimated using the log-rank test. For response prediction, we calculate accuracy (AUC) for classifying radiologic-based (partial/complete) responders and nonresponders (stable/progressive disease).</p>
      </sec>
    </sec>
    <sec id="sec4-24">
      <title>Evaluation of Bulk RNA and scRNA Submodule Contributions to BipotentR</title>
      <sec id="sec4-24-1">
        <title>BipotentR without the scRNA Submodule.</title>
        <p>We assessed how BipotentR would have performed without the scRNA submodule. TFCRs were selected that passed the filter <inline-formula><tex-math id="M115">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${P_{{\rm{regulation}}}} &lt; 0.05$\end{document}</tex-math></inline-formula>, <inline-formula><tex-math id="M116">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${B_T}$\end{document}</tex-math></inline-formula> &gt; 85% quantile of all <inline-formula><tex-math id="M117">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${B_T}$\end{document}</tex-math></inline-formula> and <inline-formula><tex-math id="M118">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${P_{{\rm{bulkRNA}}}} &lt; 0.05$\end{document}</tex-math></inline-formula>, and <inline-formula><tex-math id="M119">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\hat{\beta }_{{\rm{bulkRNA}}}}$\end{document}</tex-math></inline-formula> 85% quantile &lt; 15% quantile of all <inline-formula><tex-math id="M120">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\hat{\beta }_{{\rm{bulkRNA}}}}$\end{document}</tex-math></inline-formula>. Among the selected, 38 TFCRs with the largest score = <inline-formula><tex-math id="M121">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\rm{Norm}}({B_T}) + {\rm{Norm}}$\end{document}</tex-math></inline-formula> (<inline-formula><tex-math id="M122">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\hat{\beta }_{{\rm{bulkRNA}}}}$\end{document}</tex-math></inline-formula>) were selected for comparison with BipotentR-predicted regulators. Here <inline-formula><tex-math id="M123">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\rm{Norm}}(x)\; = \;\frac{{x - \;\min (x)}}{{\max (x) - {\rm{min}}(x)}}$\end{document}</tex-math></inline-formula>. The 38 predicted TFCRs were evaluated in a similar manner as was done for BipotentR-predicted regulators in the sections “Validation of immune roles” and “Prediction of melanoma response to anti–PD-1 using tumor activity of bipotent targets.”</p>
      </sec>
      <sec id="sec4-24-2">
        <title>BipotentR without the Bulk RNA Submodule.</title>
        <p>We assessed how BipotentR would have performed without the bulk RNA submodule. TFCRs were selected that passed the filter <inline-formula><tex-math id="M124">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${P_{{\rm{regulation}}}} &lt; 0.05$\end{document}</tex-math></inline-formula>, <inline-formula><tex-math id="M125">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${B_T}$\end{document}</tex-math></inline-formula>&gt; 85% quantile of all <inline-formula><tex-math id="M126">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${B_T}$\end{document}</tex-math></inline-formula> and <inline-formula><tex-math id="M127">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${P_{{\rm{scRNA}}}} &lt; 0.05$\end{document}</tex-math></inline-formula>, and <inline-formula><tex-math id="M128">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\hat{\beta }_{{\rm{scRNA}}}}\;$\end{document}</tex-math></inline-formula>85% quantile &lt; 15% quantile of all <inline-formula><tex-math id="M129">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\hat{\beta }_{{\rm{scRNA}}}}$\end{document}</tex-math></inline-formula>. Among the selected, 38 TFCRs with the largest score = <inline-formula><tex-math id="M130">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\rm{Norm}}({B_T}) + {\rm{Norm}}$\end{document}</tex-math></inline-formula> (<inline-formula><tex-math id="M131">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\hat{\beta }_{{\rm{scRNA}}}}\;$\end{document}</tex-math></inline-formula>) were selected for comparison with BipotentR-predicted regulators. Here <inline-formula><tex-math id="M132">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\rm{Norm}}(x)\; = \;\frac{{x - \;\min (x)}}{{\max (x) - {\rm{min}}(x)}}$\end{document}</tex-math></inline-formula>. The 38 predicted TFCRs were evaluated in a similar manner as was done for BipotentR-predicted regulators in sections “Validation of immune roles” and “Prediction of melanoma response to anti–PD-1 using tumor activity of bipotent targets.”</p>
      </sec>
    </sec>
    <sec id="sec4-25">
      <title>Benchmarking BipotentR against LISA</title>
      <p>Using (union of) genes set within the four energy metabolism pathways as input to LISA, we obtained LISA-predicted TFCRs. The top 38 LISA-predicted TFCRs were then evaluated against BipotentR-predicted TFCRs (<italic toggle="yes">n</italic> = 38). For evaluating these two TFCR sets, we compared how strongly their knockout suppressed energy metabolism genes. The suppression of energy metabolism for a given TFCR knockout was evaluated using the KnockTF database (<xref rid="bib54" ref-type="bibr">54</xref>) similar to the procedure described in section “Validation of metabolic roles.”</p>
    </sec>
    <sec id="sec4-26">
      <title>Evaluating Improvement of Predictive Power of Current ICB Biomarkers by BTAS/deepBTAS</title>
      <p>Three analyses were done to assess the improvement by BTAS/deepBTAS on current biomarkers. These analyses were done separately for PFS and OS.</p>
      <sec id="sec4-26-1">
        <title>BTAS/deepBTAS Association with ICB Survival Outcomes after Controlling for ICB Biomarker.</title>
        <p>The survival association of either BTAS or deepBTAS score was determined by controlling for levels for each ICB biomarker separately. Levels of a biomarker were controlled through a multivariate Cox proportional hazards model: <inline-formula><tex-math id="M133">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\;\lambda (t)\; = \;{\lambda _0}(t)\exp (a\;X + b\;Y)$\end{document}</tex-math></inline-formula>. Here, <inline-formula><tex-math id="M134">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\lambda (t)$\end{document}</tex-math></inline-formula> and <inline-formula><tex-math id="M135">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\lambda _0}(t)$\end{document}</tex-math></inline-formula> are hazard and baseline-hazard functions. <inline-formula><tex-math id="M136">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$X$\end{document}</tex-math></inline-formula> and <inline-formula><tex-math id="M137">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$Y$\end{document}</tex-math></inline-formula> are the BTAS (or deepBTAS) and biomarker levels of a patient tumor, respectively. <inline-formula><tex-math id="M138">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$a$\end{document}</tex-math></inline-formula> and <inline-formula><tex-math id="M139">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$b$\end{document}</tex-math></inline-formula> are the coefficients of association. The significance of association (<inline-formula><tex-math id="M140">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$a$\end{document}</tex-math></inline-formula> and <inline-formula><tex-math id="M141">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$b$\end{document}</tex-math></inline-formula>) is determined using the Wald test. Because association was estimated separately for each biomarker, multiple hypothesis correction is not required.</p>
      </sec>
      <sec id="sec4-26-2">
        <title>Performance Improvement by the Addition of BTAS/deepBTAS to Biomarkers.</title>
        <p>The improvement was quantified as an increase in the likelihood of the Cox model containing BTAS/deepBTAS and biomarker (<inline-formula><tex-math id="M142">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\lambda (t)\; = \;{\lambda _0}(t)\exp (a\;X + b\;Y)$\end{document}</tex-math></inline-formula>) over the model containing biomarker alone (<inline-formula><tex-math id="M143">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\lambda (t)\; = \;{\lambda _0}(t)\exp (b\;Y))$\end{document}</tex-math></inline-formula>. The significance of the improvement was assessed using the likelihood ratio test with <italic toggle="yes">χ</italic><sup>2</sup> test with a degree of freedom 1, which accounted for increased model complexity.</p>
      </sec>
      <sec id="sec4-26-3">
        <title>BTAS/deepBTAS Survival Association Separately on Tumors with High and Low Biomarker Levels.</title>
        <p>For each biomarker, tumors were divided into high and low tumor subcohorts (<italic toggle="yes">N</italic> = 148 each) using the median level of the biomarker. In these two subcohorts, Kaplan–Meier analyses for association with BTAS/deepBTAS were performed separately.</p>
      </sec>
    </sec>
    <sec id="sec4-27">
      <title>Statistical Analysis</title>
      <p>The tests used for statistical analyses are described in the legends of each concerned figure and have been performed using R v3.4. For each experimental group, <italic toggle="yes">n</italic> represents the number of subjects within each group. Wilcoxon rank-sum test was used for two-group comparison. Correlations were calculated using Spearman correlation analysis. A two-tailed <italic toggle="yes">P</italic> value &lt; 0.05 was considered statistically significant. Symbols for significance: ns, nonsignificant; *, &lt;0.05, **, &lt;0.01; ***, &lt;0.001; ****, &lt;0.0001. <italic toggle="yes">P</italic> values were adjusted for multiple hypotheses using the Benjamini–Hochberg correction (<xref rid="bib124" ref-type="bibr">124</xref>) throughout the article wherever applicable.</p>
    </sec>
    <sec sec-type="data-availability" id="sec4-28">
      <title>Data Availability Statement</title>
      <p>BipotentR is available at <ext-link xlink:href="http://bipotentr.dfci.harvard.edu/" ext-link-type="uri" xlink:show="new">http://bipotentr.dfci.harvard.edu/</ext-link>. The R package “BipotentR” is available at (<ext-link xlink:href="https://github.com/vinash85/TRIM" ext-link-type="uri" xlink:show="new">https://github.com/vinash85/TRIM</ext-link>). For reproducibility, data and code are shared publicly at the Zenodo repository that is linked to the BipotentR website at <ext-link xlink:href="http://bipotentr.dfci.harvard.edu/" ext-link-type="uri" xlink:show="new">http://bipotentr.dfci.harvard.edu/</ext-link>. The website also provides access to bulk and single RNA-seq data generated from the current study. AI/ML approaches developed from the study are accessible using a publicly available Web browser (<ext-link xlink:href="https://rconnect.dfci.harvard.edu/BTAS/" ext-link-type="uri" xlink:show="new">https://rconnect.dfci.harvard.edu/BTAS/</ext-link>) and a stand-alone software tool, which users can use to predict patient response to immunotherapy in any input melanoma cohort.</p>
    </sec>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="supp101" position="float" content-type="local-data">
      <label>Supplementary tables</label>
      <caption>
        <p>S1: TFCRs of energy metabolism
S2: Bipotent TFCRs
S3: Log fold change of T-cell mediated killing upon knockout of OXPHOS genes
S4: Log fold change of MHC-I protien expression upon knockout of OXPHOS genes
S5: Bipotent TFCRs of angiogenesis
S6: Bipotent TFCRs of evasion of growth repressors
S7: Datasets included in Methods sections.</p>
      </caption>
      <media xlink:href="cd-22-0244_supplementary_tables_suppst1.xlsx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="supp102" position="float" content-type="local-data">
      <label>Figure S1</label>
      <caption>
        <p>The description and validation of the BipotentR immune module</p>
      </caption>
      <media xlink:href="cd-22-0244_figure_s1_suppsf1.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="supp103" position="float" content-type="local-data">
      <label>Figure S2</label>
      <caption>
        <p>ESRRA inhibition induces antitumor immunity in vivo.</p>
      </caption>
      <media xlink:href="cd-22-0244_figure_s2_suppsf2.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="supp104" position="float" content-type="local-data">
      <label>Figure S3</label>
      <caption>
        <p>ESRRA inhibition is associated with immune infiltrations and proinflammatory signaling in patient tumors.</p>
      </caption>
      <media xlink:href="cd-22-0244_figure_s3_suppsf3.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="supp105" position="float" content-type="local-data">
      <label>Figure S4</label>
      <caption>
        <p>ESRRA inhibition correlated with immune infiltrations and proinflammatory signaling in patient tumors.</p>
      </caption>
      <media xlink:href="cd-22-0244_figure_s4_suppsf4.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="supp106" position="float" content-type="local-data">
      <label>Figure S5</label>
      <caption>
        <p>Robust in vivo antitumor elimination by ESRRA inhibition.</p>
      </caption>
      <media xlink:href="cd-22-0244_figure_s5_suppsf5.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="supp107" position="float" content-type="local-data">
      <label>Figure S6</label>
      <caption>
        <p>Energy metabolism and immune signaling by targeting ESRRA in vitro.</p>
      </caption>
      <media xlink:href="cd-22-0244_figure_s6_suppsf6.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="supp108" position="float" content-type="local-data">
      <label>Figure S7</label>
      <caption>
        <p>Energy metabolism and immune signaling by targeting ESRRA in vitro.</p>
      </caption>
      <media xlink:href="cd-22-0244_figure_s7_suppsf7.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="supp109" position="float" content-type="local-data">
      <label>Figure S8</label>
      <caption>
        <p>The effect of ESRRA inhibition on tumor microenvironments at single-cell resolutions.</p>
      </caption>
      <media xlink:href="cd-22-0244_figure_s8_suppsf8.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="supp110" position="float" content-type="local-data">
      <label>Figure S9</label>
      <caption>
        <p>ESRRAi does not affect CD8+T T-cells, and ESRRA activity increases post-immunotherapy in resistant tumors.</p>
      </caption>
      <media xlink:href="cd-22-0244_figure_s9_suppsf9.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="supp111" position="float" content-type="local-data">
      <label>Figure S10</label>
      <caption>
        <p>Machine learning evaluation of immune-metabolic targets in predicting patient response to anti-PD1 monotherapy.</p>
      </caption>
      <media xlink:href="cd-22-0244_figure_s10_suppsf10.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="supp112" position="float" content-type="local-data">
      <label>Figure S11</label>
      <caption>
        <p>Machine learning evaluation of immune-metabolic targets in predicting patient response to anti-PD1 and anti-CTLA4 combination therapy.</p>
      </caption>
      <media xlink:href="cd-22-0244_figure_s11_suppsf11.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="supp113" position="float" content-type="local-data">
      <label>Figure S12</label>
      <caption>
        <p>deepBTAS improve the performance of current ICB biomarkers.</p>
      </caption>
      <media xlink:href="cd-22-0244_figure_s12_suppsf12.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="supp114" position="float" content-type="local-data">
      <label>Figure S13</label>
      <caption>
        <p>Kaplan–Meier plots showing progression-free survival and overall survival differences for patients receiving anti-PD1 between the low-risk and high-risk groups defined by the median value of deepBTAS.</p>
      </caption>
      <media xlink:href="cd-22-0244_figure_s13_suppsf13.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="supp115" position="float" content-type="local-data">
      <label>Figure S14</label>
      <caption>
        <p>Evaluation of bulk-BipotentR (BipotentR without single-cell sub-module).</p>
      </caption>
      <media xlink:href="cd-22-0244_figure_s14_suppsf14.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="supp116" position="float" content-type="local-data">
      <label>Figure S15</label>
      <caption>
        <p>Evaluation of scRNA-BipotentR (BipotentR without bulk-tumor sub-module).</p>
      </caption>
      <media xlink:href="cd-22-0244_figure_s15_suppsf15.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="supp117" position="float" content-type="local-data">
      <label>Figure S16</label>
      <caption>
        <p>Validation of bipotent regulators of angiogenesis or growth-suppressor.</p>
      </caption>
      <media xlink:href="cd-22-0244_figure_s16_suppsf16.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="supp118" position="float" content-type="local-data">
      <label>Figure S17</label>
      <caption>
        <p>Overall design.</p>
      </caption>
      <media xlink:href="cd-22-0244_figure_s17_suppsf17.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="supp119" position="float" content-type="local-data">
      <label>Figure S18</label>
      <caption>
        <p>Evaluation of BipotentR.</p>
      </caption>
      <media xlink:href="cd-22-0244_figure_s18_suppsf18.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="supp120" position="float" content-type="local-data">
      <label>Figure S19</label>
      <caption>
        <p>Expression of markers of M1 and M2 in scRNA data of ESRRAi and Vehicle treated mice.</p>
      </caption>
      <media xlink:href="cd-22-0244_figure_s19_suppsf19.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="supp121" position="float" content-type="local-data">
      <label>Supplementary Notes</label>
      <caption>
        <p>We detailed a comparison of BipotentR with competing and alternative approaches in Supplementary notes 1, 2, 6, and 7. Supplementary Note 3-5 describes the in vitro findings of ESRRA, the potential clinical relevance of ESRRA across cancer-types, and the association of tumor activity of ESRRA with immune infiltration.</p>
      </caption>
      <media xlink:href="cd-22-0244_supplementary_notes_suppsn1.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack>
    <title>Acknowledgments</title>
    <p>A. Sahu was supported by the NIH/NCI (K99CA248953) and the Human Vaccines Project (MP19-02-190). D.E. Fisher was supported by the NIH/NCI (R01AR072304, R01AR043369, P01CA163222, and R01CA222871). K.T. Flaherty and D.E. Fisher were supported by the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation. X. Wang was supported by the China Scholarship Council (2018062104<xref rid="bib22" ref-type="bibr">22</xref>). C. Tokheim was supported by the Damon Runyon Cancer Research Foundation (DRQ-04-20). N.U. Nair was supported in part by the Intramural Research Program of the NIH, NCI, and the Center for Cancer Research. The authors from Lead Pharma, including A. Oubrie, J.P.G. Klomp, J.A.P. Rens, M. Bourajjaj, B. Jansen, I. Leenders, J. Lemmers, M. Musters, S. van Zanten, and L. van Zelst, were supported by Eurostars (Eureka, PREVAIL 11590). We thank Rafael A. Irizarry and Myles A. Brown for their valuable suggestions.</p>
    <p>The publication costs of this article were defrayed in part by the payment of publication fees. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.</p>
  </ack>
  <fn-group>
    <fn fn-type="supplementary-material">
      <p><bold>Note:</bold> Supplementary data for this article are available at Cancer Discovery Online (http://cancerdiscovery.aacrjournals.org/).</p>
    </fn>
  </fn-group>
  <sec id="sec5">
    <title>Authors’ Disclosures</title>
    <p>A. Sahu reports nonfinancial support from Lead Pharma during the conduct of the study, as well as nonfinancial support from C-Reveal Therapeutics and Checkmate Pharmaceuticals outside the submitted work. J.P.G. Klomp reports grants from Eurostars during the conduct of the study; other support from Lead Pharma outside the submitted work; and a patent for WO2021001453 pending and a patent for WO2021074365 pending. S.S. Gu reports a Sara Elizabeth O'Brien Trust Fellowship outside the submitted work. C. Tokheim reports grants from the Damon Runyon Cancer Research Foundation during the conduct of the study. M. Bourajjaj reports grants from Eurostars during the conduct of the study, as well as other support from Lead Pharma outside the submitted work. B. Jansen reports grants from Eurostars during the conduct of the study, as well as other support from Lead Pharma outside the submitted work. I. Leenders reports grants from Eurostars during the conduct of the study; other support from Lead Pharma outside the submitted work; and a patent for WO2021001453 pending and a patent for WO2021074365 pending. J. Lemmers reports grants from Eurostars during the conduct of the study; other support from Lead Pharma outside the submitted work; and a patent for WO2021001453 pending and a patent for WO2021074365 pending. S. van Zanten reports grants from Eurostars during the conduct of the study, as well as other support from Lead Pharma outside the submitted work. L. van Zelst reports grants from Eurostars during the conduct of the study, as well as other support from Lead Pharma outside the submitted work. J. Worthington reports grants from Eurostars during the conduct of the study. D. Juric reports grants and personal fees from Novartis, Genentech, Syros, Eli Lilly, and Eisai, grants from Pfizer, Amgen, InventisBio, Arvinas, Takeda, Blueprint, Ribon, and Infinity, and personal fees from Relay, PIC Therapeutics, Vibliome, and Mapkure outside the submitted work. A. Oubrie reports grants from Eurostars during the conduct of the study; other support from Lead Pharma outside the submitted work; and a patent for WO2021001453 pending and a patent for WO2021074365 pending. X.S. Liu conducted the work while on the faculty at Dana-Farber Cancer Institute and is currently a board member for and CEO of GV20 Therapeutics. D.E. Fisher reports grants from the NIH, the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, and Lead Pharma during the conduct of the study; grants from the NIH, Lead Pharma, and the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation outside the submitted work; and a financial interest in Soltego, a company developing salt inducible kinase inhibitors for topical skin-darkening treatments that might be used for a broad set of human applications. The interests of D.E. Fisher were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict-of-interest policies. K.T. Flaherty reports personal fees from Clovis Oncology, Strata Oncology, Checkmate Pharmaceuticals, Kinnate Biopharma, Scorpion Therapeutics, PIC Therapeutics, Apricity, Tvardi, xCures, Monopteros, Vibliome, ALX Oncology, Fog Pharma, Soley Therapeutics, Nextech, Takeda, Transcode Therapeutics, Oncoceutics, OMRx, Quanta Therapeutics, Lilly, and Genentech, and grants from Novartis and Sanofi during the conduct of the study. No disclosures were reported by the other authors.</p>
  </sec>
  <sec id="sec6">
    <title>Authors’ Contributions</title>
    <p><bold>A. Sahu:</bold> Conceptualization, resources, data curation, software, formal analysis, supervision, funding acquisition, validation, methodology, writing–original draft, project administration, writing–review and editing. <bold>X. Wang:</bold> Data curation, software, formal analysis, visualization, methodology, writing–review and editing. <bold>P. Munson:</bold> Validation, writing–review and editing. <bold>J.P.G. Klomp:</bold> Resources, writing–review and editing. <bold>X. Wang:</bold> Data curation. <bold>S.S. Gu:</bold> Data curation, writing–review and editing. <bold>Y. Han:</bold> Data curation. <bold>G. Qian:</bold> Data curation. <bold>P.B. Nicol:</bold> Software. <bold>Z. Zeng:</bold> Resources. <bold>C. Wang:</bold> Data curation. <bold>C. Tokheim:</bold> Data curation. <bold>W. Zhang:</bold> Data curation. <bold>J. Fu:</bold> Data curation. <bold>J. Wang:</bold> Data curation. <bold>N.U. Nair:</bold> Data curation. <bold>J.A.P. Rens:</bold> Data curation. <bold>M. Bourajjaj:</bold> Data curation. <bold>B. Jansen:</bold> Data curation. <bold>I. Leenders:</bold> Data curation. <bold>J. Lemmers:</bold> Data curation. <bold>M. Musters:</bold> Data curation. <bold>S. van Zanten:</bold> Data curation. <bold>L. van Zelst:</bold> Data curation. <bold>J. Worthington:</bold> Data curation. <bold>J.S. Liu:</bold> Project administration, writing–review and editing. <bold>D. Juric:</bold> Data curation. <bold>C.A. Meyer:</bold> Writing–review and editing. <bold>A. Oubrie:</bold> Resources, data curation. <bold>X.S. Liu:</bold> Conceptualization, supervision, writing–review and editing. <bold>D.E. Fisher:</bold> Conceptualization, supervision, project administration, writing–review and editing. <bold>K.T. Flaherty:</bold> Conceptualization, supervision, project administration, writing–review and editing.</p>
  </sec>
  <ref-list>
    <title>References</title>
    <ref id="bib1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>C</given-names></string-name>, <string-name><surname>Vegna</surname><given-names>S</given-names></string-name>, <string-name><surname>Jin</surname><given-names>H</given-names></string-name>, <string-name><surname>Benedict</surname><given-names>B</given-names></string-name>, <string-name><surname>Lieftink</surname><given-names>C</given-names></string-name>, <string-name><surname>Ramirez</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>Inducing and exploiting vulnerabilities for the treatment of liver cancer</article-title>. <source>Nature</source><year>2019</year>;<volume>574</volume>:<fpage>268</fpage>–<lpage>72</lpage>.<pub-id pub-id-type="pmid">31578521</pub-id></mixed-citation>
    </ref>
    <ref id="bib2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Palmer</surname><given-names>AC</given-names></string-name>, <string-name><surname>Sorger</surname><given-names>PK</given-names></string-name></person-group>. <article-title>Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy</article-title>. <source>Cell</source><year>2017</year>;<volume>171</volume>:<fpage>1678</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="pmid">29245013</pub-id></mixed-citation>
    </ref>
    <ref id="bib3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Benesic</surname><given-names>A</given-names></string-name>, <string-name><surname>Jalal</surname><given-names>K</given-names></string-name>, <string-name><surname>Gerbes</surname><given-names>AL</given-names></string-name></person-group>. <article-title>Drug-drug combinations can enhance toxicity as shown by monocyte-derived hepatocyte-like cells from patients with idiosyncratic drug-induced liver injury</article-title>. <source>Toxicol Sci</source><year>2019</year>;<volume>171</volume>:<fpage>296</fpage>–<lpage>302</lpage>.</mixed-citation>
    </ref>
    <ref id="bib4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nahar</surname><given-names>KJ</given-names></string-name>, <string-name><surname>Rawson</surname><given-names>RV</given-names></string-name>, <string-name><surname>Ahmed</surname><given-names>T</given-names></string-name>, <string-name><surname>Tattersall</surname><given-names>S</given-names></string-name>, <string-name><surname>Sandanayake</surname><given-names>N</given-names></string-name>, <string-name><surname>Kiely</surname><given-names>CJ</given-names></string-name>, <etal/></person-group>. <article-title>Clinicopathological characteristics and management of colitis with anti–PD-1 immunotherapy alone or in combination with ipilimumab</article-title>. <source>J Immunother Cancer</source><year>2020</year>;<volume>8</volume>:<fpage>e001488</fpage>.<pub-id pub-id-type="pmid">33234603</pub-id></mixed-citation>
    </ref>
    <ref id="bib5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Petroni</surname><given-names>G</given-names></string-name>, <string-name><surname>Formenti</surname><given-names>SC</given-names></string-name>, <string-name><surname>Chen-Kiang</surname><given-names>S</given-names></string-name>, <string-name><surname>Galluzzi</surname><given-names>L</given-names></string-name></person-group>. <article-title>Immunomodulation by anticancer cell cycle inhibitors</article-title>. <source>Nat Rev Immunol</source><year>2020</year>;<volume>20</volume>:<fpage>669</fpage>–<lpage>79</lpage>.<pub-id pub-id-type="pmid">32346095</pub-id></mixed-citation>
    </ref>
    <ref id="bib6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bartlett</surname><given-names>JB</given-names></string-name>, <string-name><surname>Dredge</surname><given-names>K</given-names></string-name>, <string-name><surname>Dalgleish</surname><given-names>AG</given-names></string-name></person-group>. <article-title>The evolution of thalidomide and its IMiD derivatives as anticancer agents</article-title>. <source>Nat Rev Cancer</source><year>2004</year>;<volume>4</volume>:<fpage>314</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="pmid">15057291</pub-id></mixed-citation>
    </ref>
    <ref id="bib7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>O'Neill</surname><given-names>LAJ</given-names></string-name>, <string-name><surname>Artyomov</surname><given-names>MN</given-names></string-name></person-group>. <article-title>Itaconate: the poster child of metabolic reprogramming in macrophage function</article-title>. <source>Nat Rev Immunol</source><year>2019</year>;<volume>19</volume>:<fpage>273</fpage>–<lpage>81</lpage>.<pub-id pub-id-type="pmid">30705422</pub-id></mixed-citation>
    </ref>
    <ref id="bib8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moreno-Gonzalo</surname><given-names>O</given-names></string-name>, 
<string-name><given-names>MF</given-names><surname>Jr</surname></string-name>, <string-name><surname>Sánchez-Madrid</surname><given-names>F</given-names></string-name></person-group>. <article-title>HDAC6 at crossroads of infection and innate immunity</article-title>. <source>Trends Immunol</source><year>2018</year>;<volume>39</volume>:<fpage>591</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">29937401</pub-id></mixed-citation>
    </ref>
    <ref id="bib9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Koga</surname><given-names>S</given-names></string-name>, <string-name><surname>Onishi</surname><given-names>H</given-names></string-name>, <string-name><surname>Masuda</surname><given-names>S</given-names></string-name>, <string-name><surname>Fujimura</surname><given-names>A</given-names></string-name>, <string-name><surname>Ichimiya</surname><given-names>S</given-names></string-name>, <string-name><surname>Nakayama</surname><given-names>K</given-names></string-name>, <etal/></person-group>. <article-title>PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor</article-title>. <source>Transl Oncol</source><year>2021</year>;<volume>14</volume>:<fpage>101152</fpage>.<pub-id pub-id-type="pmid">34134073</pub-id></mixed-citation>
    </ref>
    <ref id="bib10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ma</surname><given-names>W</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Magee</surname><given-names>NE</given-names></string-name>, <string-name><surname>Feng</surname><given-names>Y</given-names></string-name>, <string-name><surname>Shi</surname><given-names>R</given-names></string-name>, <etal/></person-group>. <article-title>BARTweb: a web server for transcriptional regulator association analysis</article-title>. <source>NAR Genom Bioinform</source><year>2021</year>;<volume>3</volume>:<fpage>lqab022</fpage>.<pub-id pub-id-type="pmid">33860225</pub-id></mixed-citation>
    </ref>
    <ref id="bib11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Z</given-names></string-name>, <string-name><surname>Qin</surname><given-names>W</given-names></string-name>, <string-name><surname>Liu</surname><given-names>S</given-names></string-name>, <string-name><surname>Liu</surname><given-names>C</given-names></string-name>, <string-name><surname>Genchev</surname><given-names>GZ</given-names></string-name>, <etal/></person-group>. <article-title>RePhine: an integrative method for identification of drug response-related transcriptional regulators</article-title>. <source>Genomics Proteomics Bioinformatics</source><year>2021</year>;<volume>19</volume>:<fpage>534</fpage>–<lpage>48</lpage>.<pub-id pub-id-type="pmid">33713851</pub-id></mixed-citation>
    </ref>
    <ref id="bib12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Das</surname><given-names>A</given-names></string-name>, <string-name><surname>Morley</surname><given-names>M</given-names></string-name>, <string-name><surname>Moravec</surname><given-names>CS</given-names></string-name>, <string-name><surname>Tang</surname><given-names>WHW</given-names></string-name>, <string-name><surname>Hakonarson</surname><given-names>H</given-names></string-name>, <collab>MAGN Consortium</collab>, <etal/></person-group>. <article-title>Bayesian integration of genetics and epigenetics detects causal regulatory SNPs underlying expression variability</article-title>. <source>Nat Commun</source><year>2015</year>;<volume>6</volume>:<fpage>8555</fpage>.<pub-id pub-id-type="pmid">26456756</pub-id></mixed-citation>
    </ref>
    <ref id="bib13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Qin</surname><given-names>Q</given-names></string-name>, <string-name><surname>Fan</surname><given-names>J</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>R</given-names></string-name>, <string-name><surname>Wan</surname><given-names>C</given-names></string-name>, <string-name><surname>Mei</surname><given-names>S</given-names></string-name>, <string-name><surname>Wu</surname><given-names>Q</given-names></string-name>, <etal/></person-group>. <article-title>Lisa: inferring transcriptional regulators through integrative modeling of public chromatin accessibility and ChIP-seq data</article-title>. <source>Genome Biol</source><year>2020</year>;<volume>21</volume>:<fpage>32</fpage>.<pub-id pub-id-type="pmid">32033573</pub-id></mixed-citation>
    </ref>
    <ref id="bib14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hanahan</surname><given-names>D</given-names></string-name>, <string-name><surname>Weinberg</surname><given-names>RA</given-names></string-name></person-group>. <article-title>Hallmarks of cancer: the next generation</article-title>. <source>Cell</source><year>2011</year>;<volume>144</volume>:<fpage>646</fpage>–<lpage>74</lpage>.<pub-id pub-id-type="pmid">21376230</pub-id></mixed-citation>
    </ref>
    <ref id="bib15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bajzikova</surname><given-names>M</given-names></string-name>, <string-name><surname>Kovarova</surname><given-names>J</given-names></string-name>, <string-name><surname>Coelho</surname><given-names>AR</given-names></string-name>, <string-name><surname>Boukalova</surname><given-names>S</given-names></string-name>, <string-name><surname>Oh</surname><given-names>S</given-names></string-name>, <string-name><surname>Rohlenova</surname><given-names>K</given-names></string-name>, <etal/></person-group>. <article-title>Reactivation of dihydroorotate dehydrogenase-driven pyrimidine biosynthesis restores tumor growth of respiration-deficient cancer cells</article-title>. <source>Cell Metab</source><year>2019</year>;<volume>29</volume>:<fpage>399</fpage>–<lpage>416</lpage>.<pub-id pub-id-type="pmid">30449682</pub-id></mixed-citation>
    </ref>
    <ref id="bib16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Farge</surname><given-names>T</given-names></string-name>, <string-name><surname>Saland</surname><given-names>E</given-names></string-name>, <string-name><surname>de Toni</surname><given-names>F</given-names></string-name>, <string-name><surname>Aroua</surname><given-names>N</given-names></string-name>, <string-name><surname>Hosseini</surname><given-names>M</given-names></string-name>, <string-name><surname>Perry</surname><given-names>R</given-names></string-name>, <etal/></person-group>. <article-title>Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism</article-title>. <source>Cancer Discov</source><year>2017</year>;<volume>7</volume>:<fpage>716</fpage>–<lpage>35</lpage>.<pub-id pub-id-type="pmid">28416471</pub-id></mixed-citation>
    </ref>
    <ref id="bib17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kuntz</surname><given-names>EM</given-names></string-name>, <string-name><surname>Baquero</surname><given-names>P</given-names></string-name>, <string-name><surname>Michie</surname><given-names>AM</given-names></string-name>, <string-name><surname>Dunn</surname><given-names>K</given-names></string-name>, <string-name><surname>Tardito</surname><given-names>S</given-names></string-name>, <string-name><surname>Holyoake</surname><given-names>TL</given-names></string-name>, <etal/></person-group>. <article-title>Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells</article-title>. <source>Nat Med</source><year>2017</year>;<volume>23</volume>:<fpage>1234</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="pmid">28920959</pub-id></mixed-citation>
    </ref>
    <ref id="bib18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lissanu Deribe</surname><given-names>Y</given-names></string-name>, <string-name><surname>Sun</surname><given-names>Y</given-names></string-name>, <string-name><surname>Terranova</surname><given-names>C</given-names></string-name>, <string-name><surname>Khan</surname><given-names>F</given-names></string-name>, <string-name><surname>Martinez-Ledesma</surname><given-names>J</given-names></string-name>, <string-name><surname>Gay</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer</article-title>. <source>Nat Med</source><year>2018</year>;<volume>24</volume>:<fpage>1047</fpage>–<lpage>57</lpage>.<pub-id pub-id-type="pmid">29892061</pub-id></mixed-citation>
    </ref>
    <ref id="bib19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Prado-García</surname><given-names>H</given-names></string-name>, <string-name><surname>Sánchez-García</surname><given-names>FJ</given-names></string-name></person-group>. <article-title>Editorial: immuno-metabolism in tumor microenvironment</article-title>. <source>Front Immunol.</source><year>2017</year>;<volume>8</volume>:<fpage>374</fpage>.<pub-id pub-id-type="pmid">28424698</pub-id></mixed-citation>
    </ref>
    <ref id="bib20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Biswas</surname><given-names>SK</given-names></string-name></person-group>. <article-title>Metabolic reprogramming of immune cells in cancer progression</article-title>. <source>Immunity</source><year>2015</year>;<volume>43</volume>:<fpage>435</fpage>–<lpage>49</lpage>.<pub-id pub-id-type="pmid">26377897</pub-id></mixed-citation>
    </ref>
    <ref id="bib21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Alfarouk</given-names><surname>KO</surname></string-name></person-group>. <article-title>Tumor metabolism, cancer cell transporters, and microenvironmental resistance</article-title>. <source>J Enzyme Inhib Med Chem</source><year>2016</year>;<volume>31</volume>:<fpage>859</fpage>–<lpage>66</lpage>.<pub-id pub-id-type="pmid">26864256</pub-id></mixed-citation>
    </ref>
    <ref id="bib22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chang</surname><given-names>C-H</given-names></string-name>, <string-name><surname>Qiu</surname><given-names>J</given-names></string-name>, <string-name><surname>O'Sullivan</surname><given-names>D</given-names></string-name>, <string-name><surname>Buck</surname><given-names>MD</given-names></string-name>, <string-name><surname>Noguchi</surname><given-names>T</given-names></string-name>, <string-name><surname>Curtis</surname><given-names>JD</given-names></string-name>, <etal/></person-group>. <article-title>Metabolic competition in the tumor microenvironment is a driver of cancer progression</article-title>. <source>Cell</source><year>2015</year>;<volume>162</volume>:<fpage>1229</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="pmid">26321679</pub-id></mixed-citation>
    </ref>
    <ref id="bib23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fischer</surname><given-names>GM</given-names></string-name>, <string-name><surname>Jalali</surname><given-names>A</given-names></string-name>, <string-name><surname>Kircher</surname><given-names>DA</given-names></string-name>, <string-name><surname>Lee</surname><given-names>WC</given-names></string-name>, <string-name><surname>McQuade</surname><given-names>JL</given-names></string-name>, <string-name><surname>Haydu</surname><given-names>LE</given-names></string-name>, <etal/></person-group>. <article-title>Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases</article-title>. <source>Cancer Discov</source><year>2019</year>;<volume>9</volume>:<fpage>628</fpage>–<lpage>45</lpage>.<pub-id pub-id-type="pmid">30787016</pub-id></mixed-citation>
    </ref>
    <ref id="bib24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ye</surname><given-names>Y</given-names></string-name>, <string-name><surname>Hu</surname><given-names>Q</given-names></string-name>, <string-name><surname>Chen</surname><given-names>H</given-names></string-name>, <string-name><surname>Liang</surname><given-names>K</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>Y</given-names></string-name>, <string-name><surname>Xiang</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy</article-title>. <source>Nat Metab</source><year>2019</year>;<volume>1</volume>:<fpage>431</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="pmid">31984309</pub-id></mixed-citation>
    </ref>
    <ref id="bib25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname><given-names>SH</given-names></string-name>, <string-name><surname>Li</surname><given-names>M</given-names></string-name>, <string-name><surname>Trousil</surname><given-names>S</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Pasca di Magliano</surname><given-names>M</given-names></string-name>, <string-name><surname>Swanson</surname><given-names>KD</given-names></string-name>, <etal/></person-group>. <article-title>Phenformin inhibits myeloid-derived suppressor cells and enhances the anti-tumor activity of PD-1 blockade in melanoma</article-title>. <source>J Invest Dermatol</source><year>2017</year>;<volume>137</volume>:<fpage>1740</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">28433543</pub-id></mixed-citation>
    </ref>
    <ref id="bib26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Purohit</surname><given-names>V</given-names></string-name>, <string-name><surname>Wagner</surname><given-names>A</given-names></string-name>, <string-name><surname>Yosef</surname><given-names>N</given-names></string-name>, <string-name><surname>Kuchroo</surname><given-names>VK</given-names></string-name></person-group>. <article-title>Systems-based approaches to study immunometabolism</article-title>. <source>Cell Mol Immunol</source><year>2022</year>;<volume>19</volume>:<fpage>409</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="pmid">35121805</pub-id></mixed-citation>
    </ref>
    <ref id="bib27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Leone</surname><given-names>RD</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>L</given-names></string-name>, <string-name><surname>Englert</surname><given-names>JM</given-names></string-name>, <string-name><surname>Sun</surname><given-names>IM</given-names></string-name>, <string-name><surname>Oh</surname><given-names>MH</given-names></string-name>, <string-name><surname>Sun</surname><given-names>IH</given-names></string-name>, <etal/></person-group>. <article-title>Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion</article-title>. <source>Science</source><year>2019</year>;<volume>366</volume>:<fpage>1013</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="pmid">31699883</pub-id></mixed-citation>
    </ref>
    <ref id="bib28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Renner</surname><given-names>K</given-names></string-name>, <string-name><surname>Singer</surname><given-names>K</given-names></string-name>, <string-name><surname>Koehl</surname><given-names>GE</given-names></string-name>, <string-name><surname>Geissler</surname><given-names>EK</given-names></string-name>, <string-name><surname>Peter</surname><given-names>K</given-names></string-name>, <string-name><surname>Siska</surname><given-names>PJ</given-names></string-name>, <etal/></person-group>. <article-title>Metabolic hallmarks of tumor and immune cells in the tumor microenvironment</article-title>. <source>Front Immunol</source><year>2017</year>;<volume>8</volume>:<fpage>248</fpage>.<pub-id pub-id-type="pmid">28337200</pub-id></mixed-citation>
    </ref>
    <ref id="bib29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scharping</surname><given-names>NE</given-names></string-name>, <string-name><surname>Delgoffe</surname><given-names>GM</given-names></string-name></person-group>. <article-title>Tumor microenvironment metabolism: a new checkpoint for anti-tumor immunity</article-title>. <source>Vaccines (Basel)</source><year>2016</year>;<volume>4</volume>:<fpage>46</fpage>.<pub-id pub-id-type="pmid">27929420</pub-id></mixed-citation>
    </ref>
    <ref id="bib30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Martínez-Reyes</surname><given-names>I</given-names></string-name>, <string-name><surname>Chandel</surname><given-names>NS</given-names></string-name></person-group>. <article-title>Mitochondrial TCA cycle metabolites control physiology and disease</article-title>. <source>Nat Commun</source><year>2020</year>;<volume>11</volume>:<fpage>102</fpage>.<pub-id pub-id-type="pmid">31900386</pub-id></mixed-citation>
    </ref>
    <ref id="bib31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shi</surname><given-names>H</given-names></string-name>, <string-name><surname>Kokoeva</surname><given-names>MV</given-names></string-name>, <string-name><surname>Inouye</surname><given-names>K</given-names></string-name>, <string-name><surname>Tzameli</surname><given-names>I</given-names></string-name>, <string-name><surname>Yin</surname><given-names>H</given-names></string-name>, <string-name><surname>Flier</surname><given-names>JS</given-names></string-name>, <etal/></person-group>. <article-title>TLR4 links innate immunity and fatty acid–induced insulin resistance</article-title>. <source>J Clin Invest</source><year>2006</year>;<volume>116</volume>:<fpage>3015</fpage>–<lpage>25</lpage>.<pub-id pub-id-type="pmid">17053832</pub-id></mixed-citation>
    </ref>
    <ref id="bib32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Calder</surname><given-names>PC</given-names></string-name></person-group>. <article-title>The relationship between the fatty acid composition of immune cells and their function</article-title>. <source>Prostaglandins Leukot Essent Fatty Acids</source><year>2008</year>;<volume>79</volume>:<fpage>101</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">18951005</pub-id></mixed-citation>
    </ref>
    <ref id="bib33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mei</surname><given-names>S</given-names></string-name>, <string-name><surname>Qin</surname><given-names>Q</given-names></string-name>, <string-name><surname>Wu</surname><given-names>Q</given-names></string-name>, <string-name><surname>Sun</surname><given-names>H</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>R</given-names></string-name>, <string-name><surname>Zang</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>Cistrome Data Browser: a data portal for ChIP-seq and chromatin accessibility data in human and mouse</article-title>. <source>Nucleic Acids Res</source><year>2017</year>;<volume>45</volume>:<fpage>D658</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="pmid">27789702</pub-id></mixed-citation>
    </ref>
    <ref id="bib34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zheng</surname><given-names>R</given-names></string-name>, <string-name><surname>Wan</surname><given-names>C</given-names></string-name>, <string-name><surname>Mei</surname><given-names>S</given-names></string-name>, <string-name><surname>Qin</surname><given-names>Q</given-names></string-name>, <string-name><surname>Wu</surname><given-names>Q</given-names></string-name>, <string-name><surname>Sun</surname><given-names>H</given-names></string-name>, <etal/></person-group>. <article-title>Cistrome data browser: expanded datasets and new tools for gene regulatory analysis</article-title>. <source>Nucleic Acids Res</source><year>2019</year>;<volume>47</volume>:<fpage>D729</fpage>–<lpage>35</lpage>.<pub-id pub-id-type="pmid">30462313</pub-id></mixed-citation>
    </ref>
    <ref id="bib35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Deblois</surname><given-names>G</given-names></string-name>, <string-name><surname>Giguère</surname><given-names>V</given-names></string-name></person-group>. <article-title>Functional and physiological genomics of estrogen-related receptors (ERRs) in health and disease</article-title>. <source>Biochim Biophys Acta</source><year>2011</year>;<volume>1812</volume>:<fpage>1032</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="pmid">21172432</pub-id></mixed-citation>
    </ref>
    <ref id="bib36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname><given-names>J</given-names></string-name>, <string-name><surname>Williams</surname><given-names>RS</given-names></string-name>, <string-name><surname>Kelly</surname><given-names>DP</given-names></string-name></person-group>. <article-title>Bcl3 interacts cooperatively with peroxisome proliferator-activated receptor gamma (PPARgamma) coactivator 1alpha to coactivate nuclear receptors estrogen-related receptor alpha and PPARalpha</article-title>. <source>Mol Cell Biol</source><year>2009</year>;<volume>29</volume>:<fpage>4091</fpage>–<lpage>102</lpage>.<pub-id pub-id-type="pmid">19451226</pub-id></mixed-citation>
    </ref>
    <ref id="bib37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Varga</surname><given-names>T</given-names></string-name>, <string-name><surname>Czimmerer</surname><given-names>Z</given-names></string-name>, <string-name><surname>Nagy</surname><given-names>L</given-names></string-name></person-group>. <article-title>PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation</article-title>. <source>Biochim Biophys Acta</source><year>2011</year>;<volume>1812</volume>:<fpage>1007</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="pmid">21382489</pub-id></mixed-citation>
    </ref>
    <ref id="bib38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>W</given-names></string-name>, <string-name><surname>Tanikawa</surname><given-names>T</given-names></string-name>, <string-name><surname>Kryczek</surname><given-names>I</given-names></string-name>, <string-name><surname>Xia</surname><given-names>H</given-names></string-name>, <string-name><surname>Li</surname><given-names>G</given-names></string-name>, <string-name><surname>Wu</surname><given-names>K</given-names></string-name>, <etal/></person-group>. <article-title>Aerobic glycolysis controls myeloid-derived suppressor cells and tumor immunity via a specific CEBPB isoform in triple-negative breast cancer</article-title>. <source>Cell Metab</source><year>2018</year>;<volume>28</volume>:<fpage>87</fpage>–<lpage>103</lpage>.<pub-id pub-id-type="pmid">29805099</pub-id></mixed-citation>
    </ref>
    <ref id="bib39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thorsson</surname><given-names>V</given-names></string-name>, <string-name><surname>Gibbs</surname><given-names>DL</given-names></string-name>, <string-name><surname>Brown</surname><given-names>SD</given-names></string-name>, <string-name><surname>Wolf</surname><given-names>D</given-names></string-name>, <string-name><surname>Bortone</surname><given-names>DS</given-names></string-name>, <string-name><surname>Ou Yang</surname><given-names>TH</given-names></string-name>, <etal/></person-group>. <article-title>The immune landscape of cancer</article-title>. <source>Immunity</source><year>2018</year>;<volume>48</volume>:<fpage>812</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="pmid">29628290</pub-id></mixed-citation>
    </ref>
    <ref id="bib40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Boissonnas</surname><given-names>A</given-names></string-name>, <string-name><surname>Fetler</surname><given-names>L</given-names></string-name>, <string-name><surname>Zeelenberg</surname><given-names>IS</given-names></string-name>, <string-name><surname>Hugues</surname><given-names>S</given-names></string-name>, <string-name><surname>Amigorena</surname><given-names>S</given-names></string-name></person-group>. <article-title>In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor</article-title>. <source>J Exp Med</source><year>2007</year>;<volume>204</volume>:<fpage>345</fpage>–<lpage>56</lpage>.<pub-id pub-id-type="pmid">17261634</pub-id></mixed-citation>
    </ref>
    <ref id="bib41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Puram</surname><given-names>SV</given-names></string-name>, <string-name><surname>Tirosh</surname><given-names>I</given-names></string-name>, <string-name><surname>Parikh</surname><given-names>AS</given-names></string-name>, <string-name><surname>Patel</surname><given-names>AP</given-names></string-name>, <string-name><surname>Yizhak</surname><given-names>K</given-names></string-name>, <string-name><surname>Gillespie</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer</article-title>. <source>Cell</source><year>2017</year>;<volume>171</volume>:<fpage>1611</fpage>–<lpage>24</lpage>.<pub-id pub-id-type="pmid">29198524</pub-id></mixed-citation>
    </ref>
    <ref id="bib42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tirosh</surname><given-names>I</given-names></string-name>, <string-name><surname>Izar</surname><given-names>B</given-names></string-name>, <string-name><surname>Prakadan</surname><given-names>SM</given-names></string-name>, <string-name><surname>Wadsworth</surname><given-names>MH</given-names><suffix>2nd</suffix></string-name>, <string-name><surname>Treacy</surname><given-names>D</given-names></string-name>, <string-name><surname>Trombetta</surname><given-names>JJ</given-names></string-name>, <etal/></person-group>. <article-title>Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq</article-title>. <source>Science</source><year>2016</year>;<volume>352</volume>:<fpage>189</fpage>–<lpage>96</lpage>.<pub-id pub-id-type="pmid">27124452</pub-id></mixed-citation>
    </ref>
    <ref id="bib43">
      <label>43.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Song</surname><given-names>Q</given-names></string-name>, <string-name><surname>Hawkins</surname><given-names>GA</given-names></string-name>, <string-name><surname>Wudel</surname><given-names>L</given-names></string-name>, <string-name><surname>Chou</surname><given-names>PC</given-names></string-name>, <string-name><surname>Forbes</surname><given-names>E</given-names></string-name>, <string-name><surname>Pullikuth</surname><given-names>AK</given-names></string-name>, <etal/></person-group>. <article-title>Dissecting intratumoral myeloid cell plasticity by single-cell RNA-seq</article-title>. <source>Cancer Med</source><year>2019</year>;<volume>8</volume>:<fpage>3072</fpage>–<lpage>85</lpage>.<pub-id pub-id-type="pmid">31033233</pub-id></mixed-citation>
    </ref>
    <ref id="bib44">
      <label>44.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zilionis</surname><given-names>R</given-names></string-name>, <string-name><surname>Engblom</surname><given-names>C</given-names></string-name>, <string-name><surname>Pfirschke</surname><given-names>C</given-names></string-name>, <string-name><surname>Savova</surname><given-names>V</given-names></string-name>, <string-name><surname>Zemmour</surname><given-names>D</given-names></string-name>, <string-name><surname>Saatcioglu</surname><given-names>HD</given-names></string-name>, <etal/></person-group>. <article-title>Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species</article-title>. <source>Immunity</source><year>2019</year>;<volume>50</volume>:<fpage>1317</fpage>–<lpage>34</lpage>.<pub-id pub-id-type="pmid">30979687</pub-id></mixed-citation>
    </ref>
    <ref id="bib45">
      <label>45.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lambrechts</surname><given-names>D</given-names></string-name>, <string-name><surname>Wauters</surname><given-names>E</given-names></string-name>, <string-name><surname>Boeckx</surname><given-names>B</given-names></string-name>, <string-name><surname>Aibar</surname><given-names>S</given-names></string-name>, <string-name><surname>Nittner</surname><given-names>D</given-names></string-name>, <string-name><surname>Burton</surname><given-names>O</given-names></string-name>, <etal/></person-group>. <article-title>Phenotype molding of stromal cells in the lung tumor microenvironment</article-title>. <source>Nat Med</source><year>2018</year>;<volume>24</volume>:<fpage>1277</fpage>–<lpage>89</lpage>.<pub-id pub-id-type="pmid">29988129</pub-id></mixed-citation>
    </ref>
    <ref id="bib46">
      <label>46.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Satpathy</surname><given-names>AT</given-names></string-name>, <string-name><surname>Granja</surname><given-names>JM</given-names></string-name>, <string-name><surname>Yost</surname><given-names>KE</given-names></string-name>, <string-name><surname>Qi</surname><given-names>Y</given-names></string-name>, <string-name><surname>Meschi</surname><given-names>F</given-names></string-name>, <string-name><surname>McDermott</surname><given-names>GP</given-names></string-name>, <etal/></person-group>. <article-title>Massively parallel single-cell chromatin landscapes of human immune cell development and intratumoral T cell exhaustion</article-title>. <source>Nat Biotechnol</source><year>2019</year>;<volume>37</volume>:<fpage>925</fpage>–<lpage>36</lpage>.<pub-id pub-id-type="pmid">31375813</pub-id></mixed-citation>
    </ref>
    <ref id="bib47">
      <label>47.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Seeler</surname><given-names>JS</given-names></string-name>, <string-name><surname>Dejean</surname><given-names>A</given-names></string-name></person-group>. <article-title>SUMO and the robustness of cancer</article-title>. <source>Nat Rev Cancer</source><year>2017</year>;<volume>17</volume>:<fpage>184</fpage>–<lpage>97</lpage>.<pub-id pub-id-type="pmid">28134258</pub-id></mixed-citation>
    </ref>
    <ref id="bib48">
      <label>48.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yilmaz</surname><given-names>M</given-names></string-name>, <string-name><surname>Maass</surname><given-names>D</given-names></string-name>, <string-name><surname>Tiwari</surname><given-names>N</given-names></string-name>, <string-name><surname>Waldmeier</surname><given-names>L</given-names></string-name>, <string-name><surname>Schmidt</surname><given-names>P</given-names></string-name>, <string-name><surname>Lehembre</surname><given-names>F</given-names></string-name>, <etal/></person-group>. <article-title>Transcription factor Dlx2 protects from TGFβ-induced cell-cycle arrest and apoptosis</article-title>. <source>EMBO J</source><year>2011</year>;<volume>30</volume>:<fpage>4489</fpage>–<lpage>99</lpage>.<pub-id pub-id-type="pmid">21897365</pub-id></mixed-citation>
    </ref>
    <ref id="bib49">
      <label>49.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tang</surname><given-names>P</given-names></string-name>, <string-name><surname>Huang</surname><given-names>H</given-names></string-name>, <string-name><surname>Chang</surname><given-names>J</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>GF</given-names></string-name>, <string-name><surname>Lu</surname><given-names>ML</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Increased expression of DLX2 correlates with advanced stage of gastric adenocarcinoma</article-title>. <source>World J Gastroenterol</source><year>2013</year>;<volume>19</volume>:<fpage>2697</fpage>–<lpage>703</lpage>.<pub-id pub-id-type="pmid">23674878</pub-id></mixed-citation>
    </ref>
    <ref id="bib50">
      <label>50.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Morishita</surname><given-names>J</given-names></string-name>, <string-name><surname>Kang</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Fidelin</surname><given-names>K</given-names></string-name>, <string-name><surname>Ryoo</surname><given-names>HD</given-names></string-name></person-group>. <article-title>CDK7 regulates the mitochondrial localization of a tail-anchored proapoptotic protein</article-title>, <source>Hid. Cell Rep.</source><year>2013</year>;<volume>5</volume>:<fpage>1481</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">24360962</pub-id></mixed-citation>
    </ref>
    <ref id="bib51">
      <label>51.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cayrol</surname><given-names>F</given-names></string-name>, <string-name><surname>Praditsuktavorn</surname><given-names>P</given-names></string-name>, <string-name><surname>Fernando</surname><given-names>TM</given-names></string-name>, <string-name><surname>Kwiatkowski</surname><given-names>N</given-names></string-name>, <string-name><surname>Marullo</surname><given-names>R</given-names></string-name>, <string-name><surname>Calvo-Vidal</surname><given-names>MN</given-names></string-name>, <etal/></person-group>. <article-title>THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors</article-title>. <source>Nat Commun</source><year>2017</year>;<volume>8</volume>:<fpage>14290</fpage>.<pub-id pub-id-type="pmid">28134252</pub-id></mixed-citation>
    </ref>
    <ref id="bib52">
      <label>52.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Klein-Hessling</surname><given-names>S</given-names></string-name>, <string-name><surname>Muhammad</surname><given-names>K</given-names></string-name>, <string-name><surname>Klein</surname><given-names>M</given-names></string-name>, <string-name><surname>Pusch</surname><given-names>T</given-names></string-name>, <string-name><surname>Rudolf</surname><given-names>R</given-names></string-name>, <string-name><surname>Flöter</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>NFATc1 controls the cytotoxicity of CD8 T cells</article-title>. <source>Nat Commun</source><year>2017</year>;<volume>8</volume>:<fpage>511</fpage>.<pub-id pub-id-type="pmid">28894104</pub-id></mixed-citation>
    </ref>
    <ref id="bib53">
      <label>53.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vaeth</surname><given-names>M</given-names></string-name>, <string-name><surname>Feske</surname><given-names>S</given-names></string-name></person-group>. <article-title>NFAT control of immune function: new frontiers for an abiding trooper</article-title>. <source>F1000Res</source><year>2018</year>;<volume>7</volume>:<fpage>260</fpage>.<pub-id pub-id-type="pmid">29568499</pub-id></mixed-citation>
    </ref>
    <ref id="bib54">
      <label>54.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Feng</surname><given-names>C</given-names></string-name>, <string-name><surname>Song</surname><given-names>C</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Qian</surname><given-names>F</given-names></string-name>, <string-name><surname>Gao</surname><given-names>Y</given-names></string-name>, <string-name><surname>Ning</surname><given-names>Z</given-names></string-name>, <etal/></person-group>. <article-title>KnockTF: a comprehensive human gene expression profile database with knockdown/knockout of transcription factors</article-title>. <source>Nucleic Acids Res</source><year>2020</year>;<volume>48</volume>:<fpage>D93</fpage>–<lpage>100</lpage>.<pub-id pub-id-type="pmid">31598675</pub-id></mixed-citation>
    </ref>
    <ref id="bib55">
      <label>55.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pan</surname><given-names>D</given-names></string-name>, <string-name><surname>Kobayashi</surname><given-names>A</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>P</given-names></string-name>, <string-name><surname>Ferrari de Andrade</surname><given-names>L</given-names></string-name>, <string-name><surname>Tay</surname><given-names>RE</given-names></string-name>, <string-name><surname>Luoma</surname><given-names>AM</given-names></string-name>, <etal/></person-group>. <article-title>A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing</article-title>. <source>Science</source><year>2018</year>;<volume>359</volume>:<fpage>770</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">29301958</pub-id></mixed-citation>
    </ref>
    <ref id="bib56">
      <label>56.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Park</surname><given-names>S</given-names></string-name>, <string-name><surname>Chang</surname><given-names>CY</given-names></string-name>, <string-name><surname>Safi</surname><given-names>R</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name><surname>Baldi</surname><given-names>R</given-names></string-name>, <string-name><surname>Jasper</surname><given-names>JS</given-names></string-name>, <etal/></person-group>. <article-title>ERRα-regulated lactate metabolism contributes to resistance to targeted therapies in breast cancer</article-title>. <source>Cell Rep</source><year>2016</year>;<volume>15</volume>:<fpage>323</fpage>–<lpage>35</lpage>.<pub-id pub-id-type="pmid">27050525</pub-id></mixed-citation>
    </ref>
    <ref id="bib57">
      <label>57.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Patch</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Searle</surname><given-names>LL</given-names></string-name>, <string-name><surname>Kim</surname><given-names>AJ</given-names></string-name>, <string-name><surname>De</surname><given-names>D</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>X</given-names></string-name>, <string-name><surname>Askari</surname><given-names>HB</given-names></string-name>, <etal/></person-group>. <article-title>Identification of diaryl ether-based ligands for estrogen-related receptor α as potential antidiabetic agents</article-title>. <source>J Med Chem</source><year>2011</year>;<volume>54</volume>:<fpage>788</fpage>–<lpage>808</lpage>.<pub-id pub-id-type="pmid">21218783</pub-id></mixed-citation>
    </ref>
    <ref id="bib58">
      <label>58.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fu</surname><given-names>J</given-names></string-name>, <string-name><surname>Li</surname><given-names>K</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>W</given-names></string-name>, <string-name><surname>Wan</surname><given-names>C</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>P</given-names></string-name>, <etal/></person-group>. <article-title>Large-scale public data reuse to model immunotherapy response and resistance</article-title>. <source>Genome Med</source><year>2020</year>;<volume>12</volume>:<fpage>21</fpage>.<pub-id pub-id-type="pmid">32102694</pub-id></mixed-citation>
    </ref>
    <ref id="bib59">
      <label>59.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bidwell</surname><given-names>BN</given-names></string-name>, <string-name><surname>Slaney</surname><given-names>CY</given-names></string-name>, <string-name><surname>Withana</surname><given-names>NP</given-names></string-name>, <string-name><surname>Forster</surname><given-names>S</given-names></string-name>, <string-name><surname>Cao</surname><given-names>Y</given-names></string-name>, <string-name><surname>Loi</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape</article-title>. <source>Nat Med</source><year>2012</year>;<volume>18</volume>:<fpage>1224</fpage>–<lpage>31</lpage>.<pub-id pub-id-type="pmid">22820642</pub-id></mixed-citation>
    </ref>
    <ref id="bib60">
      <label>60.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yuk</surname><given-names>JM</given-names></string-name>, <string-name><surname>Kim</surname><given-names>TS</given-names></string-name>, <string-name><surname>Kim</surname><given-names>SY</given-names></string-name>, <string-name><surname>Lee</surname><given-names>HM</given-names></string-name>, <string-name><surname>Han</surname><given-names>J</given-names></string-name>, <string-name><surname>Dufour</surname><given-names>CR</given-names></string-name>, <etal/></person-group>. <article-title>Orphan nuclear receptor ERRα controls macrophage metabolic signaling and A20 expression to negatively regulate TLR-induced inflammation</article-title>. <source>Immunity</source><year>2015</year>;<volume>43</volume>:<fpage>80</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="pmid">26200012</pub-id></mixed-citation>
    </ref>
    <ref id="bib61">
      <label>61.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Azizi</surname><given-names>E</given-names></string-name>, <string-name><surname>Carr</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Plitas</surname><given-names>G</given-names></string-name>, <string-name><surname>Cornish</surname><given-names>AE</given-names></string-name>, <string-name><surname>Konopacki</surname><given-names>C</given-names></string-name>, <string-name><surname>Prabhakaran</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Single-cell map of diverse immune phenotypes in the breast tumor microenvironment</article-title>. <source>Cell</source><year>2018</year>;<volume>174</volume>:<fpage>1293</fpage>–<lpage>308</lpage>.<pub-id pub-id-type="pmid">29961579</pub-id></mixed-citation>
    </ref>
    <ref id="bib62">
      <label>62.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yamada</surname><given-names>S</given-names></string-name>, <string-name><surname>Shimojima</surname><given-names>M</given-names></string-name>, <string-name><surname>Narita</surname><given-names>R</given-names></string-name>, <string-name><surname>Tsukamoto</surname><given-names>Y</given-names></string-name>, <string-name><surname>Kato</surname><given-names>H</given-names></string-name>, <string-name><surname>Saijo</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>RIG-I-like receptor and toll-like receptor signaling pathways cause aberrant production of inflammatory cytokines/chemokines in a severe fever with thrombocytopenia syndrome virus infection mouse model</article-title>. <source>J Virol</source><year>2018</year>;<volume>92</volume>:<fpage>e02246</fpage>–<lpage>17</lpage>.<pub-id pub-id-type="pmid">29643242</pub-id></mixed-citation>
    </ref>
    <ref id="bib63">
      <label>63.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gu</surname><given-names>SS</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>W</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>P</given-names></string-name>, <string-name><surname>Traugh</surname><given-names>N</given-names></string-name>, <string-name><surname>Li</surname><given-names>Z</given-names></string-name>, <etal/></person-group>. <article-title>Therapeutically increasing MHC-I expression potentiates immune checkpoint blockade</article-title>. <source>Cancer Discov</source><year>2021</year>;<volume>11</volume>:<fpage>1524</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="pmid">33589424</pub-id></mixed-citation>
    </ref>
    <ref id="bib64">
      <label>64.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Burr</surname><given-names>ML</given-names></string-name>, <string-name><surname>Sparbier</surname><given-names>CE</given-names></string-name>, <string-name><surname>Chan</surname><given-names>KL</given-names></string-name>, <string-name><surname>Chan</surname><given-names>YC</given-names></string-name>, <string-name><surname>Kersbergen</surname><given-names>A</given-names></string-name>, <string-name><surname>Lam</surname><given-names>EYN</given-names></string-name>, <etal/></person-group>. <article-title>An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer</article-title>. <source>Cancer Cell</source><year>2019</year>;<volume>36</volume>:<fpage>385</fpage>–<lpage>401</lpage>.<pub-id pub-id-type="pmid">31564637</pub-id></mixed-citation>
    </ref>
    <ref id="bib65">
      <label>65.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pech</surname><given-names>MF</given-names></string-name>, <string-name><surname>Fong</surname><given-names>LE</given-names></string-name>, <string-name><surname>Villalta</surname><given-names>JE</given-names></string-name>, <string-name><surname>Chan</surname><given-names>LJ</given-names></string-name>, <string-name><surname>Kharbanda</surname><given-names>S</given-names></string-name>, <string-name><surname>O'Brien</surname><given-names>JJ</given-names></string-name>, <etal/></person-group>. <article-title>Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance</article-title>. <source>Elife</source><year>2019</year>;<volume>8</volume>:<fpage>e47362</fpage>.<pub-id pub-id-type="pmid">31452512</pub-id></mixed-citation>
    </ref>
    <ref id="bib66">
      <label>66.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Freeman</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Vervoort</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Ramsbottom</surname><given-names>KM</given-names></string-name>, <string-name><surname>Kelly</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Michie</surname><given-names>J</given-names></string-name>, <string-name><surname>Pijpers</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>Natural killer cells suppress T cell-associated tumor immune evasion</article-title>. <source>Cell Rep</source><year>2019</year>;<volume>28</volume>:<fpage>2784</fpage>–<lpage>94</lpage>.<pub-id pub-id-type="pmid">31509742</pub-id></mixed-citation>
    </ref>
    <ref id="bib67">
      <label>67.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>N</given-names></string-name>, <string-name><surname>Bevan</surname><given-names>MJ</given-names></string-name></person-group>. <article-title>CD8(+) T cells: foot soldiers of the immune system</article-title>. <source>Immunity</source><year>2011</year>;<volume>35</volume>:<fpage>161</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">21867926</pub-id></mixed-citation>
    </ref>
    <ref id="bib68">
      <label>68.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vredevoogd</surname><given-names>DW</given-names></string-name>, <string-name><surname>Kuilman</surname><given-names>T</given-names></string-name>, <string-name><surname>Ligtenberg</surname><given-names>MA</given-names></string-name>, <string-name><surname>Boshuizen</surname><given-names>J</given-names></string-name>, <string-name><surname>Stecker</surname><given-names>KE</given-names></string-name>, <string-name><surname>de Bruijn</surname><given-names>B</given-names></string-name>, <etal/></person-group>. <article-title>Augmenting immunotherapy impact by lowering tumor TNF cytotoxicity threshold</article-title>. <source>Cell</source><year>2020</year>;<volume>180</volume>:<fpage>404</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">31978349</pub-id></mixed-citation>
    </ref>
    <ref id="bib69">
      <label>69.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Decker</surname><given-names>CE</given-names></string-name>, <string-name><surname>Young</surname><given-names>T</given-names></string-name>, <string-name><surname>Pasnikowski</surname><given-names>E</given-names></string-name>, <string-name><surname>Chiu</surname><given-names>J</given-names></string-name>, <string-name><surname>Song</surname><given-names>H</given-names></string-name>, <string-name><surname>Wei</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>Genome-scale CRISPR activation screen uncovers tumor-intrinsic modulators of CD3 bispecific antibody efficacy</article-title>. <source>Sci Rep</source><year>2019</year>;<volume>9</volume>:<fpage>20068</fpage>.<pub-id pub-id-type="pmid">31882897</pub-id></mixed-citation>
    </ref>
    <ref id="bib70">
      <label>70.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dufva</surname><given-names>O</given-names></string-name>, <string-name><surname>Koski</surname><given-names>J</given-names></string-name>, <string-name><surname>Maliniemi</surname><given-names>P</given-names></string-name>, <string-name><surname>Ianevski</surname><given-names>A</given-names></string-name>, <string-name><surname>Klievink</surname><given-names>J</given-names></string-name>, <string-name><surname>Leitner</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity</article-title>. <source>Blood</source><year>2020</year>;<volume>135</volume>:<fpage>597</fpage>–<lpage>609</lpage>.<pub-id pub-id-type="pmid">31830245</pub-id></mixed-citation>
    </ref>
    <ref id="bib71">
      <label>71.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kearney</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Vervoort</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Hogg</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Ramsbottom</surname><given-names>KM</given-names></string-name>, <string-name><surname>Freeman</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Lalaoui</surname><given-names>N</given-names></string-name>, <etal/></person-group>. <article-title>Tumor immune evasion arises through loss of TNF sensitivity</article-title>. <source>Sci Immunol</source><year>2018</year>;<volume>3</volume>:<fpage>eaar3451</fpage>.<pub-id pub-id-type="pmid">29776993</pub-id></mixed-citation>
    </ref>
    <ref id="bib72">
      <label>72.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ghandi</surname><given-names>M</given-names></string-name>, <string-name><surname>Huang</surname><given-names>FW</given-names></string-name>, <string-name><surname>Jané-Valbuena</surname><given-names>J</given-names></string-name>, <string-name><surname>Kryukov</surname><given-names>GV</given-names></string-name>, <string-name><surname>Lo</surname><given-names>CC</given-names></string-name>, <string-name><surname>McDonald</surname><given-names>ER</given-names><suffix>3rd</suffix></string-name>, <etal/></person-group>. <article-title>Next-generation characterization of the cancer cell line encyclopedia</article-title>. <source>Nature</source><year>2019</year>;<volume>569</volume>:<fpage>503</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">31068700</pub-id></mixed-citation>
    </ref>
    <ref id="bib73">
      <label>73.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Patsoukis</surname><given-names>N</given-names></string-name>, <string-name><surname>Bardhan</surname><given-names>K</given-names></string-name>, <string-name><surname>Weaver</surname><given-names>J</given-names></string-name>, <string-name><surname>Herbel</surname><given-names>C</given-names></string-name>, <string-name><surname>Seth</surname><given-names>P</given-names></string-name>, <string-name><surname>Li</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>The role of metabolic reprogramming in T cell fate and function</article-title>. <source>Curr Trends Immunol</source><year>2016</year>;<volume>17</volume>:<fpage>1</fpage>–<lpage>12</lpage>.<pub-id pub-id-type="pmid">28356677</pub-id></mixed-citation>
    </ref>
    <ref id="bib74">
      <label>74.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sun</surname><given-names>D</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name><surname>Han</surname><given-names>Y</given-names></string-name>, <string-name><surname>Dong</surname><given-names>X</given-names></string-name>, <string-name><surname>Ge</surname><given-names>J</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>R</given-names></string-name>, <etal/></person-group>. <article-title>TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment</article-title>. <source>Nucleic Acids Res</source><year>2021</year>;<volume>49</volume>:<fpage>D1420</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="pmid">33179754</pub-id></mixed-citation>
    </ref>
    <ref id="bib75">
      <label>75.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zheng</surname><given-names>L</given-names></string-name>, <string-name><surname>Qin</surname><given-names>S</given-names></string-name>, <string-name><surname>Si</surname><given-names>W</given-names></string-name>, <string-name><surname>Wang</surname><given-names>A</given-names></string-name>, <string-name><surname>Xing</surname><given-names>B</given-names></string-name>, <string-name><surname>Gao</surname><given-names>R</given-names></string-name>, <etal/></person-group>. <article-title>Pan-cancer single-cell landscape of tumor-infiltrating T cells</article-title>. <source>Science</source><year>2021</year>;<volume>374</volume>:<fpage>abe6474</fpage>.<pub-id pub-id-type="pmid">34914499</pub-id></mixed-citation>
    </ref>
    <ref id="bib76">
      <label>76.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Skinnider</surname><given-names>MA</given-names></string-name>, <string-name><surname>Squair</surname><given-names>JW</given-names></string-name>, <string-name><surname>Kathe</surname><given-names>C</given-names></string-name>, <string-name><surname>Anderson</surname><given-names>MA</given-names></string-name>, <string-name><surname>Gautier</surname><given-names>M</given-names></string-name>, <string-name><surname>Matson</surname><given-names>KJE</given-names></string-name>, <etal/></person-group>. <article-title>Cell type prioritization in single-cell data</article-title>. <source>Nat Biotechnol</source><year>2021</year>;<volume>39</volume>:<fpage>30</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">32690972</pub-id></mixed-citation>
    </ref>
    <ref id="bib77">
      <label>77.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jerby-Arnon</surname><given-names>L</given-names></string-name>, <string-name><surname>Shah</surname><given-names>P</given-names></string-name>, <string-name><surname>Cuoco</surname><given-names>MS</given-names></string-name>, <string-name><surname>Rodman</surname><given-names>C</given-names></string-name>, <string-name><surname>Su</surname><given-names>M-J</given-names></string-name>, <string-name><surname>Melms</surname><given-names>JC</given-names></string-name>, <etal/></person-group>. <article-title>A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade</article-title>. <source>Cell.</source><year>2018</year>;<volume>175</volume>:<fpage>984</fpage>–<lpage>97</lpage>.<pub-id pub-id-type="pmid">30388455</pub-id></mixed-citation>
    </ref>
    <ref id="bib78">
      <label>78.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yost</surname><given-names>KE</given-names></string-name>, <string-name><surname>Satpathy</surname><given-names>AT</given-names></string-name>, <string-name><surname>Wells</surname><given-names>DK</given-names></string-name>, <string-name><surname>Qi</surname><given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname><given-names>C</given-names></string-name>, <string-name><surname>Kageyama</surname><given-names>R</given-names></string-name>, <etal/></person-group>. <article-title>Clonal replacement of tumor-specific T cells following PD-1 blockade</article-title>. <source>Nat Med</source><year>2019</year>;<volume>25</volume>:<fpage>1251</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">31359002</pub-id></mixed-citation>
    </ref>
    <ref id="bib79">
      <label>79.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname><given-names>K</given-names></string-name>, <string-name><surname>Skora</surname><given-names>AD</given-names></string-name>, <string-name><surname>Li</surname><given-names>Z</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Q</given-names></string-name>, <string-name><surname>Tam</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Blosser</surname><given-names>RL</given-names></string-name>, <etal/></person-group>. <article-title>Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2014</year>;<volume>111</volume>:<fpage>11774</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">25071169</pub-id></mixed-citation>
    </ref>
    <ref id="bib80">
      <label>80.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Marabelle</surname><given-names>A</given-names></string-name>, <string-name><surname>Fakih</surname><given-names>M</given-names></string-name>, <string-name><surname>Lopez</surname><given-names>J</given-names></string-name>, <string-name><surname>Shah</surname><given-names>M</given-names></string-name>, <string-name><surname>Shapira-Frommer</surname><given-names>R</given-names></string-name>, <string-name><surname>Nakagawa</surname><given-names>K</given-names></string-name>, <etal/></person-group>. <article-title>Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study</article-title>. <source>Lancet Oncol</source><year>2020</year>;<volume>21</volume>:<fpage>1353</fpage>–<lpage>65</lpage>.<pub-id pub-id-type="pmid">32919526</pub-id></mixed-citation>
    </ref>
    <ref id="bib81">
      <label>81.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McGrail</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Pilié</surname><given-names>PG</given-names></string-name>, <string-name><surname>Rashid</surname><given-names>NU</given-names></string-name>, <string-name><surname>Voorwerk</surname><given-names>L</given-names></string-name>, <string-name><surname>Slagter</surname><given-names>M</given-names></string-name>, <string-name><surname>Kok</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types</article-title>. <source>Ann Oncol</source><year>2021</year>;<volume>32</volume>:<fpage>661</fpage>–<lpage>72</lpage>.<pub-id pub-id-type="pmid">33736924</pub-id></mixed-citation>
    </ref>
    <ref id="bib82">
      <label>82.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Litchfield</surname><given-names>K</given-names></string-name>, <string-name><surname>Reading</surname><given-names>JL</given-names></string-name>, <string-name><surname>Puttick</surname><given-names>C</given-names></string-name>, <string-name><surname>Thakkar</surname><given-names>K</given-names></string-name>, <string-name><surname>Abbosh</surname><given-names>C</given-names></string-name>, <string-name><surname>Bentham</surname><given-names>R</given-names></string-name>, <etal/></person-group>. <article-title>Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition</article-title>. <source>Cell</source><year>2021</year>;<volume>184</volume>:<fpage>596</fpage>–<lpage>614</lpage>.<pub-id pub-id-type="pmid">33508232</pub-id></mixed-citation>
    </ref>
    <ref id="bib83">
      <label>83.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>K</given-names></string-name>, <string-name><surname>Patkar</surname><given-names>S</given-names></string-name>, <string-name><surname>Lee</surname><given-names>JS</given-names></string-name>, <string-name><surname>Gertz</surname><given-names>EM</given-names></string-name>, <string-name><surname>Robinson</surname><given-names>W</given-names></string-name>, <string-name><surname>Schischlik</surname><given-names>F</given-names></string-name>, <etal/></person-group>. <article-title>Deconvolving clinically relevant cellular immune cross-talk from bulk gene expression using CODEFACS and LIRICS stratifies patients with melanoma to anti–PD-1 therapy</article-title>. <source>Cancer Discov</source><year>2022</year>;<volume>12</volume>:<fpage>1088</fpage>–<lpage>105</lpage>.<pub-id pub-id-type="pmid">34983745</pub-id></mixed-citation>
    </ref>
    <ref id="bib84">
      <label>84.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gide</surname><given-names>TN</given-names></string-name>, <string-name><surname>Quek</surname><given-names>C</given-names></string-name>, <string-name><surname>Menzies</surname><given-names>AM</given-names></string-name>, <string-name><surname>Tasker</surname><given-names>AT</given-names></string-name>, <string-name><surname>Shang</surname><given-names>P</given-names></string-name>, <string-name><surname>Holst</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Distinct immune cell populations define response to anti–PD-1 monotherapy and anti–PD-1/anti-CTLA-4 combined therapy</article-title>. <source>Cancer Cell</source><year>2019</year>;<volume>35</volume>:<fpage>238</fpage>–<lpage>55</lpage>.<pub-id pub-id-type="pmid">30753825</pub-id></mixed-citation>
    </ref>
    <ref id="bib85">
      <label>85.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hugo</surname><given-names>W</given-names></string-name>, <string-name><surname>Zaretsky</surname><given-names>JM</given-names></string-name>, <string-name><surname>Sun</surname><given-names>L</given-names></string-name>, <string-name><surname>Song</surname><given-names>C</given-names></string-name>, <string-name><surname>Moreno</surname><given-names>BH</given-names></string-name>, <string-name><surname>Hu-Lieskovan</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Genomic and transcriptomic features of response to anti–PD-1 therapy in metastatic melanoma</article-title>. <source>Cell</source><year>2017</year>;<volume>168</volume>:<fpage>542</fpage>.</mixed-citation>
    </ref>
    <ref id="bib86">
      <label>86.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>D</given-names></string-name>, <string-name><surname>Schilling</surname><given-names>B</given-names></string-name>, <string-name><surname>Liu</surname><given-names>D</given-names></string-name>, <string-name><surname>Sucker</surname><given-names>A</given-names></string-name>, <string-name><surname>Livingstone</surname><given-names>E</given-names></string-name>, <string-name><surname>Jerby-Amon</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma</article-title>. <source>Nat Med</source><year>2019</year>;<volume>25</volume>:<fpage>1916</fpage>–<lpage>27</lpage>.<pub-id pub-id-type="pmid">31792460</pub-id></mixed-citation>
    </ref>
    <ref id="bib87">
      <label>87.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Riaz</surname><given-names>N</given-names></string-name>, <string-name><surname>Havel</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Makarov</surname><given-names>V</given-names></string-name>, <string-name><surname>Desrichard</surname><given-names>A</given-names></string-name>, <string-name><surname>Urba</surname><given-names>WJ</given-names></string-name>, <string-name><surname>Sims</surname><given-names>JS</given-names></string-name>, <etal/></person-group>. <article-title>Tumor and microenvironment evolution during immunotherapy with nivolumab</article-title>. <source>Cell</source><year>2017</year>;<volume>171</volume>:<fpage>934</fpage>–<lpage>49</lpage>.<pub-id pub-id-type="pmid">29033130</pub-id></mixed-citation>
    </ref>
    <ref id="bib88">
      <label>88.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Freeman</surname><given-names>SS</given-names></string-name>, <string-name><surname>Sade-Feldman</surname><given-names>M</given-names></string-name>, <string-name><surname>Kim</surname><given-names>J</given-names></string-name>, <string-name><surname>Stewart</surname><given-names>C</given-names></string-name>, <string-name><surname>Gonye</surname><given-names>ALK</given-names></string-name>, <string-name><surname>Ravi</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma</article-title>. <source>Cell Rep Med</source><year>2022</year>;<volume>3</volume>:<fpage>100500</fpage>.<pub-id pub-id-type="pmid">35243413</pub-id></mixed-citation>
    </ref>
    <ref id="bib89">
      <label>89.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cox</surname><given-names>DR</given-names></string-name></person-group>. <article-title>Regression models and life-tables</article-title>. <source>J R Stat Soc</source><year>1972</year>;<volume>34</volume>:<fpage>187</fpage>–<lpage>202</lpage>.</mixed-citation>
    </ref>
    <ref id="bib90">
      <label>90.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ribas</surname><given-names>A</given-names></string-name>, <string-name><surname>Robert</surname><given-names>C</given-names></string-name>, <string-name><surname>Hodi</surname><given-names>FS</given-names></string-name>, <string-name><surname>Wolchok</surname><given-names>JD</given-names></string-name>, <string-name><surname>Joshua</surname><given-names>AM</given-names></string-name>, <string-name><surname>Hwu</surname><given-names>WJ</given-names></string-name>, <etal/></person-group>. <article-title>Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature</article-title>. <source>J Clin Oncol</source><volume>33:15s</volume>, 
<year>2015</year><fpage>(suppl; abstr 3001)</fpage>.</mixed-citation>
    </ref>
    <ref id="bib91">
      <label>91.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fehrenbacher</surname><given-names>L</given-names></string-name>, <string-name><surname>Spira</surname><given-names>A</given-names></string-name>, <string-name><surname>Ballinger</surname><given-names>M</given-names></string-name>, <string-name><surname>Kowanetz</surname><given-names>M</given-names></string-name>, <string-name><surname>Vansteenkiste</surname><given-names>J</given-names></string-name>, <string-name><surname>Mazieres</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial</article-title>. <source>Lancet</source><year>2016</year>;<volume>387</volume>:<fpage>1837</fpage>–<lpage>46</lpage>.<pub-id pub-id-type="pmid">26970723</pub-id></mixed-citation>
    </ref>
    <ref id="bib92">
      <label>92.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ayers</surname><given-names>M</given-names></string-name>, <string-name><surname>Lunceford</surname><given-names>J</given-names></string-name>, <string-name><surname>Nebozhyn</surname><given-names>M</given-names></string-name>, <string-name><surname>Murphy</surname><given-names>E</given-names></string-name>, <string-name><surname>Loboda</surname><given-names>A</given-names></string-name>, <string-name><surname>Kaufman</surname><given-names>DR</given-names></string-name>, <etal/></person-group>. <article-title>IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade</article-title>. <source>J Clin Invest</source><year>2017</year>;<volume>127</volume>:<fpage>2930</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="pmid">28650338</pub-id></mixed-citation>
    </ref>
    <ref id="bib93">
      <label>93.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Aguiar</surname><given-names>PN</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>De Mello</surname><given-names>RA</given-names></string-name>, <string-name><surname>Hall</surname><given-names>P</given-names></string-name>, <string-name><surname>Tadokoro</surname><given-names>H</given-names></string-name>, <string-name><surname>Lima Lopes</surname><given-names>Gd</given-names></string-name></person-group>. <article-title>PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data</article-title>. <source>Immunotherapy</source><year>2017</year>;<volume>9</volume>:<fpage>499</fpage>–<lpage>506</lpage>.<pub-id pub-id-type="pmid">28472902</pub-id></mixed-citation>
    </ref>
    <ref id="bib94">
      <label>94.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ock</surname><given-names>CY</given-names></string-name>, <string-name><surname>Hwang</surname><given-names>JE</given-names></string-name>, <string-name><surname>Keam</surname><given-names>B</given-names></string-name>, <string-name><surname>Kim</surname><given-names>SB</given-names></string-name>, <string-name><surname>Shim</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Jang</surname><given-names>HJ</given-names></string-name>, <etal/></person-group>. <article-title>Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers</article-title>. <source>Nat Commun</source><year>2017</year>;<volume>8</volume>:<fpage>1050</fpage>.<pub-id pub-id-type="pmid">29051489</pub-id></mixed-citation>
    </ref>
    <ref id="bib95">
      <label>95.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cristescu</surname><given-names>R</given-names></string-name>, <string-name><surname>Mogg</surname><given-names>R</given-names></string-name>, <string-name><surname>Ayers</surname><given-names>M</given-names></string-name>, <string-name><surname>Albright</surname><given-names>A</given-names></string-name>, <string-name><surname>Murphy</surname><given-names>E</given-names></string-name>, <string-name><surname>Yearley</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy</article-title>. <source>Science</source><year>2018</year>;<volume>362</volume>:<fpage>eaar3593</fpage>.<pub-id pub-id-type="pmid">30309915</pub-id></mixed-citation>
    </ref>
    <ref id="bib96">
      <label>96.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Steiniche</surname><given-names>T</given-names></string-name>, <string-name><surname>Rha</surname><given-names>SY</given-names></string-name>, <string-name><surname>Chung</surname><given-names>HC</given-names></string-name>, <string-name><surname>Georgsen</surname><given-names>JB</given-names></string-name>, <string-name><surname>Ladekarl</surname><given-names>M</given-names></string-name>, <string-name><surname>Nordsmark</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>T-cell–inflamed gene expression profile (GEP) and PD-L1 expression in patients (pts) with esophageal cancer (EC)</article-title>. <source>J Clin Oncol</source><volume>37:4s</volume>, 
<year>2019</year><fpage>(suppl; abstr 26)</fpage>.</mixed-citation>
    </ref>
    <ref id="bib97">
      <label>97.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jiang</surname><given-names>P</given-names></string-name>, <string-name><surname>Gu</surname><given-names>S</given-names></string-name>, <string-name><surname>Pan</surname><given-names>D</given-names></string-name>, <string-name><surname>Fu</surname><given-names>J</given-names></string-name>, <string-name><surname>Sahu</surname><given-names>A</given-names></string-name>, <string-name><surname>Hu</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response</article-title>. <source>Nat Med</source><year>2018</year>;<volume>24</volume>:<fpage>1550</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">30127393</pub-id></mixed-citation>
    </ref>
    <ref id="bib98">
      <label>98.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pérez-Guijarro</surname><given-names>E</given-names></string-name>, <string-name><surname>Yang</surname><given-names>HH</given-names></string-name>, <string-name><surname>Araya</surname><given-names>RE</given-names></string-name>, <string-name><surname>El Meskini</surname><given-names>R</given-names></string-name>, <string-name><surname>Michael</surname><given-names>HT</given-names></string-name>, <string-name><surname>Vodnala</surname><given-names>SK</given-names></string-name>, <etal/></person-group>. <article-title>Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy</article-title>. <source>Nat Med</source><year>2020</year>;<volume>26</volume>:<fpage>781</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="pmid">32284588</pub-id></mixed-citation>
    </ref>
    <ref id="bib99">
      <label>99.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zuin</surname><given-names>J</given-names></string-name>, <string-name><surname>Roth</surname><given-names>G</given-names></string-name>, <string-name><surname>Zhan</surname><given-names>Y</given-names></string-name>, <string-name><surname>Cramard</surname><given-names>J</given-names></string-name>, <string-name><surname>Redolfi</surname><given-names>J</given-names></string-name>, <string-name><surname>Piskadlo</surname><given-names>E</given-names></string-name>, <etal/></person-group>. <article-title>Nonlinear control of transcription through enhancer-promoter interactions</article-title>. <source>Nature</source><year>2022</year>;<volume>604</volume>:<fpage>571</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">35418676</pub-id></mixed-citation>
    </ref>
    <ref id="bib100">
      <label>100.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Katzman</surname><given-names>JL</given-names></string-name>, <string-name><surname>Shaham</surname><given-names>U</given-names></string-name>, <string-name><surname>Cloninger</surname><given-names>A</given-names></string-name>, <string-name><surname>Bates</surname><given-names>J</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>T</given-names></string-name>, <string-name><surname>Kluger</surname><given-names>Y</given-names></string-name></person-group>. <article-title>DeepSurv: personalized treatment recommender system using a Cox proportional hazards deep neural network</article-title>. <source>BMC Med Res Methodol</source><year>2018</year>;<volume>18</volume>:<fpage>24</fpage>.<pub-id pub-id-type="pmid">29482517</pub-id></mixed-citation>
    </ref>
    <ref id="bib101">
      <label>101.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Haybar</surname><given-names>H</given-names></string-name>, <string-name><surname>Rezaeeyan</surname><given-names>H</given-names></string-name>, <string-name><surname>Shahjahani</surname><given-names>M</given-names></string-name>, <string-name><surname>Shirzad</surname><given-names>R</given-names></string-name>, <string-name><surname>Saki</surname><given-names>N</given-names></string-name></person-group>. <article-title>T-bet transcription factor in cardiovascular disease: Attenuation or inflammation factor?</article-title><source>J Cell Physiol</source><year>2019</year>;<volume>234</volume>:<fpage>7915</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="pmid">30536907</pub-id></mixed-citation>
    </ref>
    <ref id="bib102">
      <label>102.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Di Giovangiulio</surname><given-names>M</given-names></string-name>, <string-name><surname>Rizzo</surname><given-names>A</given-names></string-name>, <string-name><surname>Franzè</surname><given-names>E</given-names></string-name>, <string-name><surname>Caprioli</surname><given-names>F</given-names></string-name>, <string-name><surname>Facciotti</surname><given-names>F</given-names></string-name>, <string-name><surname>Onali</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Tbet expression in regulatory T cells is required to initiate Th1-mediated colitis</article-title>. <source>Front Immunol</source><year>2019</year>;<volume>10</volume>:<fpage>2158</fpage>.<pub-id pub-id-type="pmid">31572375</pub-id></mixed-citation>
    </ref>
    <ref id="bib103">
      <label>103.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>S</given-names></string-name>, <string-name><surname>Lu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>C</given-names></string-name></person-group>. <article-title>Inhibition of histone demethylase JMJD1C attenuates cardiac hypertrophy and fibrosis induced by angiotensin II</article-title>. <source>J Recept Signal Transduct Res</source><year>2020</year>;<volume>40</volume>:<fpage>339</fpage>–<lpage>47</lpage>.<pub-id pub-id-type="pmid">32122211</pub-id></mixed-citation>
    </ref>
    <ref id="bib104">
      <label>104.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Choi</surname><given-names>SH</given-names></string-name>, <string-name><surname>Ruggiero</surname><given-names>D</given-names></string-name>, <string-name><surname>Sorice</surname><given-names>R</given-names></string-name>, <string-name><surname>Song</surname><given-names>C</given-names></string-name>, <string-name><surname>Nutile</surname><given-names>T</given-names></string-name>, <string-name><surname>Vernon Smith</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Six novel loci associated with circulating VEGF levels identified by a meta-analysis of genome-wide association studies</article-title>. <source>PLoS Genet</source><year>2016</year>;<volume>12</volume>:<fpage>e1005874</fpage>.<pub-id pub-id-type="pmid">26910538</pub-id></mixed-citation>
    </ref>
    <ref id="bib105">
      <label>105.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Boeckel</surname><given-names>JN</given-names></string-name>, <string-name><surname>Guarani</surname><given-names>V</given-names></string-name>, <string-name><surname>Koyanagi</surname><given-names>M</given-names></string-name>, <string-name><surname>Roexe</surname><given-names>T</given-names></string-name>, <string-name><surname>Lengeling</surname><given-names>A</given-names></string-name>, <string-name><surname>Schermuly</surname><given-names>RT</given-names></string-name>, <etal/></person-group>. <article-title>Jumonji domain-containing protein 6 (Jmjd6) is required for angiogenic sprouting and regulates splicing of VEGF-receptor 1</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2011</year>;<volume>108</volume>:<fpage>3276</fpage>–<lpage>81</lpage>.<pub-id pub-id-type="pmid">21300889</pub-id></mixed-citation>
    </ref>
    <ref id="bib106">
      <label>106.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhong</surname><given-names>C</given-names></string-name>, <string-name><surname>Tao</surname><given-names>B</given-names></string-name>, <string-name><surname>Yang</surname><given-names>F</given-names></string-name>, <string-name><surname>Xia</surname><given-names>K</given-names></string-name>, <string-name><surname>Yang</surname><given-names>X</given-names></string-name>, <string-name><surname>Chen</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>Histone demethylase JMJD1C promotes the polarization of M1 macrophages to prevent glioma by upregulating miR-302a</article-title>. <source>Clin Transl Med</source><year>2021</year>;<volume>11</volume>:<fpage>e424</fpage>.<pub-id pub-id-type="pmid">34586733</pub-id></mixed-citation>
    </ref>
    <ref id="bib107">
      <label>107.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Park</surname><given-names>SA</given-names></string-name>, <string-name><surname>Sung</surname><given-names>NJ</given-names></string-name>, <string-name><surname>Choi</surname><given-names>BJ</given-names></string-name>, <string-name><surname>Kim</surname><given-names>W</given-names></string-name>, <string-name><surname>Kim</surname><given-names>SH</given-names></string-name>, <string-name><surname>Surh</surname><given-names>YJ</given-names></string-name></person-group>. <article-title>Gremlin-1 augments the oestrogen-related receptor α signalling through EGFR activation: implications for the progression of breast cancer</article-title>. <source>Br J Cancer</source><year>2020</year>;<volume>123</volume>:<fpage>988</fpage>–<lpage>99</lpage>.<pub-id pub-id-type="pmid">32572171</pub-id></mixed-citation>
    </ref>
    <ref id="bib108">
      <label>108.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name><surname>Han</surname><given-names>F</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name><surname>Tu</surname><given-names>M</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>A novel miR-1291-ERRα-CPT1C axis modulates tumor cell proliferation, metabolism and tumorigenesis</article-title>. <source>Theranostics</source><year>2020</year>;<volume>10</volume>:<fpage>7193</fpage>–<lpage>210</lpage>.<pub-id pub-id-type="pmid">32641987</pub-id></mixed-citation>
    </ref>
    <ref id="bib109">
      <label>109.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>S</given-names></string-name>, <string-name><surname>Huo</surname><given-names>X</given-names></string-name></person-group>. <article-title>Comprehensive analysis of ESRRA in endometrial cancer</article-title>. <source>Technol Cancer Res Treat</source><year>2021</year>;<volume>20</volume>:<fpage>1533033821992083</fpage>.<pub-id pub-id-type="pmid">33525981</pub-id></mixed-citation>
    </ref>
    <ref id="bib110">
      <label>110.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Van den Bossche</surname><given-names>J</given-names></string-name>, <string-name><surname>Baardman</surname><given-names>J</given-names></string-name>, <string-name><surname>Otto</surname><given-names>NA</given-names></string-name>, <string-name><surname>van der Velden</surname><given-names>S</given-names></string-name>, <string-name><surname>Neele</surname><given-names>AE</given-names></string-name>, <string-name><surname>van den Berg</surname><given-names>SM</given-names></string-name>, <etal/></person-group>. <article-title>Mitochondrial dysfunction prevents repolarization of inflammatory macrophages</article-title>. <source>Cell Rep</source><year>2016</year>;<volume>17</volume>:<fpage>684</fpage>–<lpage>96</lpage>.<pub-id pub-id-type="pmid">27732846</pub-id></mixed-citation>
    </ref>
    <ref id="bib111">
      <label>111.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vats</surname><given-names>D</given-names></string-name>, <string-name><surname>Mukundan</surname><given-names>L</given-names></string-name>, <string-name><surname>Odegaard</surname><given-names>JI</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name><surname>Smith</surname><given-names>KL</given-names></string-name>, <string-name><surname>Morel</surname><given-names>CR</given-names></string-name>, <etal/></person-group>. <article-title>Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation</article-title>. <source>Cell Metab</source><year>2006</year>;<volume>4</volume>:<fpage>13</fpage>–<lpage>24</lpage>.<pub-id pub-id-type="pmid">16814729</pub-id></mixed-citation>
    </ref>
    <ref id="bib112">
      <label>112.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Koo</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Garg</surname><given-names>NJ</given-names></string-name></person-group>. <article-title>Metabolic programming of macrophage functions and pathogens control</article-title>. <source>Redox Biol</source><year>2019</year>;<volume>24</volume>:<fpage>101198</fpage>.<pub-id pub-id-type="pmid">31048245</pub-id></mixed-citation>
    </ref>
    <ref id="bib113">
      <label>113.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname><given-names>SY</given-names></string-name>, <string-name><surname>Yang</surname><given-names>CS</given-names></string-name>, <string-name><surname>Lee</surname><given-names>HM</given-names></string-name>, <string-name><surname>Kim</surname><given-names>JK</given-names></string-name>, <string-name><surname>Kim</surname><given-names>YS</given-names></string-name>, <string-name><surname>Kim</surname><given-names>YR</given-names></string-name>, <etal/></person-group>. <article-title>ESRRA (estrogen-related receptor α) is a key coordinator of transcriptional and post-translational activation of autophagy to promote innate host defense</article-title>. <source>Autophagy</source><year>2018</year>;<volume>14</volume>:<fpage>152</fpage>–<lpage>68</lpage>.<pub-id pub-id-type="pmid">28841353</pub-id></mixed-citation>
    </ref>
    <ref id="bib114">
      <label>114.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Crotzer</surname><given-names>VL</given-names></string-name>, <string-name><surname>Blum</surname><given-names>JS</given-names></string-name></person-group>. <article-title>Autophagy and its role in MHC-mediated antigen presentation</article-title>. <source>J Immunol</source><year>2009</year>;<volume>182</volume>:<fpage>3335</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="pmid">19265109</pub-id></mixed-citation>
    </ref>
    <ref id="bib115">
      <label>115.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>P</given-names></string-name>, <string-name><surname>Cescon</surname><given-names>M</given-names></string-name>, <string-name><surname>Bonaldo</surname><given-names>P</given-names></string-name></person-group>. <article-title>Autophagy-mediated regulation of macrophages and its applications for cancer</article-title>. <source>Autophagy</source><year>2014</year>;<volume>10</volume>:<fpage>192</fpage>–<lpage>200</lpage>.<pub-id pub-id-type="pmid">24300480</pub-id></mixed-citation>
    </ref>
    <ref id="bib116">
      <label>116.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>C</given-names></string-name>, <string-name><surname>Yosef</surname><given-names>N</given-names></string-name>, <string-name><surname>Gaublomme</surname><given-names>J</given-names></string-name>, <string-name><surname>Wu</surname><given-names>C</given-names></string-name>, <string-name><surname>Lee</surname><given-names>Y</given-names></string-name>, <string-name><surname>Clish</surname><given-names>CB</given-names></string-name>, <etal/></person-group>. <article-title>CD5L/AIM regulates lipid biosynthesis and restrains Th17 cell pathogenicity</article-title>. <source>Cell</source><year>2015</year>;<volume>163</volume>:<fpage>1413</fpage>–<lpage>27</lpage>.<pub-id pub-id-type="pmid">26607793</pub-id></mixed-citation>
    </ref>
    <ref id="bib117">
      <label>117.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Palmer</surname><given-names>CS</given-names></string-name>, <string-name><surname>Anzinger</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Butterfield</surname><given-names>TR</given-names></string-name>, <string-name><surname>McCune</surname><given-names>JM</given-names></string-name>, <string-name><surname>Crowe</surname><given-names>SM</given-names></string-name></person-group>. <article-title>A simple flow cytometric method to measure glucose uptake and glucose transporter expression for monocyte subpopulations in whole blood</article-title>. <source>J Vis Exp</source><year>2016</year>;<volume>114</volume>:<fpage>54255</fpage>.</mixed-citation>
    </ref>
    <ref id="bib118">
      <label>118.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name><surname>Green</surname><given-names>M</given-names></string-name>, <string-name><surname>Choi</surname><given-names>JE</given-names></string-name>, <string-name><surname>Gijón</surname><given-names>M</given-names></string-name>, <string-name><surname>Kennedy</surname><given-names>PD</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>JK</given-names></string-name>, <etal/></person-group>. <article-title>CD8<sup>+</sup> T cells regulate tumour ferroptosis during cancer immunotherapy</article-title>. <source>Nature</source><year>2019</year>;<volume>569</volume>:<fpage>270</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">31043744</pub-id></mixed-citation>
    </ref>
    <ref id="bib119">
      <label>119.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Katzenelenbogen</surname><given-names>Y</given-names></string-name>, <string-name><surname>Sheban</surname><given-names>F</given-names></string-name>, <string-name><surname>Yalin</surname><given-names>A</given-names></string-name>, <string-name><surname>Yofe</surname><given-names>I</given-names></string-name>, <string-name><surname>Svetlichnyy</surname><given-names>D</given-names></string-name>, <string-name><surname>Jaitin</surname><given-names>DA</given-names></string-name>, <etal/></person-group>. <article-title>Coupled scRNA-seq and intracellular protein activity reveal an immunosuppressive role of TREM2 in cancer</article-title>. <source>Cell</source><year>2020</year>;<volume>182</volume>:<fpage>872</fpage>–<lpage>85</lpage>.<pub-id pub-id-type="pmid">32783915</pub-id></mixed-citation>
    </ref>
    <ref id="bib120">
      <label>120.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>S</given-names></string-name>, <string-name><surname>Zang</surname><given-names>C</given-names></string-name>, <string-name><surname>Xiao</surname><given-names>T</given-names></string-name>, <string-name><surname>Fan</surname><given-names>J</given-names></string-name>, <string-name><surname>Mei</surname><given-names>S</given-names></string-name>, <string-name><surname>Qin</surname><given-names>Q</given-names></string-name>, <etal/></person-group>. <article-title>Modeling cis-regulation with a compendium of genome-wide histone H3K27ac profiles</article-title>. <source>Genome Res</source><year>2016</year>;<volume>26</volume>:<fpage>1417</fpage>–<lpage>29</lpage>.<pub-id pub-id-type="pmid">27466232</pub-id></mixed-citation>
    </ref>
    <ref id="bib121">
      <label>121.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>Z</given-names></string-name>, <string-name><surname>Ersoz</surname><given-names>E</given-names></string-name>, <string-name><surname>Lai</surname><given-names>CQ</given-names></string-name>, <string-name><surname>Todhunter</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Tiwari</surname><given-names>HK</given-names></string-name>, <string-name><surname>Gore</surname><given-names>MA</given-names></string-name>, <etal/></person-group>. <article-title>Mixed linear model approach adapted for genome-wide association studies</article-title>. <source>Nat Genet</source><year>2010</year>;<volume>42</volume>:<fpage>355</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="pmid">20208535</pub-id></mixed-citation>
    </ref>
    <ref id="bib122">
      <label>122.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kuznetsova</surname><given-names>A</given-names></string-name>, <string-name><surname>Brockhoff</surname><given-names>PB</given-names></string-name>, <string-name><surname>Christensen</surname><given-names>RHB</given-names></string-name></person-group>. <article-title>lmerTest package: tests in linear mixed effects models</article-title>. <source>J Stat Softw</source><year>2017</year>;<volume>82</volume>:<fpage>1</fpage>–<lpage>26</lpage>.</mixed-citation>
    </ref>
    <ref id="bib123">
      <label>123.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bates</surname><given-names>D</given-names></string-name>, <string-name><surname>Mächler</surname><given-names>M</given-names></string-name>, <string-name><surname>Bolker</surname><given-names>B</given-names></string-name>, <string-name><surname>Walker</surname><given-names>S</given-names></string-name></person-group>. <article-title>Fitting linear mixed-effects models using lme4</article-title>. <source>J Stat Softw</source><year>2015</year>;<volume>67</volume>:<fpage>1</fpage>–<lpage>48</lpage>.</mixed-citation>
    </ref>
    <ref id="bib124">
      <label>124.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hochberg</surname><given-names>Y</given-names></string-name>, <string-name><surname>Benjamini</surname><given-names>Y</given-names></string-name></person-group>. <article-title>More powerful procedures for multiple significance testing</article-title>. <source>Stat Med</source><year>1990</year>;<fpage>811</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">2218183</pub-id></mixed-citation>
    </ref>
    <ref id="bib125">
      <label>125.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Robin</surname><given-names>X</given-names></string-name>, <string-name><surname>Turck</surname><given-names>N</given-names></string-name>, <string-name><surname>Hainard</surname><given-names>A</given-names></string-name>, <string-name><surname>Tiberti</surname><given-names>N</given-names></string-name>, <string-name><surname>Lisacek</surname><given-names>F</given-names></string-name>, <string-name><surname>Sanchez</surname><given-names>J-C</given-names></string-name>, <etal/></person-group>. <article-title>pROC: an open-source package for R and S+ to analyze and compare ROC curves</article-title>. <source>BMC Bioinf</source><year>2011</year>;<volume>12</volume>:<fpage>77</fpage>.</mixed-citation>
    </ref>
    <ref id="bib126">
      <label>126.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Josse</surname><given-names>J</given-names></string-name>, <string-name><surname>Husson</surname><given-names>F</given-names></string-name></person-group>. <article-title>missMDA: a package for handling missing values in multivariate data analysis</article-title>. <source>J Stat Softw</source><year>2016</year>;<volume>70</volume>:<fpage>1</fpage>–<lpage>31</lpage>.</mixed-citation>
    </ref>
    <ref id="bib127">
      <label>127.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>C</given-names></string-name>, <string-name><surname>Sun</surname><given-names>D</given-names></string-name>, <string-name><surname>Huang</surname><given-names>X</given-names></string-name>, <string-name><surname>Wan</surname><given-names>C</given-names></string-name>, <string-name><surname>Li</surname><given-names>Z</given-names></string-name>, <string-name><surname>Han</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>Integrative analyses of single-cell transcriptome and regulome using MAESTRO</article-title>. <source>Genome Biol</source><year>2020</year>;<volume>21</volume>:<fpage>198</fpage>.<pub-id pub-id-type="pmid">32767996</pub-id></mixed-citation>
    </ref>
    <ref id="bib128">
      <label>128.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mei</surname><given-names>S</given-names></string-name>, <string-name><surname>Meyer</surname><given-names>CA</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>R</given-names></string-name>, <string-name><surname>Qin</surname><given-names>Q</given-names></string-name>, <string-name><surname>Wu</surname><given-names>Q</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>P</given-names></string-name>, <etal/></person-group>. <article-title>Cistrome Cancer: a web resource for integrative gene regulation modeling in cancer</article-title>. <source>Cancer Res</source><year>2017</year>;<volume>77</volume>:<fpage>e19</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="pmid">29092931</pub-id></mixed-citation>
    </ref>
    <ref id="bib129">
      <label>129.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>He</surname><given-names>L</given-names></string-name>, <string-name><surname>Kulminski</surname><given-names>AM</given-names></string-name></person-group>. <article-title>NEBULA: a fast negative binomial mixed model for differential expression and co-expression analyses of large-scale multi-subject single-cell data</article-title>. <source>Commun Biol</source><year>2021</year>;<volume>4</volume>:<fpage>629</fpage>.<pub-id pub-id-type="pmid">34040149</pub-id></mixed-citation>
    </ref>
    <ref id="bib130">
      <label>130.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brown</surname><given-names>MB</given-names></string-name></person-group>. <article-title>400: A method for combining non-independent, one-sided tests of significance</article-title>. <source>Biometrics</source><year>1975</year>;<volume>31</volume>:<fpage>987</fpage>.</mixed-citation>
    </ref>
    <ref id="bib131">
      <label>131.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>W</given-names></string-name>, <string-name><surname>Xu</surname><given-names>H</given-names></string-name>, <string-name><surname>Xiao</surname><given-names>T</given-names></string-name>, <string-name><surname>Cong</surname><given-names>L</given-names></string-name>, <string-name><surname>Love</surname><given-names>MI</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>F</given-names></string-name>, <etal/></person-group>. <article-title>MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens</article-title>. <source>Genome Biol</source><year>2014</year>;<volume>15</volume>:<fpage>554</fpage>.<pub-id pub-id-type="pmid">25476604</pub-id></mixed-citation>
    </ref>
    <ref id="bib132">
      <label>132.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Love</surname><given-names>MI</given-names></string-name>, <string-name><surname>Anders</surname><given-names>S</given-names></string-name>, <string-name><surname>Huber</surname><given-names>W</given-names></string-name></person-group>. <article-title>Analyzing RNA-seq data with DESeq2</article-title>. <source>Genome Biol</source><year>2014</year>;<volume>15</volume>:<fpage>550</fpage>.<pub-id pub-id-type="pmid">25516281</pub-id></mixed-citation>
    </ref>
    <ref id="bib133">
      <label>133.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Daley</surname><given-names>TP</given-names></string-name>, <string-name><surname>Lin</surname><given-names>Z</given-names></string-name>, <string-name><surname>Lin</surname><given-names>X</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Wong</surname><given-names>WH</given-names></string-name>, <string-name><surname>Qi</surname><given-names>LS</given-names></string-name></person-group>. <article-title>CRISPhieRmix: a hierarchical mixture model for CRISPR pooled screens</article-title>. <source>Genome Biol</source><year>2018</year>;<volume>19</volume>:<fpage>159</fpage>.<pub-id pub-id-type="pmid">30296940</pub-id></mixed-citation>
    </ref>
    <ref id="bib134">
      <label>134.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Newman</surname><given-names>AM</given-names></string-name>, <string-name><surname>Liu</surname><given-names>CL</given-names></string-name>, <string-name><surname>Green</surname><given-names>MR</given-names></string-name>, <string-name><surname>Gentles</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Feng</surname><given-names>W</given-names></string-name>, <string-name><surname>Xu</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>Robust enumeration of cell subsets from tissue expression profiles</article-title>. <source>Nat Methods</source><year>2015</year>;<volume>12</volume>:<fpage>453</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">25822800</pub-id></mixed-citation>
    </ref>
    <ref id="bib135">
      <label>135.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kanehisa</surname><given-names>M</given-names></string-name>, <string-name><surname>Furumichi</surname><given-names>M</given-names></string-name>, <string-name><surname>Tanabe</surname><given-names>M</given-names></string-name>, <string-name><surname>Sato</surname><given-names>Y</given-names></string-name>, <string-name><surname>Morishima</surname><given-names>K</given-names></string-name></person-group>. <article-title>KEGG: new perspectives on genomes, pathways, diseases and drugs</article-title>. <source>Nucleic Acids Res</source><year>2017</year>;<volume>45</volume>:<fpage>D353</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="pmid">27899662</pub-id></mixed-citation>
    </ref>
    <ref id="bib136">
      <label>136.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Barbie</surname><given-names>DA</given-names></string-name>, <string-name><surname>Tamayo</surname><given-names>P</given-names></string-name>, <string-name><surname>Boehm</surname><given-names>JS</given-names></string-name>, <string-name><surname>Kim</surname><given-names>SY</given-names></string-name>, <string-name><surname>Moody</surname><given-names>SE</given-names></string-name>, <string-name><surname>Dunn</surname><given-names>IF</given-names></string-name>, <etal/></person-group>. <article-title>Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1</article-title>. <source>Nature</source><year>2009</year>;<volume>462</volume>:<fpage>108</fpage>–<lpage>12</lpage>.<pub-id pub-id-type="pmid">19847166</pub-id></mixed-citation>
    </ref>
    <ref id="bib137">
      <label>137.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hänzelmann</surname><given-names>S</given-names></string-name>, <string-name><surname>Castelo</surname><given-names>R</given-names></string-name>, <string-name><surname>Guinney</surname><given-names>J</given-names></string-name></person-group>. <article-title>GSVA: gene set variation analysis for microarray and RNA-seq data</article-title>. <source>BMC Bioinf</source><year>2013</year>;<volume>14</volume>:<fpage>7</fpage>.</mixed-citation>
    </ref>
    <ref id="bib138">
      <label>138.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gentles</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Newman</surname><given-names>AM</given-names></string-name>, <string-name><surname>Liu</surname><given-names>CL</given-names></string-name>, <string-name><surname>Bratman</surname><given-names>SV</given-names></string-name>, <string-name><surname>Feng</surname><given-names>W</given-names></string-name>, <string-name><surname>Kim</surname><given-names>D</given-names></string-name>, <etal/></person-group>. <article-title>The prognostic landscape of genes and infiltrating immune cells across human cancers</article-title>. <source>Nat Med</source><year>2015</year>;<volume>21</volume>:<fpage>938</fpage>–<lpage>45</lpage>.<pub-id pub-id-type="pmid">26193342</pub-id></mixed-citation>
    </ref>
    <ref id="bib139">
      <label>139.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mariathasan</surname><given-names>S</given-names></string-name>, <string-name><surname>Turley</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Nickles</surname><given-names>D</given-names></string-name>, <string-name><surname>Castiglioni</surname><given-names>A</given-names></string-name>, <string-name><surname>Yuen</surname><given-names>K</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells</article-title>. <source>Nature</source><year>2018</year>;<volume>554</volume>:<fpage>544</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">29443960</pub-id></mixed-citation>
    </ref>
    <ref id="bib140">
      <label>140.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lerner</surname><given-names>SP</given-names></string-name>, <string-name><surname>McConkey</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Hoadley</surname><given-names>KA</given-names></string-name>, <string-name><surname>Chan</surname><given-names>KS</given-names></string-name>, <string-name><surname>Kim</surname><given-names>WY</given-names></string-name>, <string-name><surname>Radvanyi</surname><given-names>F</given-names></string-name>, <etal/></person-group>. <article-title>Bladder cancer molecular taxonomy: summary from a consensus meeting</article-title>. <source>Bladder Cancer</source><year>2016</year>;<volume>2</volume>:<fpage>37</fpage>–<lpage>47</lpage>.<pub-id pub-id-type="pmid">27376123</pub-id></mixed-citation>
    </ref>
    <ref id="bib141">
      <label>141.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Subramanian</surname><given-names>A</given-names></string-name>, <string-name><surname>Tamayo</surname><given-names>P</given-names></string-name>, <string-name><surname>Mootha</surname><given-names>VK</given-names></string-name>, <string-name><surname>Mukherjee</surname><given-names>S</given-names></string-name>, <string-name><surname>Ebert</surname><given-names>BL</given-names></string-name>, <string-name><surname>Gillette</surname><given-names>MA</given-names></string-name>, <etal/></person-group>. <article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2005</year>;<volume>102</volume>:<fpage>15545</fpage>–<lpage>50</lpage>.<pub-id pub-id-type="pmid">16199517</pub-id></mixed-citation>
    </ref>
    <ref id="bib142">
      <label>142.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>Z</given-names></string-name>, <string-name><surname>Huang</surname><given-names>A</given-names></string-name>, <string-name><surname>Sun</surname><given-names>J</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>T</given-names></string-name>, <string-name><surname>Qin</surname><given-names>FXF</given-names></string-name>, <string-name><surname>Wu</surname><given-names>A</given-names></string-name></person-group>. <article-title>Inference of immune cell composition on the expression profiles of mouse tissue</article-title>. <source>Sci Rep</source><year>2017</year>;<volume>7</volume>:<fpage>40508</fpage>.<pub-id pub-id-type="pmid">28084418</pub-id></mixed-citation>
    </ref>
    <ref id="bib143">
      <label>143.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yu</surname><given-names>G</given-names></string-name>, <string-name><surname>Wang</surname><given-names>LG</given-names></string-name>, <string-name><surname>Han</surname><given-names>Y</given-names></string-name>, <string-name><surname>He</surname><given-names>QY</given-names></string-name></person-group>. <article-title>clusterProfiler: an R package for comparing biological themes among gene clusters</article-title>. <source>OMICS</source><year>2012</year>;<volume>16</volume>:<fpage>284</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">22455463</pub-id></mixed-citation>
    </ref>
    <ref id="bib144">
      <label>144.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stuart</surname><given-names>T</given-names></string-name>, <string-name><surname>Butler</surname><given-names>A</given-names></string-name>, <string-name><surname>Hoffman</surname><given-names>P</given-names></string-name>, <string-name><surname>Hafemeister</surname><given-names>C</given-names></string-name>, <string-name><surname>Papalexi</surname><given-names>E</given-names></string-name>, <string-name><surname>Mauck</surname><given-names>WM</given-names><suffix>3rd</suffix></string-name>, <etal/></person-group>. <article-title>Comprehensive integration of single-cell data</article-title>. <source>Cell</source><year>2019</year>;<volume>177</volume>:<fpage>1888</fpage>–<lpage>902</lpage>.<pub-id pub-id-type="pmid">31178118</pub-id></mixed-citation>
    </ref>
    <ref id="bib145">
      <label>145.</label>
      <mixed-citation publication-type="journal"><collab>Tabula Muris Consortium</collab>. <article-title>A single-cell transcriptomic atlas characterizes ageing tissues in the mouse</article-title>. <source>Nature</source><year>2020</year>;<volume>583</volume>:<fpage>590</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">32669714</pub-id></mixed-citation>
    </ref>
    <ref id="bib146">
      <label>146.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Aran</surname><given-names>D</given-names></string-name>, <string-name><surname>Looney</surname><given-names>AP</given-names></string-name>, <string-name><surname>Liu</surname><given-names>L</given-names></string-name>, <string-name><surname>Wu</surname><given-names>E</given-names></string-name>, <string-name><surname>Fong</surname><given-names>V</given-names></string-name>, <string-name><surname>Hsu</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage</article-title>. <source>Nat Immunol</source><year>2019</year>;<volume>20</volume>:<fpage>163</fpage>–<lpage>72</lpage>.<pub-id pub-id-type="pmid">30643263</pub-id></mixed-citation>
    </ref>
    <ref id="bib147">
      <label>147.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>C</given-names></string-name>, <string-name><surname>Liu</surname><given-names>B</given-names></string-name>, <string-name><surname>Kang</surname><given-names>B</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Z</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Chen</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>SciBet as a portable and fast single cell type identifier</article-title>. <source>Nat Commun</source><year>2020</year>;<volume>11</volume>:<fpage>1818</fpage>.<pub-id pub-id-type="pmid">32286268</pub-id></mixed-citation>
    </ref>
    <ref id="bib148">
      <label>148.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>D</given-names></string-name>, <string-name><surname>Huo</surname><given-names>D</given-names></string-name>, <string-name><surname>Xie</surname><given-names>H</given-names></string-name>, <string-name><surname>Wu</surname><given-names>L</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name><surname>Liu</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>CHG: a systematically integrated database of cancer hallmark genes</article-title>. <source>Front Genet</source><year>2020</year>;<volume>11</volume>:<fpage>29</fpage>.<pub-id pub-id-type="pmid">32117445</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
